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SUMMARY	  	  Skeletal	   muscle	   can	   adapt	   its	   mass	   in	   response	   to	   physical	   activity,	  metabolism	   and	   hormones.	   The	   control	   of	   muscle	   size	   depends	   on	   the	  coordinated	   balance	   between	   protein	   synthesis	   and	   protein	   degradation.	  Mechanical	   overload	   or	   anabolic	   hormonal	   stimulation	   shifts	   the	   balance	  towards	  protein	  synthesis	  leading	  to	  an	  increase	  in	  fiber	  size,	  a	  process	  called	  hypertrophy.	  Conversely,	  in	  catabolic	  conditions	  protein	  degradation	  exceeds	  protein	   synthesis	   resulting	   into	   muscle	   weakness	   and	   muscle	   atrophy.	  Muscle	   loss	   and	   weakness	   occurs	   in	   several	   pathological	   conditions	   like	  disuse,	   denervation,	   immobilization,	   sepsis,	   burn	   injury,	   cancer,	   AIDS,	  diabetes,	   heart	   and	   renal	   failure	   and	   in	   aging.	   Muscle	   atrophy	   is	   an	   active	  process	   which	   requires	   the	   activation	   of	   specific	   signalling	   pathways	   and	  transcriptional	   programs.	   Gene	   expression	   studies	   revealed	   a	   set	   of	   genes,	  named	   atrogenes	   (atrophy	   related	   genes),	   which	   are	   commonly	   up-­‐	   and	  down-­‐regulated	  in	  different	  catabolic	  conditions	  (Bodine	  et	  al.,	  2001;	  Gomes	  et	   al.,	   2001;	   Lecker	   et	   al.,	   2004;	   Sacheck	   et	   al.,	   2007;	   Sandri	   et	   al.,	   2004).	  These	  genes	  encode	  for	  enzymes	  that	  catalyze	  important	  steps	  in	  autophagy-­‐lysosome	  pathway,	  ubiquitin-­‐proteasome	  system,	  unfolded	  protein	  response,	  ROS	   detoxification,	   DNA	   repair,	  mitochondrial	   function	   and	   energy	   balance	  pathways.	  Skeletal	  muscle	  growth	  is	  regulated	  by	  the	  IGF1-­‐AKT-­‐mTOR-­‐FoxO	  signalling	   pathway	   (Sandri,	   2013).	   FoxO	   family	   of	   transcription	   factors	  activity	   	   is	   suppressed	   during	   growth	   by	   AKT.	   On	   the	   other	   hand,	   in	   the	  absence	  of	  growth	  factors,	  like	  IGF1	  or	  insulin,	  AKT	  is	  not	  activated	  and	  does	  not	   block	   FoxOs	   which	   can	   translocate	   into	   the	   nucleus	   and	   interact	   with	  promoters	   of	   their	   target	   genes	   (Sandri	   et	   al.,	   2004).	   	   Activation	   of	   FoxOs	  promotes	   the	   expression	   of	   the	   essential	   atrophy-­‐related	   ubiquitin	   ligases	  atrogin-­‐1	  and	  MuRF-­‐1	  and	  leads	  to	  a	  dramatic	  loss	  of	  muscle	  mass	  (Kamei	  et	  al.,	   2004;	   Sandri	   et	   al.,	   2004).	   In	   addition,	   autophagy	   and	   expression	   of	  autophagy-­‐related	   genes	   is	   also	   under	   FoxO3	   control	   (Mammucari	   et	   al.,	  2007;	   Zhao	   et	   al.,	   2007).	   Thus	   FoxO	   coordinates	   the	   two	  major	   proteolytic	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system	   of	   the	   cell,	   the	   autophagy-­‐lysosome	   and	   the	   ubiquitin-­‐proteasome.	  However,	   the	   activation	   of	   the	   few	   atrogenes	   reported	   to	   be	   regulated	   by	  FoxO	  cannot	  sustain	  all	  the	  protein	  breakdown	  during	  atrophy.	  Nevertheless	  several	  other	  genes	  among	   the	  atrogenes	  are	  of	  potential	   interest	  but	   their	  particular	  role	  and	  regulation	  in	  muscle	  wasting	  is	  still	  unknown.	  Moreover,	  other	   unknown	   players	   are	   certainly	   important	   for	   muscle	   protein	  breakdown.	   For	   this	   reason,	   in	   this	   PhD	   project	   we	   propose,	   by	   a	   loss	   of	  function	  approach,	  to	  unravel	  the	  role	  of	  FoxO	  family	  in	  gene	  regulation	  and	  muscle	  adaptation	  during	   catabolic	   conditions.	   	  The	  FoxO	   family	   in	   skeletal	  muscle	   is	   comprised	   of	   four	   isoforms:	   FoxO1,	   FoxO3,	   FoxO4	   and	   FoxO6.	  Therefore,	  to	  simultaneously	  delete	  the	  three	  major	  expressed	  FoxO	  genes	  in	  skeletal	   muscle,	   we	   generated	   muscle-­‐specific	   conditional	   FoxO1,3,4	  knockout	   mice.	   These	   animals	   resulted	   to	   be	   fully	   viable,	   phenotypically	  normal	   and	   indistinguishable	   in	   appearance	   from	   aged-­‐matched	   control	  mice.	  To	   characterize	   the	   role	  of	  FoxO1,3,4	   in	   skeletal	  muscle,	  we	  analyzed	  the	  phenotype	  of	  knockout	  	  mice	  under	  conditions	  of	  muscle	  wasting.	  Initially	  we	   used	   starvation	   as	   a	  model	   of	  muscle	   loss.	   because	   it	   is	   an	   established	  condition	   that	   induces	   nuclear	   translocation	   of	   FoxO	   members	   and	   their	  binding	   to	   target	   promoters	   (Mammucari	   et	   al.,	   2007;	   Sandri	   et	   al.,	   2004).	  Interestingly,	   FoxO1,3,4	   	   knock-­‐out	   mice	   were	   completely	   protected	   from	  muscle	   loss	   and	  muscle	  weakness	   after	   fasting.	  Moreover,	   deletion	  of	   FoxO	  resulted	  in	  suppression	  of	  autophagy	  during	  fasting.	  	  To	  further	  determine	  if	  the	  role	  of	  FoxO1,3,4	  is	  critical	  in	  different	  catabolic	  conditions,	  we	  then	  used	  denervation	  as	  another	  model	  of	  muscle	  atrophy.	  Quantification	  of	  fibre	  size	  revealed	  that	  FoxO-­‐deficient	  muscles	  were	  partially	  protected	  from	  atrophy.	  Thus,	   FoxO	   family	   members	   are	   necessary	   for	   muscle	   loss	   but	   their	  involvement	  in	  the	  atrophy	  programme	  depends	  on	  the	  catabolic	  condition.	  	  Since	   muscle	   atrophy	   is	   characterized	   by	   a	   transcriptional-­‐dependent	  regulation	  of	  atrogenes	  we	  decided	   to	  perform	  gene	  expression	  profiling	   in	  fed	   and	   fasting	   conditions	   in	   FoxO1,3,4	   -­‐/-­‐	   and	   controls	   to	   identify	   genes	  under	  FoxO	  regulation.	  Then,	  we	  compared	  the	  list	  of	  	  FoxO-­‐dependent	  genes	  with	  the	  list	  of	  atrogenes	  and	  we	  founded	  that	  29	  of	  63	  atrophy	  related-­‐genes	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were	  not	  induced	  in	  FoxO	  null	  muscles	  during	  fasting.	  Interestingly,	  the	  lists	  of	  FoxO-­‐dependent	  genes	  during	  denervation	  and	  fasting	  do	  not	  completely	  overlap	   confirming	   that	   FoxO	   trascription	   factors	   are	   more	   sensitive	   in	  conditions	  of	  nutrient	  deprivation.	  Finally	  we	  identified	  new	  FoxO-­‐dependent	  ubiquitin	  ligases	  including	  MUSA1	  recently	  identified	  in	  our	  lab	  and	  another	  one	   that	   we	   name	   SMART	   (Specific	   of	   Muscle	   Atrophy	   and	   Regulated	   by	  Transcription).	  We	  confirmed	  	  by	  IP	  experiments	  	  that	  SMART	  forms	  an	  SCF	  complex	  with	  Skp1,	  Cullin1	  and	  Roc1	  	  and	  therefore	  belongs	  to	  the	  SCF	  family	  of	  E3	  ligases.	  To	  validate	  the	  hypothesis	  that	  SMART	  had	  a	  role	  in	  promoting	  atrophy	  during	  denervation,	  we	  knocked	  down	  SMART	  in	  tibialis	  anterior	  in	  vivo	   in	   innervated	   and	   denervated	  muscles.	   Importantly,	   SMART	   inhibition	  significantly	  protected	  denervated	  muscles	  from	  atrophy.	  Therefore,	  SMART	  is	  an	  additional	  critical	  gene	  whose	  upregulation	   is	  required	   for	  atrophy.	   In	  conclusion,	   this	   PhD	   project	   identified	   the	   FoxO	   signature	   in	   protein	  breakdown.	   This	   information	  would	   be	   valuable	   in	   order	   to	   	   block	  muscle	  wasting	  in	  many	  systemic	  disease	  and	  to	  promote	  pharmacological	  strategies	  against	  muscle	  loss.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   8	  
RIASSUNTO	  	  Il	   muscolo	   scheletrico	   è	   in	   grado	   di	   adattare	   la	   sua	   massa	   in	   risposta	   all’	  esercizio	   fisico,	   al	   metabolismo	   e	   a	   gli	   ormoni.	   Il	   controllo	   della	   massa	  muscolare	   dipende	   quindi	   da	   un	   coordinato	   equilibrio	   tra	   sintesi	   e	  degradazione	   proteica.	   L’esercizio	   fisico	   e	   gli	   stimoli	   anabolici	   spostano	  questo	  equilibrio	  verso	  la	  sintesi	  proteica,	  la	  quale	  porta	  ad	  un	  aumento	  delle	  dimensioni	   delle	   fibre	   muscolari	   attraverso	   un	   	   processo	   noto	   come	  ipertrofia.	   Al	   contrario,	   in	   condizioni	   cataboliche,	   la	   degradazione	   proteica	  aumenta	   rispetto	   alla	   sintesi	   portando	   a	   debolezza	  muscolare	   e	   atrofia.	   La	  perdita	   di	   massa	   e	   forza	   sono	   una	   conseguenza	   di	   diverse	   condizioni	  patalogiche	   come	   il	   disuso,	   la	   denervazione,	   l’	   immobilizzazione,	   la	   sepsi,	  ustioni,	   cancro,	   AIDS,	   diabete	   ed	   invecchiamento.	   L’atrofia	   muscolare	   è	   un	  processo	   catabolico	   che	   richiede	   l’attivazione	  di	   	   specifiche	  vie	  di	   segnale	   e	  programmi	   trascrizionali.	   Studi	  di	   espressione	   genica	  hanno	   identificato	  un	  set	   di	   geni,	   chiamati	   atrogenes	   (geni	   correlati	   all’atrofia),	   che	   sono	  comunemente	   up-­‐regolati	   e	   down-­‐	   regolati	   in	   differenti	   condizioni	  cataboliche.	   (Bodine	   et	   al.,	   2001;	   Gomes	   et	   al.,	   2001;	   Lecker	   et	   al.,	   2004;	  Sacheck	  et	  al.,	  2007;	  Sandri	  et	  al.,	  2004).	  Questi	   geni	   codificano	   per	   enzimi	   che	   catalizzano	   importanti	   step	   nei	  principali	  pathway	  cellulari	  come	  il	  sistema	  autofagico	  lisosomiale,	  il	  sistema	  ubiquitina-­‐proteasoma,	  stress	  del	  reticolo,	  sistemi	  di	  riparazione	  del	  DNA	  ed	  enzimi	   che	   regolano	  attività	  mitocondriali.	   La	   crescita	  muscolare	  è	   regolata	  dalla	   via	   di	   segnale	   IGF1-­‐AKT-­‐mTOR-­‐FoxO	   (Sandri,	   2013).	   L’	   attività	   dei	  fattori	   trascrizionali	   FoxO	   è	   quindi	   abolita	   durante	   la	   crescita	   muscolare	  tramite	  l’	  attivazione	  della	  chinasi	  AKT.	  In	  assenza	  però	  di	  fattori	  di	  crescita	  come	  IGF1	  o	  insulina,	  la	  chinasi	  AKT	  non	  è	  attivata	  e	  risulta	  dunque	  incapace	  di	  bloccare	  FoxO	  che	  può	  traslocare	  nel	  nucleo	  e	  legare	  i	  promotori	  dei	  suoi	  geni	   target	   (Sandri	   et	   al.,	   2004).	   L’	   attivazione	   dei	   fattori	   FoxO	   promuove	  l’espressione	   di	   essenziali	   ubiquitine	   ligasi	   legate	   all’	   atrofia	   	   atrogin-­‐1	   e	  MuRF-­‐1	  e	  porta	  ad	  una	  drammatica	  perdita	  della	  massa	  muscolare	  (Kamei	  et	  al.,	  2004;	  Sandri	  et	  al.,	  2004),	  inoltre	  è	  noto	  che	  	  l’autofagia	  e	  l’espressione	  di	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alcuni	   dei	   geni	   correlati	   all’	   atrofia	   sono	   sotto	   il	   controllo	   del	   fattore	  trascrizionale	   FoxO3	   (Mammucari	   et	   al.,	   2007;	   Zhao	   et	   al.,	   2007).	   I	   fattori	  FoxO	  coordinano	   i	  due	  principali	  sistemi	  proteolitici	  della	  cellula:	   il	  sistema	  autofagico	   lisosomiale	   e	   il	   sistema	   ubiquitina	   proteasoma.	   Tuttavia,	   l’	  attivazione	   degli	   atrogenes	   controllati	   trascrizionalmente	   da	   FoxO	   non	   è	  sufficiente,	  da	  sola,	  a	  giustificare	  la	  completa	  perdita	  della	  massa	  muscolare;	  tra	   gli	   atrogenes	   vi	   sono	   dunque	   diversi	   altri	   geni	   che	   giocano	   un	   ruolo	   di	  potenziale	  interesse	  nella	  regolazione	  nell’	  atrofia	  muscolare	  la	  cui	  funzione	  però,	  è	  ancora	  sconosciuta.	  	  Per	   questo	   motivo,	   nel	   mio	   progetto	   di	   dottorato,	   abbiamo	   caratterizzato	  attraverso	   la	   metodica	   del	   loss	   of	   function	   il	   ruolo	   dei	   fattori	   trascrizionali	  FoxO	  nella	  regolazione	  genica	  e	  nell’	  adattamento	  del	  muscolo	  scheletrico	  in	  condizioni	  cataboliche.	  La	  famiglia	  dei	  fattori	  trascrizionali	  FoxO	  comprende	  4	   isoforme	  FoxO1,	  FoxO3,	  FoxO4	  e	  FoxO6.	  Per	  eliminare	  simultaneamente	   i	  fattori	   FoxO	   specificamente	   nel	  muscolo	   abbiamo	   generato	   dei	   topi	   knock-­‐out	  muscolo	  specifici	  per	  i	  fattori	  FoxO1,3,4	  che	  sono	  principalmente	  espressi	  nel	  muscolo.	   Questi	   animali	   sono	   risultati	   essere	   vitali,	   ed	   apparentemente	  indistinguibili	  dai	  loro	  topi	  di	  controllo.	  Per	  caratterizzare	  il	  ruolo	  dei	  fattori	  Foxo1,3,4	   nel	   muscolo	   scheletrico,	   abbiamo	   analizzato	   il	   fenotipo	   dei	   topi	  knock-­‐out	  in	  condizioni	  in	  cui	  vi	  era	  perdita	  di	  massa.	  Inizialmente	  abbiamo	  utilizzato	   il	   digiuno,	  una	  delle	   condizioni	   in	   cui	  FoxO	  è	  attivo	  e	   trasloca	  nel	  nucleo	  dove	  trascrive	  i	  suoi	  geni	  target,	  come	  modello	  di	  atrofia.	  I	  topi	  FoxO1,3,4	  erano	  completamente	  protetti	  dalla	  perdita	  di	  massa	  e	  forza	  in	   seguito	  al	  digiuno,	   ed	   inoltre	   la	  delezione	  dei	   fattori	  FoxO	  portava	  ad	  un	  completo	  blocco	  del	  flusso	  autofagico	  durante	  il	  digiuno.	  Per	  determinare	  se	  il	   ruolo	   dei	   fattori	   FoxO	   è	   critico	   nelle	   differenti	   condizioni	   	   di	   atrofia,	  abbiamo	  deciso	  di	  utilizzare	  la	  denervazione	  come	  altro	  modello	  di	  perdita	  di	  massa	  muscolare.	  La	  quantificazione	  dell’	  area	  delle	  fibre	  mostrava	  in	  questo	  caso	  una	  parziale	  protezione	  dall’	  atrofia	  suggerendo	  che	  i	  fattori	  FoxO	  sono	  necessari	  nel	  promuovere	   la	  perdita	  di	  massa	  ma	  il	   loro	  coinvolgimento	  nel	  programma	  atrofico	  dipende	  dal	  dipo	  di	  condizione	  catabolica.	  Com’è	  noto	  l’	  atrofia	   muscolare	   è	   caratterizzata	   dall’	   attivazione	   di	   uno	   specifico	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programma	   genico,	   dunque,	   abbiamo	   per	   prima	   cosa	   identificato	   i	   geni	  regolati	  trascrizionalmente	  da	  FoxO	  attraverso	  un’	  analisi	  di	  gene	  expression	  
profiling	   condotta	   su	   topi	   FoxO1,3,4	   knock-­‐out	   e	   controlli	   ,	   alimentati	   e	   a	  digiuno.	  Abbiamo	  quindi	  paragonato	  la	  lista	  dei	  geni	  regolati	  da	  FoxO	  con	  la	  lista	   degli	   atrogenes	   e	   abbiamo	   trovato	   che	   29	   di	   63	   atrogenes	  non	   erano	  espressi	   nei	   muscoli	   dei	   topi	   FoxO	   knock-­‐out	   durante	   il	   digiuno.	   Degno	   di	  nota	   è	   che	   la	   lista	   dei	   geni	   controllati	   da	   FoxO	   nella	   denervazione	   e	   nel	  digiuno	   non	   era	   completamente	   sovrapponibile	   confermando	   che	   i	   fattori	  FoxO	   erano	   maggiormente	   coinvolti	   nel	   processo	   atrofico	   in	   condizioni	   di	  carenza	   di	   nutrienti.	   Infine	   abbiamo	   identificato	   nuove	   ubiquitine	   ligasi	  regolate	  dai	  fattori	  FoxO	  tra	  cui	  MUSA1,	  recentemente	  identificata	  nel	  nostro	  laboratorio,	   e	   una	   nuova	   unquitina	   ligasi	   a	   cui	   abbiamo	   dato	   il	   nome	   di	  SMART	   (Specific	   of	   Muscle	   Atrophy	   and	   Regulated	   by	   Transcription).	  Attraverso	   esperimenti	   di	   immunoprecipitazione	   abbiamo	   confermato	   che	  SMART	  apparteneva	  alla	  famiglia	  delle	  E3	  ubiquitina	  ligasi	  SCF	  dal	  momento	  che	   formava	   un	   complesso	   con	   le	   altre	   componenti	   Skp1,	   Cullin1	   e	   Roc1	   .	  Successivamente	   per	   validare	   l’ipotesi	   che	   SMART	   avesse	   un	   ruolo	   nel	  promuovere	   l’	   atrofia	   muscolare	   	   abbiamo	   bloccato	   la	   sua	   espressione	   nei	  muscoli	  tibiali	  di	  topi	  innervati	  e	  denervati	  e	  abbiamo	  constatato	  che	  il	  blocco	  di	   SMART	   proteggeva	   i	   muscoli	   denervati	   dall’	   altrofia.	   Pertanto,	   SMART	  rappresenta	  un	  nuovo	  gene	  critico	  per	  il	  programma	  atrofico.	  In	  conclusione,	  questo	  progetto	  di	  dottorato	  identifica	  il	  ruolo	  di	  FoxO	  nella	  perdita	  di	  massa	  muscolare.	  Queste	   informazioni	   potrebbero	   risultare	   utili	   per	   combattere	   l’	  atrofia	  muscolare	   in	  molte	  malattie	   sistemiche	   suggerendo	   nuove	   strategie	  farmacologiche	  che	  blocchino	  la	  perdita	  di	  massa	  muscolare.	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INTRODUCTION	  	  
	  
1.1	  SKELETAL	  MUSCLE	  
1.1.1	  STRUCTURE	  AND	  FUNCTION	  	  	  Skeletal	  muscle	  is	  one	  of	  the	  most	  dynamic	  and	  plastic	  tissues	  of	  the	  human	  body.	   In	   humans,	   skeletal	   muscle	   comprises	   approximately	   40	  %	   of	   total	  body	  weight	  and	  contains	  50–75	  %	  of	  all	  body	  proteins.	  	  Muscle	  is	  composed	  by	  multinucleated	   ,elongated	   and	   cylindrical	   cells	   called	  muscle	   fibres	   that	  run	  parallel	   to	  each	  other	  within	  a	  muscle.	  These	   cells	   are	   incredibly	   large,	  with	  diameters	  of	  up	  to	  100	  µm	  and	  lengths	  of	  up	  to	  30	  cm.	  Muscles	  fibres	  are	  organized	   in	   bundles	   and	   separated	   by	   specific	   membrane	   system.	   Each	  	  muscle	   is	   surrounded	   by	   a	   connective	   tissue	  membrane	   called	   epimysium;	  each	  bundle	  of	  muscle	  fiber	  is	  called	  a	  fasciculus	  and	  is	  surrounded	  by	  a	  layer	  of	  connective	  tissue,	  called	  perimysium.	  Within	  the	  fasciculus,	  each	  individual	  muscle	   fiber	   is	   surrounded	   by	   connective	   tissue	   called	   the	   endomysium	  (Figure	  1).	  	  	  
                        	  
Fig.1:	  Schematic	  representation	  of	  skeletal	  muscle	  structure.	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The	  contractile	  machinery	  of	  skeletal	  muscles	  is	  organized	  in	  highly	  ordered	  supramolecular	  structures,	  the	  sarcomeres,	  which	  are	  associated	  in	  series,	  to	  form	   the	  myofibrils,	   and	   in	   parallel,	   thus	   generating	   the	   striated	  pattern	   of	  muscle	   fibers.	   The	   sarcomere	   was	   described	   first	   thank	   to	   microscopy	  techniques	   that	   individuated	   isotropic	   (light	   band)	   and	   anisotropic	   (dark	  band)	  zones,	   forming	  the	  specific	  striated	  aspect	  of	   the	  skeletal	  muscle.	  For	  this	   reason,	   sarcomere	   is	   usually	   defined	   as	   the	   segment	   between	   two	  neighbour	  Z-­‐lines,	   that	  appears	  as	  a	  series	  of	  dark	   lines.	  Surrounding	  the	  Z-­‐line,	   there	   is	   the	  region	  of	   the	   I-­‐band	  (the	   light	  band).	  Following	   the	   I-­‐band	  there	   is	   the	   A-­‐band	   (the	   dark	   band).	   Within	   the	   A-­‐band,	   there	   is	   a	   paler	  region	  called	  the	  H-­‐band.	  Finally,	  inside	  the	  H-­‐band	  there	  is	  a	  thin	  M-­‐line,	  the	  middle	   of	   the	   sarcomere.	   These	   bands	   are	   not	   only	  morphological	   unit	   but	  also	   functional,	   because	   are	   characterized	   by	   the	   presence	   of	   different	  contractile	  proteins	   required	   for	  muscle	  contraction.	   In	   fact,	   actin	   filaments	  (thin	  filaments)	  are	  the	  major	  component	  of	  the	  I-­‐band	  and	  extend	  into	  the	  A	  band.	  Myosin	   filaments	  (thick	   filaments)	  extend	  throughout	  the	  A-­‐band	  and	  are	   thought	   to	   overlap	   in	   the	  M	   band.	   A	   huge	   protein,	   called	   titin,	   extends	  from	  the	  Z-­‐line	  of	  the	  sarcomere,	  where	  it	  binds	  to	  the	  thin	  filament	  system,	  to	  the	  M-­‐band,	  where	  it	  is	  thought	  to	  interact	  with	  the	  thick	  filaments.	  Several	  proteins	  important	  for	  the	  stability	  of	  the	  sarcomeric	  structure	  are	  found	  in	  the	  Z-­‐line	  as	  well	  as	  in	  the	  M	  band	  of	  the	  sarcomere	  (Figure2).	  Actin	  filaments	  and	  titin	  molecules	  are	  cross-­‐linked	  in	  the	  Z-­‐disc	  via	  the	  Z-­‐line	  protein	  alpha-­‐actinin.	   The	   M-­‐band	   myosin	   as	   well	   as	   the	   M	   proteins	   bridge	   the	   thick	  filament	  system	  to	  the	  M-­‐band	  part	  of	  titin	  (the	  elastic	  filaments).	  Moreover	  several	  regulatory	  proteins,	  such	  as	  tropomyosin	  and	  troponin	  bind	  myosin	  molecules,modulating	  its	  capacity	  of	  contraction.	  Muscle	  contraction	  is	  due	  to	  the	  excitation-­‐contraction	  coupling,	  by	  which	  an	  electrical	   stimulus	   is	   converted	   into	   mechanical	   contraction.	   The	   general	  scheme	  is	  that	  an	  action	  potential	  arrives	  to	  depolarize	  the	  cell	   membrane.	  By	  mechanisms	  specific	  to	  the	  muscle	  type,	  this	  depolarization	  results	   in	  an	  increase	  in	  cytosolic	  calcium	  that	  is	  called	  a	  calcium	  transient.	  This	  increase	  in	  calcium	  activates	  calcium	  sensitive	  contractile	  proteins	  that	  then	  use	  ATP	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to	  cause	  cell	  shortening.	  Concerning	  skeletal	  muscle,	  upon	  contraction,	  the	  A-­‐bands	   do	   not	   change	   their	   length,	   whereas	   the	   I	   bands	   and	   the	   H-­‐zone	  shorten.	  This	   is	   called	   the	  sliding	   filament	  hypothesis	   	  which	   is	  now	  widely	  accepted.	  There	  are	  projections	  from	  the	  thick	  filaments,	  called	  cross-­‐bridges	  which	  contain	  the	  part	  (head)	  of	  myosin	  linked	  to	  actin.	   Myosin	  head	  is	  able	  to	  hydrolyze	  ATP	  and	  converting	  chemical	  energy	  into	  mechanical	  energy.	  	  	  
	  
Fig.2:	  Schematic	  representation	  of	  skeletal	  muscle	  sarcomere.	  
	  To	   allow	   the	   simultaneous	   contraction	   of	   all	   sarcomeres,	   the	   sarcolemma	  penetrates	  into	  the	  cytoplasm	  of	  the	  muscle	  cell	  between	  myofibrils,	  forming	  membranous	  tubules	  called	  transverse	  tubules	  (T-­‐tubules)	  (Figure	  3).	  The	  T-­‐tubules	   are	   electrically	   coupled	  with	   the	   terminal	   cisternae	  which	   continue	  into	   the	  sarcoplasmic	  reticulum.	  Thus	   the	  Sarcoplasmic	  Reticulum,	  which	   is	  the	  enlargement	  of	  smooth	  Endoplasmic	  Reticulum	  (ER)	  and	  which	  contains	  the	   majority	   of	   calcium	   ions	   required	   for	   contraction,	   extends	   from	   both	  sides	  of	  T-­‐tubules	  into	  the	  myofibrils.	  Anatomically,	  the	  structure	  formed	  by	  T-­‐tubules	  surrounded	  by	   two	  smooth	  ER	  cisternae	   is	   called	   the	   triad	  and	   it	  allows	  the	  transmission	  of	  membrane	  depolarization	  from	  the	  sarcolemma	  to	  the	   ER.	   The	   contraction	   starts	   when	   an	   action	   potential	   diffuses	   from	   the	  motor	  neuron	  to	  the	  sarcolemma	  and	  then	  it	  travels	  along	  T-­‐tubules	  until	   it	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reaches	   the	   sarcoplasmic	   reticulum.	   Here	   the	   action	   potential	   changes	   the	  permeability	  of	  the	  sarcoplasmic	  reticulum,	  allowing	   the	  flow	  of	  calcium	  ions	  into	  the	  cytosol	  between	  the	  myofibrils.	  The	  release	  of	  calcium	  ions	  induces	  the	  myosin	  heads	  to	  interact	  with	  the	  actin,	  allowing	  the	  muscle	  contraction.	  The	   contraction	   process	   is	   ATP	   dependent,	   the	   energy	   is	   provided	   by	  mitochondria	  which	  are	  located	  closed	  to	  Z	  line	  and	  also	  is	  determine	  by	  fibre	  type	  composition.	  
	  
Fig.3:	  Schematic	  representation	  of	  organization	  of	  T-­‐tubuls	  and	  triad	  in	  skeletal	  muscle.	  
	  Mammalian	  muscle	  fibres	  are	  divided	  into	  distinct	  classes	  :	  type	  I,	  also	  called	  slow	  fibres,	  and	  type	  II	  fast	  fibres.	  This	  classification	  is	  specific	  only	  for	  	  the	  mechanical	  properties.	  However,	  the	  diversity	  between	  muscle	  fibers	   is	  due	  also	   a	   peculiar	   features	   such	   as	   for	   example	   myosin	   ATPase	   enzymes,	  predominance	   of	   glycolytic	   or	  mitochondrial	   activities	   and	   is	   exents	   to	   any	  subcellular	   system	   .	   The	   different	   fibre	   types	   are	   also	   characterized	   by	  different	   Myosin	   Heavy	   Chain	   (MHC)	   proteins	   expression.	   The	   fibre	   type	   I	  expresses	   the	   slow	   isoform	   of	   MHC	   (MHCβ	   or	   MHC1),	   and	   shows	   a	   great	  content	   of	   mitochondria,	   high	   levels	   of	   myoglobin,	   high	   capillary	   densities	  and	   high	   oxidative	   capacity.	  Muscles	   containing	  many	   type	   I	   fibres	   display	  red	  colour	  for	  the	  great	  vascularization	  and	  for	  the	  high	  myoglobin	  content.	  The	  type	  II,	   fast,	  myofibers	  are	  divided	  in	  three	  groups	  depending	  on	  which	  myosin	  is	  expressed.	  In	  fact	  distinct	  genes	  encode	  for	  MHC	  IIa,IIx	  (also	  called	  IId)	   and	   IIb.	   Type	   IIa	   myofibers	   are	   faster	   than	   type	   I,	   but	   they	   are	   still	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relatively	   fatigue-­‐resistant.	   IIa	   fibers	   are	   relatively	   slower	   than	   IIx	   and	   IIb	  and	   have	   an	   oxidative	  metabolism	  due	   to	   the	   rich	   content	   of	  mitochondria	  (Schiaffino	   and	   Reggiani,	   2011)(Schiaffino	   and	   Reggiani,	   1996).	   Given	   all	  these	   characteristics,	   IIa	   fibres	   are	   also	   defined	   fast	   oxidative	   fibres.	   They	  exhibit	   fast	   contraction,	   high	   oxidative	   capacity	   and	   a	   relative	   fatigue	  resistance.	   The	   IIx	   and	   IIb	   fibre	   types	   are	   called	   fast-­‐glycolitic	   fibres	   and	  show	   a	   prominent	   glycolitic	   metabolism	   containing	   few	   mitochondria	   of	  small	  size,	  high	  myosin	  ATPase	  activity,	  expression	  of	  MHC	  IIb	  and	  MHC	  IIx	  proteins,	  the	  fastest	  rate	  of	  contraction	  and	  the	  highest	  level	  of	  fatigability.	  	  The	   fibre-­‐type	   profile	   of	   different	   muscles	   is	   initially	   established	   during	  development	   independently	   of	   neural	   influence,	   but	   nerve	   activity	   has	   a	  major	   role	   in	   the	   maintenance	   and	   modulation	   of	   its	   properties	   in	   adult	  muscle.	   Indeed	   during	   postnatal	   development	   and	   regeneration,	   a	   default	  nerve	  activity-­‐independent	  pathway	  of	  muscle	  fibre	  differentiation,	  which	  is	  controlled	  by	  thyroid	  hormone,	  leads	  to	  the	  activation	  of	  a	  fast	  gene	  program.	  On	  the	  contrary,	  the	  post	  natal	   induction	  and	  maintenance	  of	  the	  slow	  gene	  program	   is	   dependent	   on	   slow	  motoneuron	   activity.	   The	  muscle	   fibre-­‐type	  then	  undergoes	  further	  changes	  during	  postnatal	  life,	  for	  example	  fibre-­‐type	  switching	   could	   be	   induced	   in	   adult	   skeletal	   muscles	   by	   changes	   in	   nerve	  activity	  (Murgia	  et	  al.,	  2000).	  The	   transcription	   of	   different	   fiber	   type-­‐specific	   genes	   must	   be	   precisely	  coordinated	  in	  skeletal	  muscle	  fibers	  to	  maintain	  muscle	  function	  during	  the	  transition	   phase.	   Different	   signaling	   pathways	   control	   muscle	   fiber	   type–specific	  gene	  programs,	  moreover	  fiber	  type	  transformation	  involves	  changes	  in	   all	   muscle	   cell	   compartments,	   including	   components	   of	   the	   excitation-­‐contraction	   coupling,	   cell	   metabolism,	   and	   contractile	   machinery.	   Muscle	  fiber	   type	   switching	   involves	   the	   coordinated	   antithetic	   regulation	   of	  different	  fast	  and	  slow	  gene	  programs.	  The	  first	  mechanism	  involves	  the	  role	  of	   transcription	   factors,	   such	  as	   the	  calcineurin-­‐dependent	  nuclear	   factor	  of	  activated	  T-­‐cells	   (NFAT)	   transcription	   factors	   	   that	  may	  act	  as	  activators	  or	  repressors	   of	   distinct	  MyHC	   genes.	   A	   second	  mechanism,	   operating	   in	   cis	   ,	  involves	   the	   role	   of	   bidirectional	   promoters	   located	   between	   closely	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associated	  MyHC	  genes	  and	  a	  third	  mechanism	  for	  coordinated	  regulation	  of	  fast	   and	   slow	   gene	   programs	   involves	   some	   muscle-­‐specific	   microRNAs	  (miRNAs)	   that	   are	   located	  within	  MYH	  genes	   .These	   include	  miR-­‐208b	   and	  miR-­‐499	   ,	   indeed	   experiments	   of	   deletion	   have	   shown	   that	   miR-­‐208b	   and	  miR-­‐499	  play	  redundant	  roles	  in	  the	  specification	  of	  muscle	  fiber	  identity	  by	  activating	   slow	   and	   repressing	   fast	   myofiber	   gene	   programs:	   deletion	   of	  either	   miR-­‐208b	   or	   miR-­‐499	   did	   not	   alter	   the	   fiber	   type	   profile,	   whereas	  double	   knockout	   mice	   showed	   a	   marked	   slow-­‐to-­‐fast	   switch	   in	   fiber	   type	  profile	  and	  MyHC	  expression	  .(Schiaffino	  and	  Reggiani,	  2011).	  (Figure	  4)	  
	  	  	  	  	  	  	  	  	  	   	  
Fig.4:	   The	   mechanisms	   for	   the	   coordinated	   regulation	   of	   different	   Myh	   genes	   during	  
fiber	  type	  switching.	  
A)transcription	   factors	   acting	   as	   both	   activators	   (green)	   and	   repressors	   (red)	   of	  Myh	  
genes,	   such	  as	  NFATc1;	  B)	   bidirectional	   promoters	   generating	  both	   sense	   (green)	   and	  
antisense	  (red)	  transcripts	  of	  tandem	  genes	  C)	  microRNAs	  hosted	  in	  Myh	  genes,	  like	  miR-­‐
499	  embedded	  in	  Myh7b	  and	  mir-­‐208b	  embedded	  in	  Myh7,	  which	  inhibit	  transcriptional	  
repressors.Dotted	  lines	  indicate	  that	  the	  mechanism	  of	  repression	  of	  fast	  Myh	  genes	  by	  
miR-­‐499	  and	  miR-­‐208b	  is	  indirect	  and	  as	  yet	  undefined.	  
	  
1.2	  MUSCLE	  HYPERTROPHY	  AND	  ATROPHY	  	  Maintenance	   of	   skeletal	   muscle	   mass	   is	   essential	   for	   health	   and	   survival.	  Skeletal	  muscle	  mass	   and	  muscle	   fiber	   size	   vary	   according	   to	   physiological	  and	   pathological	   conditions	   and	   this	   is	   due	   to	   several	   mechanisms	   that	  regulate	  the	  rate	  of	  muscle	  growth	  and	  muscle	  loss.	  This	  event	  is	  the	  result	  	  of	  a	  balance	  between	  protein	   synthesis	   and	  degradation.	   In	  particular,	  muscle	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growth	   is	   mainly	   due	   to	   protein	   synthesis,	   that,	   when	   exceeds,	   leads	   to	  muscle	  hypertrophy.	  On	  the	  contrary,	  excessive	  protein	  degradation,	   loss	  of	  organelles	  and	  cytoplasm	  are	  major	  causes	  of	  muscle	  atrophy.	  
1.2.1	  MUSCLE	  HYPERTROPHY	  
	  Skeletal	  muscle	   is	   a	   highly	   plastic	   tissue	   that	  modifies	   its	   size	   through	   the	  regulation	  of	   signaling	  pathways	   that	   control	  protein	   synthesis	   and	  protein	  degradation.	  The	  adaptive	  changes	  of	  muscle	  fibers	  can	  occur	  in	  response	  to	  different	   stimuli	   like	   for	   example	   neural	   stimulation,	   loading	   conditions,	  exercise,	  and	  hormonal	  signals.	  Muscle	  hypertrophy	  happen	  when	  the	  overall	  rates	   of	   protein	   synthesis	   exceed	   the	   rates	   of	   protein	   degradation	   and	   it	   is	  characterized	  by	  an	   increase	   in	   size	  of	   skeletal	  muscle	   through	  a	  growth	   in	  size	   of	   its	   component	   cells.	   Actually,	   two	  major	   signaling	   pathways	   control	  protein	   synthesis,	   the	   IGF1–Akt–mTOR	   pathway,	   acting	   as	   a	   positive	  regulator,	   and	   the	   Myostatin–Smad2/3	   pathway,	   acting	   as	   a	   negative	  regulator,	  but	  also	  additional	  pathways	  have	  recently	  been	  identified	  (figure	  5).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Fig.5:	  Major	  pathways	  that	  control	  muscle	  fiber	  size.	  (Bonaldo	  and	  Sandri,	  2013).	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  It	   has	   been	   well	   demonstrated	   that	   the	   Akt/mTOR	   signaling	   pathway	   is	   a	  major	   regulator	   of	   muscle	   growth,	   indeed	   muscle-­‐specific	   IGF-­‐1	   over-­‐expression	   in	   transgenic	   mice	   results	   in	   muscle	   hypertrophy	   and,	  importantly,	   the	   growth	   of	   muscle	   mass	   matches	   with	   a	   physiological	  increase	   of	   muscle	   strength. Furthermore,	   the	   over-­‐expression	   of	   a	  constitutively	   active	   form	   of	   AKT,	   a	   downstream	   target	   of	   IGF-­‐1,	   in	   adult	  skeletal	  muscle	   induced	  muscle	   hypertrophy	   and	   also	  AKT	   transgenic	  mice	  display	   muscle	   hypertrophy	   and	   protection	   from	   denervation-­‐induced	  atrophy,	   showing	   that	   AKT	   pathway	   promotes	   muscle	   growth	   and	  simultaneously	  blocks	  protein	  degradation	  (Schiaffino	  et	  al.,	  2013).	  Moreover,	   Akt	   kinase	   promotes	   hypertrophy	   by	   activating	   downstream	  signalling	  pathways	  throught	  the	  phosphorilation	  of	  different	  substrates	  	  that	  can	  act	  in	  different	  ways	  on	  protein	  synthesis. The	  pathways	  downstream	  of	  mammalian	   target	   of	   rapamycin	   (mTOR)	   and	   the	   pathway	   activated	   by	  phosphorylating	   and	   thereby	   inhibiting	   glycogen	   synthase	   kinase	   3	   (GSK3)	  (Rommel	   et	   al.,	   2001).	   In	   the	   first	   case,	   AKT	   activates	  mTOR,	   that	   is	   a	   key	  regulator	   of	   cell	   growth,	   promoting	   the	   activation	   of	   S6	   kinase	   (S6K)	   and	  blocking	   the	   inhibition	   of	   eif4e	   binding	   protein	   1	   (4EBP1)	   on	   eukaryotic	  translation	   initiation	   factor	   4E	   (eif4e),	   thus	   leading	   to	   protein	   synthesis.	   In	  the	   other	   case,	   the	   inhibition	   of	   GSK3β	   from	   AKT	   stimulates	   proteins	  synthesis,	  since	  GSK3β	  normally	  blocks	  protein	  translation	  initiated	  by	  eIF2B	  protein	   (Glass,	   2005).	  However,	  Akt	   is	   able	   to	   suppress	   catabolic	   pathways	  blocking	   protein	   degradation.	   IGF-­‐1	   treatment	   or	   AKT	   overexpression	  inhibits	  	  FoxO	  expression	  in	  myotubes	  and	  also	  prevents	  induction	  of	  atrophy	  mediators,	   Atrogin-­‐1	   and	   MuRF1	   (Sandri	   et	   al.,	   2004;	   Stitt	   et	   al.,	   2004).	  Recently,	   it	   has	   been	   reported	   that	   also	   TGF-­‐β	   pathway	   contributes	   to	  regulation	   of	  muscle	  mass	   in	   adulthood	   (Sartori	   et	   al.,	   2009).	   Activation	   of	  TGF-­‐β	  signaling	   for	  example	  by	  myostatin	  treatment	  or	  overexpression	  was	  	  linked	  with	  decreased	  phosphorylation	  of	  Akt	  and	  other	  mTOR	  downstream	  target	  such	  as	  ribosomal	  protein	  S6,	  p70S6K	  and	  4E-­‐BP1	  (Amirouche	  et	  al.,	  2009).	  
	   19	  
Bone	  morphogenetic	  protein	  (BMP)	  signalling,	  acting	  through	  Smad1,	  Smad5	  and	  Smad8	  (Smad1/5/8),	   is	  one	  of	   the	   fundamental	  hypertrophic	  signals	   in	  mice. In	  support	  of	  this,	  Sartori	  et	  al.	  showed	  that	  when	  the	  BMP	  pathway	  is	  blocked	  or	  myostatin	  expression	  is	  increased,	  more	  Smad4	  is	  phosphorylated	  by	  Smad2/3,	  leading	  to	  an	  activation	  of	  atrophic	  pathway. Importantly, they	  identify	  a	  new	  E3	  ubiquitin-­‐ligase,	  named	  MUSA1,	  that	  is	  negatively	  regulated	  by	  BMP	  SMAD1-­‐5-­‐8	   signal	   and	   is	   required	   for	  muscle	  mass	   loss.	  This	  work	  provided	  evidences	  that	  also	  BMP	  signalling	   is	   involved	   in	   the	  regulation	  of	  adult	   muscle	   mass	   in	   normal	   and	   pathological	   conditions	   (Sartori	   et	   al.,	  2013).	  
1.2.2	  MUSCLE	  ATROPHY	  	  
 The	  loss	  of	  muscle	  mass	  also	  known	  as	  muscle	  atrophy,	  is	  a	  complex	  process	  that	   occurs	   as	   a	   consequence	   of	   a	   variety	   of	   stressors,	   including	   neural	  inactivity,	   mechanical	   unloading,	   inflammation,	   metabolic	   stress,	   and	  elevated	  glucocorticoids.	  In	  1969,	  Goldberg	  demonstrated	  that	  an	  increase	  in	  protein	  degradation	  contributed	  to	  the	  loss	  of	  muscle	  mass	  and	  myofibrillar	  proteins	   following	   denervation	   and	   glucocorticoid	   treatment	   (Goldberg,	  1969).	   In	   all	   of	   these	   catabolic	   states,	   the	   loss	   of	   muscle	   mass	   involves	   a	  common	  pattern	  of	  transcriptional	  changes,	  including	  induction	  of	  genes	  for	  protein	  degradation	  and	  decreased	  expression	  of	   various	  genes	   involved	   in	  different	   cellular	   processes	   like	   energy	   production	   and	   various	   genes	   for	  growth-­‐related	   processes.	   This	   group	   of	   coordinately	   regulated	   genes	   are	  called	   “atrogenes”(Lecker	   et	   al.,	   2006).	   Among	   the	   upregulated	   atrophy-­‐related	  genes	  there	   is	  a	  subset	  of	   transcripts	  related	  to	  protein	  degradation	  pathways.	   In	  particular,	   there	   is	  a	  dramatic	   (8-­‐	   to	  40-­‐fold)	   induction	  of	   two	  muscle-­‐specific	   ubiquitin	   ligases,	   atrogin-­‐1/MAFbx	   and	   MuRF-­‐1,	   whose	  induction	   occurs	   before	   the	   onset	   of	   muscle	   weight	   loss	   and	   which	   is	  necessary	   for	   rapid	   atrophy	   (Gomes	   et	   al.,	   2001).	   Atrogin-­‐1,	   also	   known	  as	  MAFbx,	  contains	  an	  F-­‐box	  domain,	  a	  protein	  motif	  of	  approximately	  50	  amino	  acids	  that	  functions	  as	  a	  site	  of	  protein-­‐protein	  interaction	  and	  belong	  to	  SCF	  
	   20	  
complex	   (Skp1,	   Cullin,	   F-­‐box)(Gomes	   et	   al.,	   2001).	   The	   F-­‐box	   protein	  interacts	  with	  the	  substrates,	  while	  Cul1-­‐Roc1	  components	  are	  associate	  with	  the	  E2	  Ub-­‐conjugating	  enzymes,	  finally	  Skp1	  is	  an	  adaptor	  that	  brings	  F-­‐box	  protein	   to	   the	   Cul1-­‐Roc1-­‐E2	   complex.	   Most	   substrates	   require	   the	  phosphorylation	   to	   interact	   with	   the	   F-­‐box	   protein	   in	   an	   SCF	   complex	  (Jackson	   and	   Eldridge,	   2002).	  MuRF1	   belongs	   to	   the	   RING	   finger	   E3	   ligase	  subfamily,	   characterized	   by	   three	   RING-­‐finger	   domains	   (Borden	   and	  Freemont,	  1996)	  which	  are	  required	  for	  ubiquitin-­‐ligase	  activity	  (Kamura	  et	  al.,	  1999).	  These	  domains	   include	  a	  B-­‐box,	  whose	   function	   is	   still	  unknown,	  and	   a	   coiled-­‐coil	   domain,	   which	   may	   be	   required	   for	   the	   formation	   of	  heterodimers	   between	   MuRF1	   and	   a	   related	   protein,	   MuRF2.	   Knockout	  animals	   lacking	   either	  MuRF1	   or	   atrogin-­‐1	   show	   a	   reduced	   rate	   of	  muscle	  atrophy	  after	  denervation	  (Bodine	  et	  al.,	  2001),	  confirming	  that	  these	  ligases	  are	  necessary	  for	  the	  atrophy	  program.	  The	  molecules	  and	  cellular	  pathways	  regulating	   skeletal	   muscle	   atrophy	   are	   still	   being	   discovered;	   however,	  tremendous	  progress	  has	  been	  made	  in	  the	  last	  decade	  to	  identify	  other	  key	  transcription	   factors,	  signaling	  pathways,	  and	  cellular	  processes	   involved	   in	  the	   initiation	   and	   sustained	   breakdown	   of	  muscle	  mass	   under	   a	   variety	   of	  conditions	  (Bodine	  and	  Baehr,	  2014).	  Moreover,	  muscle	   loss	   is	  mediated	  by	  two	   highly	   conserved	   pathways:	   ubiquitin-­‐proteasomal	   system	   (UPS)	   and	  autophagy-­‐lisosomal	  pathway	  (ALP)	  and	  several	  evidences	  strongly	  support	  a	  major	  role	  of	  UPS	  during	  muscle	  loss. 	  
1.3	  PROTEIN	  DEGRADATION	  SYSTEMS	  
	  Eukaryotes	   have	   two	   major	   intracellular	   protein	   degradation	   pathways,	  namely	  the	  ubiquitin-­‐proteasome	  system	  (UPS)	  and	  autophagy.	  Proteasomal	  degradation	   has	   high	   selectivity;	   the	   proteasome	   generally	   recognizes	   only	  ubiquitinated	   substrates,	   which	   are	   primarily	   short-­‐lived	   proteins.	   By	  contrast,	   degradation	   by	   lysosome	   is	   specific	   for	   long-­‐lived	   protein	   and	   in	  this	   case	   cytosolic	   components	   and	   organelles	   can	   be	   delivered	   to	   the	  lysosome	  by	  autophagy	  (Mizushima	  and	  Komatsu,	  2011).	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1.3.1	  UBIQUITIN	  PROTEASOME	  SYSTEM	  	  The	  Ubiquitin	  Proteasome	  System	  (UPS)	  is	  one	  of	  the	  mayor	  mechanism	  that	  control	  proteolysis	  and,	  ubiquitination	  of	  protein	  substrates.	  It	  is	  required	  to	  clear	   the	   cell	   from	   dysfunctional	   and	   altered	   proteins	   and	   is	   reported	   to	  increase	   during	   catabolic	   conditions. Through	   the	   concerted	   actions	   of	   a	  series	  of	  enzymes,	  proteins	  are	  marked	  for	  proteasomal	  degradation	  by	  being	  linked	  to	  the	  polypeptide	  co-­‐factor,	  ubiquitin.	   	  The	  ubiquitination	  of	  protein	  substrates,	   occurs	   through	   the	   sequential	   action	   of	   distinct	   enzymes:	  E1(ubiquitin-­‐activating	   enzyme),	   E2(ubiquitin-­‐conjugating	   enzyme)	   and	  E3(ubiquitin-­‐protein-­‐ligase).	  The	  rate	  limiting	  enzyme	  of	  UPS	  is	  the	  E3	  which	  catalyzes	  the	  transfer	  of	  ubiquitin	  from	  the	  E2	  to	  the	  lysine	  in	  the	  substrate.	  This	   reaction	   is	   highly	   specific.	   Thus,	   the	   amount	   and	   the	   type	   of	   proteins	  degraded	  by	   the	  proteasome	   is	   largely	  determined	  by	  which	  E3	   ligases	   are	  activated.	   This	   tagging	   process	   leads	   to	   their	   recognition	   by	   the	   26S	  proteasome,	   a	   very	   large	   multicatalytic	   protease	   complex	   that	   degrades	  ubiquitinated	  proteins	  to	  small	  peptides	  (figure	  6).	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  Fig.6:	  The	  ubiquitin	  (Ub)-­‐proteasome	  pathway	  (UPP)	  of	  protein	  degradation.(Lecker	  et	  
al.,	  2006)	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The	   ubiquitin-­‐proteasomal	   pathway	   is	   constitutively	   operative	   in	   normal	  skeletal	   muscle	   and	   is	   responsible	   for	   the	   turnover	   of	   most	   soluble	   and	  myofibrillar	  muscle	  proteins	  upon	  changes	   in	  muscle	  activity	   (Lecker	  et	  al.,	  2006).	   A	   decrease	   in	   muscle	   mass	   is	   associated	   with:	   (1)	   increased	  conjugation	   of	   ubiquitin	   to	   muscle	   proteins;	   (2)	   increased	   proteasomal	  ATPdependent	   activity;	   (3)	   increased	   protein	   breakdown	   that	   can	   be	  efficiently	   blocked	   by	   proteasome	   inhibitors;	   and	   (4)	   upregulation	   of	  transcripts	   encoding	  ubiquitin,	   some	  ubiquitin-­‐conjugating	   enzymes	   (E2),	   a	  few	  ubiquitin-­‐protein	  ligases	  (E3)	  and	  several	  proteasome	  subunits.	  Moreover,	  among	   the	  different	  E3s,	  only	  a	   few	  have	  been	   found	   to	  regulate	  atrophy	   process	   and	   to	   be	   transcriptionally	   induced	   in	   atrophying	  muscle.	  	  The	  first	  to	  be	  identified	  were	  Atrogin-­‐1/MAFbx	  and	  MuRF1.	  These	  two	  E3s	  are	  specifically	  expressed	  in	  striated	  and	  smooth	  muscles.	  Atrogin-­‐1/MAFbx	  and	   MuRF1	   knockout	   mice	   are	   resistant	   to	   muscle	   atrophy	   induced	   by	  denervation	   (Bodine	   et	   al.,	   2001),	   while	   knockdown	   of	   Atrogin-­‐1	   spare	  muscle	  mass	  in	  fasted	  animals	  (Cong	  et	  al.,	  2011).	  	  Since	   two	   ubiqutin	   ligases	   cannot	   effort	   for	   the	   degradation	   of	   all	   the	  sarcomeric	  and	  soluble	  proteins,	  additional	  E3s	  are	  involved	  in	  muscle	  loss	  in	  fact	   the	   characterization	   of	   these	   E3s	   and	   their	   respective	   substrates	   in	  skeletal	   muscle	   atrophy	   might	   be	   an	   important	   step	   to	   understand	   the	  mechanisms	  that	  control	  muscle	  mass	  loss	  and,	  moreover,	  to	  develop	  targets	  for	  pharmacological	  intervention	  in	  muscle	  disease.	  
1.3.2	  AUTOPHAGY-­‐LYSOSOMAL	  SYSTEM	  
	  Autophagy	   is	   an	   evolutionarily	   conserved	   process	   that	   is	   induced	   under	  nutrient	  poor	  conditions	  to	  allow	  cells	  to	  degrade	  and	  recycle	  the	  breakdown	  products	   that	   are	   released	   into	   the	   cytoplasm,	   where	   they	   presumably	  provide	  a	  source	  of	  metabolites	  to	  support	  biosynthesis	  and	  other	  processes.	  Autophagy	   is	   also	   responsible	   for	   the	   degradation	   of	   protein	   aggregates,	  which	  would	  otherwise	  accumulate	  and	  cause	  cytotoxicity.	  Three	  main	  types	  of	   autophagy	   exist:	   chaperone-­‐mediated	   autophagy,	   microautophagy,	   and	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macroautophagy,	  all	  of	  which	  function	  to	  deliver	  intracellular	  contents	  to	  the	  lysosome	   (figure	   7).	   In	   chaperone-­‐mediated	   autophagy,	   cytosolic	   proteins	  are	   selectively	   and	   individually	   transported	   into	   the	   lysosome	   for	  degradation.	   In	   microautophagy,	   a	   portion	   of	   the	   cytoplasm	   is	   directly	  engulfed	   by	   the	   lysosome.	   In	   macroautophagy	   (hereafter	   referred	   to	   as	  autophagy),	   cytoplasmic	   components	   including	  proteins	  and	  organelles,	   are	  engulfed	  by	  double-­‐membrane	  structures	  known	  as	  autophagosomes,	  which	  fuse	   to	   lysosomal	   vesicles	   where	   the	   contents	   are	   degraded	   into	   their	  components	  (for	  example,	  from	  proteins	  to	  aminoacids).	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Fig.7:	  Scheme	  of	  the	  different	  type	  of	  autophagy:	  macroautophagy	  (a),	  microautophagy	  
(b),	  chaperone-­‐mediated	  autophagy	  (c)	  (Cuervo,	  2011).	  In	   addition,	   autophagy	   can	   be	   upregulated	   during	   metabolic,	   genotoxic,	   or	  hypoxic	   stress	   conditions	   and	   acts	   as	   an	   adaptive	  mechanism	   essential	   for	  cell	   survival.	   The	   generation	   of	   transgenic	   mice	   for	   LC3,	   the	   mammalian	  homolog	   of	   the	   essential	   autophagy	   gene	  Atg8,	   fused	  with	  GFP	   defined	   the	  amount	  of	  autophagy	  in	  different	  tissues	  and	  the	  capacity	  of	  	  different	  organs	  to	   respond	   fasting	  by	  activating	  autophagosome	   formation.	   Indeed,	   skeletal	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muscle	  has	  been	  found	  to	  be	  one	  of	  the	  tissues	  with	  the	  highest	  induction	  of	  autophagy.	   In	   fast	   skeletal	   muscle	   of	   transgenic	   mice,	   food	   deprivation	  induced	  the	  rapid	  appearance	  of	  cytoplasmic	  fluorescent	  dots,	  corresponding	  to	  autophagosomes	  (Mizushima	  et	  al.,	  2004).	  Skeletal	  muscle	   is	  a	  major	  site	  of	  metabolic	   activity	   and	   serves	   as	   a	   source	   of	   aminoacids	   because	   during	  catabolic	  periods	  amino	  acids	  generated	  from	  muscle	  protein	  breakdown	  are	  utilized	   by	   the	   liver	   to	   produce	   glucose	   and	   to	   support	   acutephase	   protein	  synthesis	  (Lecker	  et	  al.,	  2006).	  This	  role	  in	  recycling	  is	  complementary	  to	  that	  of	   the	   ubiquitin-­‐proteasome	   system,	   which	   degrades	   proteins	   to	   generate	  oligopeptides	  that	  are	  subsequently	  degraded	  into	  amino	  acids	  (Lecker	  et	  al.,	  2006).	  Restoration	  of	  cellular	  (or	  local)	  levels	  of	  amino	  acids	  reactivates	  the	  serine/threonine	   protein	   kinase	  mTORC1	   (mammalian	   target	   of	   rapamycin	  complex	   1)	   and	   terminates	   autophagy	   (Yu	   et	   al.,	   2010).	   Autophagy	   is	  suppressed	   by	   mTOR,	   which	   is	   in	   turn	   controlled	   directly	   by	   the	   level	   of	  intracellular	   amino	  acids	  and	   indirectly	  by	  growth	   factors	  via	  Akt/PKB	  and	  cell	   energy	   status	   via	  AMPK.	  Accordingly,	   rapamycin,	   a	   specific	   inhibitor	   of	  mTOR,	   activates	   autophagy.	   However,	   autophagy	   can	   also	   be	   induced	   by	  mTOR-­‐independent	   mechanisms:	   leucine	   starvation	   has	   been	   reported	   to	  induce	  mTOR-­‐independent	  autophagy	   in	  cultured	  myotubes	   (Mordier	  et	  al.,	  2000).	  Autophagy	   is	   induced	   in	  skeletal	  muscle	   in	   the	   immediate	  post-­‐natal	  period	  when	   glycogen-­‐filled	   autophagosomes	   are	   abundant	   (Schiaffino	   and	  Hanzlikova,	   1972).	   The	   crucial	   role	   of	   autophagy	   in	   the	   newborn	   is	  demonstrated	  by	  the	  finding	  that	  mice	  deficient	  in	  autophagy	  genes	  Atg5	  or	  Atg7	   die	   soon	   after	   birth	   during	   the	   critical	   starvation	   period	   when	  transplacental	  nutrient	  supply	  is	  suddenly	  interrupted	  (Komatsu	  et	  al.,	  2005;	  Kuma	   et	   al.,	   2004).	   Autophagy	   is	   also	   implicated	   in	   wide	   range	   of	   diverse	  human	  diseases,	  plays	  a	  role	  also	  in	  muscular	  disorders,	  such	  as	  Pompe	  and	  Danon	  disease	  and	  X-­‐linked	  myopathy,	  liver	  diseases	  and	  pathogen	  infection	  (Levine	  and	  Kroemer,	  2008).	  In	  particolar	  in	  skeletal	  muscle,	  both	  excessive	  and	  defective	  autophagy	  are	  highly	  correlated	  with	   the	   loss	  of	  muscle	  mass	  (Petrovski	  and	  Das,	  2010),	   instead	  muscle	  atrophy	  can	  be	  a	  consequence	  of	  lack	  of	  autophagy,	  shown	  through	  muscle-­‐specific	  ablation	  of	   the	  Atg7	  gene	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(encoding	   autophagy-­‐related	   protein-­‐7)	   (Masiero	   et	   al.,	   2009)	   or	   the	   Atg5	  gene	   (Raben	   et	   al.,	   2008),	   two	   key	   autophagy	   genes;	   although	   in	   Atg5-­‐deficient	  muscle,	  pathology	  was	  less	  severe.	  Moreover,	  Grumati	  et	  al.	  showed	  that	  muscle	  atrophy	   in	  Col6a1-­‐deficient	  mice	  (models	  of	  Bethlem	  myopathy	  and	   Ullrich	   congenital	   muscular	   dystrophy	   (UCMD)	   was	   ameliorated	   by	   a	  low-­‐protein	   diet	   and	   by	   genetic	   and	   pharmacologic	   approaches	   that	   can	  activate	   autophagy.	   Indeed,	   loss	   of	   collagen-­‐6	   leads	   to	   an	   activation	   of	   Akt,	  which	   decreases	   autophagy	   through	   inactivation	   of	   the	   transcription	   factor	  FoxO3	  and	  activation	  of	  mTOR	  (Grumati	  et	  al.,	  2010).	  	  
1.4	  THE	  FoxO	  FAMILY	  OF	  TRASCRIPTION	  FACTORS	  The	  FoxO	  family	   is	  a	  subclass	  of	  Forkhead	  transcription	   factors.	   In	  humans,	  Forkhead	   proteins	   (Fox)	   have	   been	   divided	   on	   the	   basis	   of	   sequence	  similarity,	  into	  19	  subgroups	  which	  are	  classified	  by	  alphabetic	  letters	  form	  A	  to	  S.	  Fox	  proteins	  contain	  a	  sequence	  of	  80–100	  amino	  acids	  forming	  a	  motif	  that	  binds	  to	  DNA:	  the	  forkhead	  motif.	  This	  motif	  is	  also	  known	  as	  the	  winged	  helix	  due	  to	  the	  butterfly	  like	  appearance	  of	  the	  loops	  in	  the	  protein	  structure	  of	   the	   domain	   (Kaestner	   et	   al.,	   2000).	   FoxO	   subfamily	   is	   conserved	   from	  
Caenorhabditis	   elegans	   to	   mammalians.	   	   In	   addition	   to	   the	   forkhead	   DNA-­‐binding-­‐domain	  motif,	   FoxO	   factors	   contain	   a	  nuclear	   localization	   sequence	  (NLS),	  a	  nuclear	  export	  sequence	  (NES),	  and	  a	  transactivation	  domain	  in	  their	  C	  terminal	  region	  in	  which	  a	  helical	  motif	  (LXXLL,	  where	  L	  is	  a	  leucine	  and	  X	  any	  amino	  acid)	  is	  quite	  important	  for	  FoxO	  transcriptional	  activity	  (Nakae	  et	  al.,	   2006).	   Importantly,	   FoxO1,	   3	   and	   6	   proteins	   have	   similar	   length	   of	  approximately	  650	  amino-­‐acid	  residues,	  whereas	  FoxO4	  sequence	  is	  shorter	  and	  contains	  about	  500	  amino-­‐acid	  residues	  (Figure	  8).	  Analysis	  of	  multiple	  sequence	  alignment	   shows	   that	   several	   regions	  of	  FoxO	  proteins	  are	  highly	  conserved.	  The	  regions	  which	  display	  the	  highest	  sequence	  homology	  include	  N-­‐terminal	   region	   surrounding	   the	   AKT	   phosphorylation	   site	   (Thr32),	   the	  DBD	   (Dna	   binding	   domain),	   the	   region	   containing	   (NLS)	   and	   the	   COOH-­‐terminal	   trans	   activation	   domain	   (Obsil	   and	   Obsilova,	   2008).	   Because	   the	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DNA	  binding	  domain	   is	   shared,	  FoxOs	  should	  bind	  similar	  or	   identical	  DNA	  sequences	   within	   the	   genome.	   The	   core	   of	   consensus	   	   sequence	   has	   been	  determined	  by	  using	  gel	  shift	  experiments	  and	  it	  has	  the	  following	  sequence:	  5’-­‐TTGTTTAC-­‐3’.	  The	  members	  of	  the	  forkhead	  box	  class	  O	  (FoxO)	  subfamily	  are	   involved	   in	   several	   physiological	   and	   pathological	   processes,	   including	  aging,	   cancer,	   and	   neurological	   diseases	   and	   regulate	   metabolism,	   cellular	  proliferation,	  apoptosis,	  stress	  tolerance	  and	  possibly	  lifespan,	  thus	  they	  are	  highly	  conserved	  through	  evolution.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  
	  Fig.8;	   Description	   of	   mammalian	   FoxO	   proteins	   expressed	   in	   skeletal	   muscle.	   The	  
following	   are	   indicated:	   locations	   of	   the	   forkhead	   domain	   (FD),	   nuclear	   localization	  
sequence	   (NLS)	   nuclear	   export	   sequence	   (NES)and	   helical	   motif	   (LXXLL),Akt	  
phosphorylation	   sites	   (blue	   circles)	   and	   AMPK	   phosphorylation	   sites	   (red	   circles)	  
(Sanchez	  et	  al.,	  2014).	  
	  Caenorhabditis	   elegans	   and	   Drosophila	   each	   possess	   one	   FoxO	   factor,	  whereas	   the	   mammalian	   FoxO	   family	   comprises	   four	   members	   (FoxO1,	  FoxO3,	   FoxO4,	   and	   FoxO6)	   that	   mainly	   differ	   in	   their	   tissue-­‐specific	  expression.	  Nonetheless,	  it	  is	  notable	  that,	  contrary	  to	  FoxO1,3	  and	  4,	  which	  are	  expressed	  relatively	  ubiquitously,	  FoxO6	   is	  expressed	  predominantly	   in	  the	  central	  nervous	  system	  (Salih	  et	  al.,	  2012),	  although	  it	   is	  also	  present	  in	  oxidative	   muscles	   (Chung	   et	   al.,	   2013).	   All	   these	   trascription	   factors	   are	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inhibited	   by	   growth	   factor	   signaling.	   In	   the	   presence	   of	   insulin	   and	   insulin	  like	  growth	  factor	  (IGF)	  the	  phosphoinositide	  3	  kinase	  (PI3K)-­‐AKT	  signaling	  pathway	   is	   activated	   and	   protein	   Kinase	   AKT	   directly	   phosphorilates	   FoxO	  factors	   at	   three	   conserved	   residues,	   resulting	   in	   FoxO	   exclusion	   from	   the	  nucleus	   and	   repression	   of	   transcriptional	   activity	   (Brunet	   et	   al.,	   1999).	   An	  exception	   is	   FoxO6,	   which	   is	   phosphorylated	   at	   only	   2	   of	   three	  phosphorylation	  sites	  and	  it	  is	  not	  regulated	  by	  nucleus	  cytoplasmic	  shuttling	  (Jacobs	  et	  al.,	  2003).	   In	  the	  absence	  of	   insulin	  or	  growth	  factor	  signaling,	  or	  during	   starvation,	   FoxOs	   translocate	   to	   the	   nucleus	   where	   they	   activate	  programs	   of	   gene	   expression.	   On	   the	   other	   hand,	   also	   the	   adenosine	  monophosphate-­‐activated-­‐protein	   kinase	   (AMPK),	   positively	   regulated	   by	  stimuli	   that	   decrease	   cellular	   energy	   levels,	   phosphorylates	   FoxO3	   at	   six	  regulatory	   sites	   (Thr-­‐179,	  Ser-­‐399,	  Ser-­‐413,	  Ser-­‐355,	  Ser-­‐588,	  and	  Ser-­‐626)	  in	  vitro	  and	  promotes	  its	  activation	  (Greer	  et	  al.,	  2007)	  (figure	  9).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Fig.9;	  Antagonist	  regulation	  of	  FoxO	  proteins	  by	  the	  IGF-­‐1/	  PI3K/Akt	  axis	  and	  AMPK	  
(Sanchez	  et	  al.,	  2014).	  
	  
	  Moreover,	  AMPK	  activation	  is	  associated	  with	  increasing	  levels	  of	  FoxO1	  and	  FoxO3	  mRNAs	  and	  protein	  content.	  FoxOs	  are	   targeted	   for	  phosphorylation	  by	  a	  plethora	  of	  protein	  kinases	   in	  different	   residues.	  Each	  kinase	  modifies	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different	   sites	   on	  FoxOs	   and	   results	   in	   different	   changes	   in	   FoxO	   functions.	  These	  include	  JNK	  (Essers	  et	  al.,	  2004),	  MST1	  (Lehtinen	  et	  al.,	  2006),	  ERK	  and	  p38	   MAPK	   (Asada	   et	   al.,	   2007).	   This	   results	   in	   different	   type	   of	   post-­‐translational	  modifications	   (PTMs)	   such	  as	   acetylation/deacetylation,	  mono	  or	   polyubiquitination,	   glycosylation	   and	   arginine	   and	   lysine	   methylation	  (Eijkelenboom	  and	  Burgering,	  2013).	  These	  post-­‐translational	  modifications	  (PTMs)	   modify	   their	   transcriptional	   activities	   and	   also	   regulate	   the	  subcellular	  localization	  of	  FoxO	  family	  proteins,	  as	  well	  as	  their	  half-­‐life,	  DNA	  binding,	   transcriptional	   activity	   and	   ability	   to	   interact	   with	   other	   cellular	  proteins.	   Like	   phosphorylation,	   acetylation	   also	   regulates	   different	   FoxO	  protein	  functions.	  Multiple	  deacetylases	  and	  acetylases	  have	  been	  identified	  to	   modify	   FoxOs	   to	   change	   their	   DNA-­‐binding	   activity,	   stability	   and	  interaction	  with	   other	   proteins.	   FoxOs	   can	   be	   deacetylated	   by	   sirtuins	   and	  HDACs;	  however,	  the	  exact	  effect	  of	  FoxO	  deacetylation	  is	  still	  not	  clear.	  Sirt1,	  an	  NAD-­‐dependent	  class	  III	  HDAC,	  deacetylates	  FoxO3	  and	  forms	  a	  complex	  with	  FoxO3	  in	  response	  to	  oxidative	  stress	  (Brunet	  et	  al.,	  2004).	  However,	  the	  acetylation	   of	   FoxOs	   attenuates	   FoxO-­‐mediated	   transcriptional	   activity.	   For	  example,	  peroxide	  stress	  induces	  the	  binding	  of	  CBP	  to	  FoxO4	  and	  acetylates	  FoxO4,	   leading	   to	   the	   inhibition	   of	   FoxO4	   transcriptional	   activity	   (van	   der	  Horst	  et	  al.,	  2004).	  Recently,	  Bertaggia	  and	  colleagues	  	  have	  demonstrated	  in	  skeletal	   muscle	   that	   FoxO3	   interacts	   with	   the	   histone	   acetyl-­‐transferase	  p300,	  and	   its	  acetylation	  causes	  cytosolic	   relocalization	  and	  degradation.	   In	  particular	  they	  founded	  lysine	  262	  critical	  for	  FoxO3	  activity	  (Bertaggia	  et	  al.,	  2012). Moreover,	  others	  have	  confirmed	  the	  negative	  action	  of	  p300	  and	  CBP	  on	  FoxOs	  in	  skeletal	  muscle.	  In	  fact	  overexpression	  of	  HAT	  in	  soleus	  muscle	  inhibits	   FoxO3	   and	   FoxO4	   action	  while	   has	   no	   effect	   on	   FoxO1	   (Senf	   et	   al.,	  2011)	  (figure	  10).	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Fig.10;	  Schematic	  model	   for	   the	   regulation	   of	   FoxO	   transcription	   factors	   by	   reversible	  
phosphorylation	  and	  acetylation	  (Daitoku	  et	  al.,	  2011).	  The	  degradation	  of	  FoxOs	  is	  mediated	  by	  the	  ubiquitin-­‐	  proteasome	  pathway.	  It	   has	   been	   shown	   that	   FoxO	   proteins	   are	   also	   subject	   to	   poly-­‐	   and	  mono-­‐ubiquitination.	   The	  most	   important	   regulators	   of	   FoxOs	   trascription	   factor	  degradation	   are	   several	   E3	   ubiquitin	   ligases:	   Skp2,	   a	   subunit	   of	   the	  skp1/cul1/F-­‐box	  protein	  that	  ubiquitinates	  and	  promotes	  the	  degradation	  of	  FoxO1	   when	   it	   is	   phosphorylated	   by	   Akt	   (Huang	   et	   al.,	   2005),	   MDM2	   an	  ubiquitin	  ligase	  specific	  for	  p53	  which	  is	  able	  to	  bind	  FoxO1	  and	  3	  to	  promote	  their	  poly-­‐ubiquitination	  and	  degradation	   (Fu	  et	   al.,	   2009).	  As	   I	  mentioned,	  MDM2	  is	  considered	  to	  be	  an	  E3	  that	  promotes	  FoxO1-­‐3	  poly-­‐ubiquitination,	  recent	   findings	   have	   shown	   that	   MDM2	   also	   promotes	   FoxO4	   nuclear	  localization	   and	   increases	   transcriptional	   activity	   under	   oxidative	   stress	  (Brenkman	   et	   al.,	   2008).	   The	   diversity	   of	   this	   upstream	   regulation	   and	   the	  downstream	   effects	   of	   FoxOs	   suggest	   that	   they	   function	   as	   homeostasis	  regulators	   to	   maintain	   tissue	   homeostasis	   over	   time	   and	   coordinate	   a	  response	   to	   environmental	   changes,	   including	   growth	   factor	   deprivation,	  metabolic	   stress	   (starvation)	   and	   oxidative	   stress.	   Nevertheless,	   depending	  of	  their	  activation	  level,	  FoxO	  proteins	  can	  exhibit	  ambivalent	  functions.	  For	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example,	  a	  basal	  level	  of	  FoxO	  factors	  are	  necessary	  for	  cellular	  homeostasis	  and	   also	   to	  maintain	   quality	   control.	   However,	   exacerbated	   activation	  may	  occur	  in	  the	  course	  of	  several	  diseases,	  resulting	  in	  metabolic	  disorders	  and	  atrophy.	  
1.5	  REGULATION	  OF	  SKELETAL	  MUSCLE	  HOMEOSTASIS	  BY	  
FoxO	  PROTEINS.	  
	  Skeletal	   muscle	   shows	   singular	   adaptive	   capabilities	   in	   response	   to	   such	  stimuli	  as	  nutritional	  interventions,	  environmental	  factors	  (hypoxia),	  loading	  conditions,	   and	   contractile	   activity.	   All	   of	   these	   stimuli	   induce	   changes	   in	  energy	   metabolism	   and	   muscle	   mass,	   especially	   by	   altering	   the	   balance	  between	  protein	  synthesis	  and	  protein	  degradation	  or	  fiber	  composition.	  For	   this	   reason,	   FoxO	   trascription	   factors	   are	   increasingly	   taken	   into	  consideration.	  Four	  FoxO	  family	  members	  are	  expressed	  in	  mammals,	  FoxO1	  (also	  known	  as	  FoxO1a),	  FoxO3	  (also	  known	  as	  FoxO3a),	  FoxO4,	  and	  FoxO6,	  and	  all	  of	   them	  are	  expressed	   in	  skeletal	  muscles. Emerging	  evidence	   from	  multiple	   systems	   indicate	   that	   FoxOs	   orchestrate	   the	   expression	   of	   genes	  involved	  in	  cellular	  quality	  control,	  and	  in	  particular	  the	  protein	  homeostasis	  (proteostasis)	   network.	   The	   regulation	   of	   these	   proteins,	   especially	   their	  dynamic	   control	   by	   two	  major	   actors	   in	   skeletal	   muscle	   homeostasis,	   AKT	  and	   AMPK,	   are	   specific,	   as	   is	   the	   implication	   of	   each	   FoxO	  member	   in	   the	  regulation	   of	   cellular	   processes	   in	   response	   to	   physiological	   and	  pathophysiological	  conditions.	  In	  particular,	  FoxO1	  and	  FoxO3	  play	  a	  crucial	  role	  in	  the	  regulation	  of	  skeletal	  muscle	  mass	  and	  homeostasis.	  	  	  
	  
1.5.1	  	  FoxO1	  AND	  FoxO3	  REGULATE	  ENERGY	  METABOLISM	  IN	  
SKELETAL	  MUSCLE.	  	  The	   skeletal	   muscle	   is	   one	   of	   the	   major	   peripheral	   tissues	   that	   are	  responsible	   for	   insulin-­‐mediated	   fuel	   metabolism	   and	   energy	   expenditure. Skeletal	   muscle	   accounts	   for	   >30%	   of	   resting	   metabolic	   rate	   and	   80%	   of	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whole-­‐body	  glucose	  uptake.	  FoxO1	  is	  particularly	   involved	  in	  the	  regulation	  of	   energy	   metabolism	   in	   muscle,	   indeed it	   maintains	   energy	   homeostasis	  during	   fasting	   and	   provides	   energy	   supply	   through	   breakdown	   of	  carbohydrates,	  a	  process	  that	  leads	  to	  atrophy	  and	  underlies	  glycemic	  control	  in	  insulin	  resistance.	  Expression	   of	   FoxO1	   is	   increased	   in	   skeletal	  muscle	   by	   energy	   deprivation	  (such	   as	   fasting,	   calorie	   restriction,	   and	   severe	   diabetes),	   suggesting	   that	  FoxO1	   may	   mediate	   the	   response	   of	   skeletal	   muscle	   to	   changes	   in	   energy	  metabolism. Skeletal	   muscle	   metabolism	   switches	   from	   oxidation	   of	  carbohydrates	  to	  fatty	  acids	  as	  the	  major	  energy	  source	  during	  fasting	  when	  the	   plasma	   glucose	   concentration	   is	   low.	   FoxO1	   controls	   this	   switch	   by	  upregulating	   3	   enzymes:	   pyruvate	   dehydrogenase	   kinase-­‐4	   (PDK4)	   that	  shuts	   down	   glucose	   oxidation	   by	   targeting	   pyruvate	   dehydrogenase	   (PDH)	  (Furuyama	   et	   al.,	   2003),	   lipoprotein	   lipase	   that	   hydrolyzes	   plasma	  triglycerides	   into	   fatty	  acids,	  and	  fatty	  acid	  translocase	  CD36	  that	   facilitates	  fatty	   acid	   uptake	   into	   skeletal	   muscle	   (Bastie	   et	   al.,	   2005). Last,	   FoxO1	  regulates	  the	  expression	  of	  adipon.ectin	  receptors	  (AdipR),	  which	  transmit	  a	  signal	  for	  increased	  fatty	  acid	  oxidation	  in	  muscle	  and	  adiponectin	  sensitivity	  (Tsuchida	  et	  al.,	  2004)	  (figure	  11).	  Concerning	   FoxO3,	   its	   role	   in	   mitochondrial	   energy	   metabolism	   under	  nutrient	   restriction	   has	   recently	   been	   assessed	   (Peserico	   et	   al.,	   2013).	  Specifically,	  Peserico	  et	  all	  showed	  that	  in	  myoutubes	  a	  low	  glucose	  condition	  leads	   FoxO3	   accumulation	   	   into	   mitochondria	   in	   an	   AMPK	   dependent	  manner.	   In	   this	   way,	   FoxO3	   is	   able	   to	   form	   a	  multicomplex	   with	   SIRT3	   (a	  specific	   mitochondria	   sirtuin),	   mitochondrial	   RNA	   polymerase	   at	  mitochondrial	   DNA-­‐regulatory	   regions	   (mtDNA-­‐RR)	   and	   regulates	  mitochondrial	  transcription	  .	  In	  summary,	  in	  the	  FoxO	  family,	  FoxO1	  appears	  to	   be	   the	   major	   regulator	   of	   muscle	   energy	   homeostasis	   through	   the	  regulation	  of	  glycolytic	  and	  lipolytic	  flux.	  Importantly,	  the	  function	  of	  FoxO3	  in	  mitochondrial	  metabolism	  is	  emerging.	  The	  involvement	  of	  FoxO4	  and	  6	  in	  skeletal	  muscle	  energy	  metabolism	  still	  remains	  to	  be	  characterized	  (Sanchez	  et	  al.,	  2014).	  




Fig	  11:	  Metabolic	  regulation	  by	  FoxO1	  and	  FoxO3	  in	  skeletal	  muscle	  (Sanchez	  et	  al.,	  
2014).	  	  
1.5.2	  	  FoxO1	  AND	  FoxO3	  GOVERN	  PROTEIN	  BREAKDOWN	  
	  Cross-­‐talk	  between	  protein	  breakdown	  and	  protein	  synthesis	  is	  necessary	  to	  maintain	   muscle	   mass.	   The	   role	   of	   FoxO	   transcription	   factors	   in	   the	  regulation	   of	   skeletal	   muscle	   protein	   degradation	   it	   has	   well	   studied.	  Activation	  of	  FoxO1	  or	  FoxO3	  in	  the	  skeletal	  muscle,	  in	  catabolic	  conditions,	  can	   increase	   protein	   breakdown	   through	   ubiquitin-­‐proteasome	   and	  autophagy-­‐lysosome	   pathways,	   the	   2	   major	   mechanisms	   causing	   muscle	  atrophy. The	  ubiquitin–proteasome	  system	  is	  assumed	  to	  play	  a	  major	  role	  in	  muscle	  protein	  degradation	  since	   the	  discovery	  of	   two	  E3	  ubiquitin	   ligases,	  MAFbx/atrogin-­‐1	   and	  MuRF1,	  which	   are	   overexpressed	   in	   various	   atrophy	  models.	   The	   function	   of	   E3	   ubiquitin	   ligases	   is	   to	   target	   specific	   protein	  substrates	   for	   degradation	   by	   the	   26S	   proteasome	   and	   FoxO1	   and	   3	   are	  required	  for	  the	  transcription	  of	  MAFbx/atrogin-­‐1	  and	  MuRF1.	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In	  vivo	   studies	  of	  FoxO1	   inactivation	  or	  overexpression	  have	  showed	  that	   it	  affects	   to	   a	   great	   extend	   skeletal	  muscle	  mass.	  Mice	   overexpressing	   FoxO1	  lose	  their	  glycemic	  control	  due	  to	  a	  decrease	  in	  skeletal	  muscle	  mass	  (Kamei	  et	   al.,	   2004).	   These	   effects	   of	   FoxO1	   are	   mediated	   by	   its	   actions	   in	   three	  genes,	  atrogin-­‐1	  and	  myostatin	  and	  4E-­‐binding	  protein-­‐1.	  FoxO1	  promotes	  the	  expression	  of	  atrogin-­‐1,	   a	  muscle-­‐specific	  ubiquitin	   ligase	  which	  along	  with	  MuRF1	  controls	  muscle	  atrophy	  (Sandri	  et	  al.,	  2004).	  Indeed,	  inactivation	  of	  FoxO1	   in	   myotubes	   or	   rodent	   muscle	   decreases	   both	   muscle	   atrophy	   and	  
atrogin-­‐1	   expression.	   In	   addition,	   constitutive	   activation	   of	   FoxO1	   in	   the	  same	   cells	   enhances	   the	   transcriptional	   activity	   of	   myostatin,	   another	  muscle-­‐specific	  protein	  causing	  muscle	  loss,	  through	  direct	  binding	  of	  FoxO1	  to	   the	   myostatin	   promoter	   (Allen	   and	   Unterman,	   2007).	   Finally,	   FoxO1	  induces	   the	   translational	   inhibitor	   4E-­‐binding	   protein-­‐1	   by	   binding	   to	   its	  promoter,	   thereby	   suppressing	   protein	   synthesis	   (Southgate	   et	   al.,	   2007).	  FoxO3	  is	  the	  master	  regulator	  of	  autophagy	  in	  adult	  muscles	  (Mammucari	  et	  al.,	   2007).	   Expression	   of	   FoxO3	   is	   sufficient	   and	   required	   to	   activate	  lysosomal-­‐dependent	   protein	   breakdown	   in	   cell	   culture	   and	   in	   vivo.	  However,	   the	   role	  of	  FoxOs	   trascription	   factors	   in	   the	   control	  of	   autophagy	  induction,	   today	   is	   not	   completely	   defined.	   Moreover	   several	   autophagy	  genes	   including	   LC3,	   Gabarap,	   Bnip3,	   VPS34,	   Atg12	   are	   under	   FoxO3	  regulation.	   Gain	   and	   loss	   of	   function	   experiments	   identified	   BNIP3,	   a	   BH3-­‐only	   protein,	   as	   a	   central	   player	   downstream	   of	   FoxO	   in	   muscle	   atrophy	  (Mammucari	   et	   al.,	   2007;	   Tracy	   et	   al.,	   2007).	   These	   studies	   allowed	   to	  identify	  the	  most	  potent	  autophagy	  inhibitor	  in	  skeletal	  muscles:	  AKT	  kinase.	  Acute	   activation	  of	  AKT	   in	   adult	  mice	  or	   in	  muscle	   cell	   cultures	   completely	  inhibits	   autophagosome	   formation	   and	   lysosomal-­‐dependent	   protein	  degradation	  during	  fasting	  (Mammucari	  et	  al.,	  2007;	  Zhao	  et	  al.,	  2007;	  Zhao	  et	  al.,	  2008).	  A	  clear	  pathway	  has	  been	   identified	   in	  muscle,	   as	  we	  know	   in	  presence	  of	  nutrients	  IGF1/Insulin	  signalling	  pathway	  is	  activated,	  this	  leads	  to	   the	  activation	  of	  AKT.	  When	  AKT	   is	  phosphorylated	   (P-­‐AKT),	   it	   activates	  mTOR,	  thus	  increasing	  protein	  synthesis	  rate,	  and	  blocking	  autophagy;	  on	  the	  contrary,	  P-­‐AKT	  phosphorylates	  FoxO,	  that	  in	  this	  way	  is	  sequestered	  in	  the	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cytosol,	   and	   its	   transcriptional	   action	   is	   blocked,	   leading	   to	   autophagy	  inhibition.	  When	  FoxO	  is	  in	  the	  nucleus	  can	  promote	  transcription	  of	  several	  genes,	   in	   particular	   some	   autophagy	   genes	   such	   as	   Bnip3,	   LC3	   and	   p62,	  leading	   to	   autophagy	   activation.	   These	   evidences	   suggest	   that	   FoxOs	   factor	  control	   the	   skeletal	  muscle	  ubiquitin-­‐proteasome	  and	  autophagy–lysosomal	  pathways	   independently.	   Moreover,	   Zhao	   et	   colleagues	   demostrate	   that	  decreased	   IGF-­‐1-­‐PI3K-­‐Akt	   signaling	   activates	   autophagy	   not	   only	   through	  mTOR	   but	   also	   more	   slowly	   by	   a	   transcription-­‐dependent	   mechanism	  involving	   FoxO3.	   Whereby,	   expression	   of	   a	   constitutively	   active	   form	   of	  FoxO3	  promotes	   LC3	   lipidation,	  mimic	   induction	   of	   autophagy	   (Zhao	   et	   al.,	  2007).	   Furthermore,	   overexpression	   of	   FoxO3	   in	   cultured	  mammalian	   cells	  leads	  to	  a	  fourfold	  increase	  in	  glutamine	  synthetase	  activity	  and	  subsequent	  increase	  in	  glutamine	  levels.	  Thus,	  high	  glutamine	  levels	  induce	  autophagy	  	  at	  least	  in	  part	  by	  blocking	  the	  mTOR	  pathway	  (van	  der	  Vos	  et	  al.,	  2012)	  (figure	  12).	  
	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
Fig	  12;	  Antagonistic	  interaction	  between	  FOXOs	  and	  the	  mTORC1	  pathway	  in	  autophagy.	  
(Webb	  and	  Brunet,	  2014).	  
	  Moreover,	   FoxO1	   directly	   targets	   cathepsin	   L,	   a	   lysosomal	   protease	   in	  muscle,	  and	   induces	   its	  expression	  during	   fasting	   	   connoting	  a	   role	  of	  FoxO	  factors	   in	   lysosomal	   degradation	   (Yamazaki	   et	   al.,	   2010).	   Although	   the	  implication	   of	   FoxO	   proteins	   in	   the	   transcription	   lysosomal	   hydrolases	   has	  been	  partially	  described,	  their	  potential	  role	  in	  the	  genesis	  of	  lysosomes	  has	  not	   been	   investigated.	   Similarly,	   the	   potential	   role	   of	   FoxO1	   in	   skeletal	  muscle	  autophagy	  remains	  to	  be	  characterized.	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1.5.3	  REGULATION	  OF	  MUSCLE	  MASS	  BY	  FoxO	  TRASCRIPTION	  
FACTORS	  
	  The	  maintenance	  of	  muscle	  mass	  is	  achieved	  by	  a	  dynamic	  balance	  between	  	  atrophy	  and	  hypertrophy.	  Skeletal	  muscle	  atrophy	  occurs	  under	  a	  variety	  of	  conditions	   and	   can	   result	   from	   alterations	   in	   both	   protein	   synthesis	   and	  protein	   degradation.	   Activation	   of	   the	   cell’s	   proteolytic	   systems	   is	  transcriptionally	   regulated	   by	   specific	   signalling	   pathways	   but	   the	  identification	  of	  the	  precise	  signalling	  cascades	  that	  direct	  muscle	  wasting	  is	  only	   at	   the	   initial	   phase.	   Gene	   expression	   studies	   revealed	   a	   set	   of	   genes	  which	   are	   commonly	   up-­‐	   and	   down-­‐regulated	   in	   different	   atrophying	  conditions.	   These	   genes	   are	   called	   atrophy-­‐related-­‐genes	   or	   atrogenes	  	  (Sacheck	   et	   al.,	   2007).	   Among	   these	   atrophy-­‐related	   genes	   were	   several	  belonging	   to	   the	   major	   cellular	   degradation	   systems,	   the	   ubiquitin	  proteasome	   and	   autophagy-­‐lysosome.	   FoxO	   transcription	   factors	   are	   key	  regulators	  of	  muscle	  atrophy	  indeed,	  the	  up-­‐regulation	  of	  several	  ubiquitin–proteasome	  and	  autophagy-­‐related	  genes	  is	  normally	  blocked	  by	  Akt	  through	  negative	  regulation	  of	  FoxO.	  The	  first	  ubiquitin	  ligases	  that	  were	  identified	  to	  play	  a	  role	  in	  muscle	  loss	  were	  Atrogin-­‐1/MAFbx	  and	  MuRF1	  as	  I	  said	  before.	  Mice	   lacking	   these	   two	   enzymes	   are	   partially	   resistant	   to	   muscle	   atrophy	  induced	   by	   denervation	   (Bodine	   et	   al.,	   2001).	  However,	   the	   action	   of	   these	  two	   ubiquitin	   ligases	   can	   not	   account	   for	   the	   degradation	   of	   all	   muscle	  proteins.	   A	   number	   of	   additional	   unknown	   ubiquitin	   ligases	   (E3s)	   are	  presumably	   activated	   during	   atrophy	   to	   promote	   the	   clearance	   of	  myofibrillar	  and	  soluble	  proteins	  and/or	   to	   limit	  anabolic	  processes.	  Sandri	  et	   al,	  were	   the	   first	   to	  discover	   that	   FoxO3	  was	   sufficient	   to	   induce	  muscle	  loss	   through	   its	   induction	   of	   Atrogin-­‐1/MAFbx	   and	   MURF1	   expression.	  Importantly,	   in	  subsequent	  work,	  was	   found	  that	   inactivation	  of	  autophagic	  flux	   by	   LC3	   silencing	   partially	   prevents	   FoxO3	   mediated	   muscle	   loss,	  suggesting	   the	   major	   role	   of	   the	   autophagic	   pathway	   in	   FoxO3	   mediated	  atrophy	  (Mammucari	  et	  al.,	  2007).	  Thus,	   FoxO1	   and	   FoxO3	   act	   through	   an	   exacerbation	   of	   the	   ubiquitin-­‐proteasomal	   and	   autophagy–lysosomal	   degradation	   pathways	   in	   muscle	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atrophy.	   Moreover,	   FoxO	   factors,	   especially	   FoxO3,	   are	   involved	   in	  mitochondrial	   dysfunction	   and	   elimination	   by	   regulating	   the	   mitophagic	  pathway	  under	  atrophy.	  Although	  all	  these	  findings	  support	  the	  concept	  that	  FoxO	  family	  plays	  an	  important	  role	  in	  muscle	  wasting,	  the	  specific	  function	  of	   FoxOs	   in	   skeletal	  muscle	  maintenance/loss	   and	   in	   atrogenes	   expression	  has	  not	  been	  determined	  by	  loss-­‐of-­‐function	  approaches. 	   	  
	  
1.6	  AIM	  OF	  THE	  WORK	  	  
	  
	  Skeletal	  muscle	   is	   a	   plastic	   tissue	   and	   adapts	   its	  mass	   as	   a	   consequence	   of	  physical	  activity,	  metabolism	  and	  hormones.	  Maintenance	  of	  skeletal	  muscle	  mass	  is	  essential	  for	  health	  and	  survival.	  A	  decrease	  in	  protein	  synthesis	  and	  an	  increase	  in	  protein	  degradation	  have	  been	  shown	  to	  contribute	  to	  muscle	  protein	   loss.	   In	  my	   lab	  we	   focus	  our	  attention	  on	   the	  study	  of	   the	  signaling	  pathways	   that	   control	   muscle	   mass	   and	   cause	   muscle	   atrophy.	   In	   this	  	  condition	  proteolitic	  pathways,	   such	  as	  Ubiquitin	  proteasome	  system	  (UPS)	  and	  Autophagy	   lysosome	   system	   (ALS),	   are	   activated	   and	   the	   transcription	  factors	   FoxO1	   and	   FoxO3	   has	   been	   demonstrated	   to	   be	   involved	   in	   the	  regulation	  of	  their	  components.	  The	  aim	  of	  my	  PhD	  project	   is	  focused	  on	  the	  characterization	  of	  the	  role	   	  of	  FoxOs	   transcription	   factors	   in	  skeletal	  muscle.	   In	  order	   to	  clarify	   this	   issue,	  we	  used	  muscle-­‐specific	  FoxO1-­‐3-­‐4	  deficient	  mice	  and	  also	  inducibile	  muscle	  specific	  FoxOs	  knock-­‐out	  mice	  to	  minimize	  the	  chance	  of	  any	  adaptation	  and	  compensations	  that	  occur	  with	  constitutive	  deletion	  of	  genes.	  Throught	   loss	  of	   function	   approaches	  we	  want	   to	   understand	   	  which	   are	   the	   FoxO	   target	  genes	   necessary	   for	   maintaining	   an	   atrophy	   program	   and	   the	   function	   of	  these	  genes	  in	  skeletal	  muscle	  during	  catabolic	  conditions.	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2.	  MATERIALS	  AND	  METHODS	  	  
2.1	  GENERATION	  OF	  MUSCLE-­‐SPECIFIC	  FoxO1-­‐3-­‐4	  KNOCKOUT	  
MICE	  	  	  Muscle-­‐specific	   FOXO1,3,4	   knockout	   mice	   were	   obtained	   in	   my	   lab.	   Mice	  bearing	  FoxO1,3,4-­‐floxed	  alleles	  (FoxO1,3,4f/f)	  	  were	  crossed	  with	  transgenic	  mice	  expressing	  Cre	  either	  under	  the	  control	  of	  a	  Myosin	  Light	  Chain	  1	   fast	  promoter	   (MLC1f-­‐Cre)	   that	   is	   expressed	   only	   in	   skeletal	  muscle	   during	   the	  embryonic	   development,	   (Bothe	   et	   al.,	   2000).	   To	   obtain	   inducible	   muscle-­‐specific	   FOXO1,3,4	   knockout	   mice,	   	   flox/flox	   mice	   were	   crossed	   with	  transgenic	   mice	   expressing	   a	   Cre-­‐recombinase	   fused	   with	   a	   modified	  estrogen	   receptor	   domain	   (Cre-­‐ERTM)	   driven	   by	   Human	   Skeletal	   Actin	  promoter	  (HSA)	  (Schuler	  et	  al.,	  2005).	  Tamoxifen-­‐inducible	  Cre	  was	  activated	  by	   special	   tamoxifen	   diet	   (Tam400/Cre-­‐ER	   Harlan)	   or	   by	   i.p.	   Tamoxifen	  injection.	  	  
2.1.1	  Genotyping	  of	  muscle	  specific	  FoxO1-­‐3-­‐4	  	  knockout	  mice	  	  	  Mice	   were	   identified	   by	   analyzing	   the	   presence	   of	   Cre	   recombinase	   on	  genomic	  Dna.	  To	  extract	  Dna	  we	  used	  	  a	  lysis	  buffer	  containing	  TRIS-­‐HCL	  1M	  pH	   7.5	   and	   Proteinase	   K	   10mg/mL	   (Life	   Technologies).	   The	   samples	   were	  denaturated	  by	  incubation	  for	  1	  hour	  at	  57°C	  and	  then	  the	  proteinase	  K	  was	  inactivated	  at	  99°C	   for	  5	  minutes.	  Genomic	  DNA	   isolated	   from	  FoxO1,3,4f/f	  mice	   was	   subjected	   to	   PCR	   analysis.	   Cre-­‐mediated	   recombination	   was	  confirmed	  by	  PCR	  with	  genomic	  DNA	  from	  gastrocnemius	  muscles	  using	  the	  primers	  :	  Cre	  forward:	  NSP-­‐780:	  CACCAGCCAGCTATCAACTCG	  	  Cre	  reverse:	  NSP-­‐979:	  TTACATTGGTCCAGCCACCAG	  	  We	  prepared	  a	  20	  μl	  total	  volume	  mix	  for	  each	  sample	  with:	  	  Template	  DNA:	  2	  μl	  	  Primer	  NSP-­‐780	  (10	  μM):	  0.2	  μl	  	  Primer	  NSP-­‐979	  (10	  μM):	  0.2	  μl	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GoTaq	  Green	  master	  mix	  2X	  (Promega):	  10	  μl	  	  Water	  	  Program:	  	  step	  1:	  94°	  C	  for	  3	  minutes	  	  step	  2:	  94°	  C	  for	  45	  seconds	  	  step	  3	  61°	  C	  for	  30	  seconds	  	  step	  4	  72°C	  1	  minute	  	  step	  5:	  go	  to	  step	  2	  for	  40	  times	  	  We	  detected	  Cre-­‐recombinase	  DNA	  (200	  bp)	  with	  a	  2%	  agarose	  gel.	  The	  genotyping	  analysis	  for	  each	  specific	  FoxO	  member	  was	  performed	  with	  the	  combination	  of	  the	  following	  primers:	  	  FoxO1	  forward:	  GCT	  TAG	  AGC	  AGA	  GAT	  GTT	  CTC	  ACA	  TT,	  FoxO1	  reverse1:	  CCA	  GAG	  TCT	  TTG	  TAT	  CAG	  GCA	  AAT	  AA	  	  FoxO1	  reverse2:	  CAA	  GTC	  CAT	  TAA	  TTC	  AGC	  ACA	  TTG	  A	  	  FoxO3	  forward1:	  AGA	  TTT	  ATG	  TTC	  CCA	  CTT	  GCT	  TCC	  T-­‐	  FoxO3	  forward2:	  TGC	  TTT	  GAT	  ACT	  ATT	  CCA	  CAA	  ACC	  C	  FoxO3	  reverse:	  ATT	  CCT	  TTG	  GAA	  ATC	  AAC	  AAA	  ACT	  	  FoxO4	  forward1:	  TGA	  GAA	  GCC	  ATT	  GAA	  GAT	  CAG	  A	  	  FoxO4	  forward2:	  CTA	  CTT	  CAA	  GGA	  CAA	  GGG	  TGA	  CAG	  	  FoxO4	  reverse:	  CTT	  CTC	  TGT	  GGG	  AAT	  AAA	  TGT	  TTG	  G	  
2.2	  ANIMALS	  and	  In	  vivo	  TRASFECTION	  EXPERIMENTS.	  	  Animals	   were	   handled	   by	   specialized	   personnel	   under	   the	   control	   of	  inspectors	  of	  the	  Veterinary	  Service	  of	  the	  Local	  Sanitary	  Service	  (ASL	  16—Padova),	   the	   local	   officers	   of	   the	   Ministry	   of	   Health.	   Mice	   were	   housed	   in	  individual	   cages	   in	   an	   environmentally	   controlled	   room	   (23	   °C,	   12-­‐h	   light–dark	   cycle)	   with	   ad	   libitum	   access	   to	   food	   and	   water.	   All	   procedures	   are	  specified	   in	   the	  projects	  approved	  by	   the	   Italian	  Ministero	  Salute,	  Ufficio	  VI	  (authorization	  numbers	  C65)	  and	  by	  the	  Ethics	  Committee	  of	  the	  University	  of	  Padova.	  All	  experiments	  were	  performed	  on	  2-­‐	  to	  4-­‐month-­‐old	  male	  (28–32g)	  and	  female	  mice	  (25–28g);	  mice	  of	  the	  same	  sex	  and	  age	  were	  used	  for	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each	   individual	   experiment.	   In	   vivo	   transfection	   experiments	   were	  performed	  by	  i.m.	  injection	  of	  expression	  plasmids	  in	  TA	  muscle	  followed	  by	  electroporation.	   The	   animals	   were	   anesthetized	   by	   an	   intraperitoneal	  injection	   of	   xylazine	   (Xilor)	   (20	   mg/Kg)	   and	   Zoletil	   (10	   mg/Kg).	   Tibialis	  anterior	   (TA)	   muscle	   was	   isolated	   through	   a	   small	   hindlimb	   incision,	   and	  DNA	  was	  injected	  along	  the	  muscle	  length.	  Electric	  pulses	  were	  then	  applied	  by	  two	  stainless	  steel	  spatula	  electrodes	  placed	  on	  each	  side	  of	   the	   isolated	  muscle	   belly	   (50	   Volts/cm,	   5	   pulses,	   200	   ms	   intervals).	   For	   fasting	  experiments,	  control	  animals	  were	  fed	  ad	  libitum;	  food	  pellets	  were	  removed	  from	  the	  cages	  of	  the	  fasted	  animals.	  Denervation	  was	  performed	  by	  cutting	  the	   sciatic	   nerve	   of	   the	   left	   limb,	  while	   the	   right	   limb	  was	   used	   as	   control.	  Muscles	  were	  removed	  at	  various	  time	  periods	  after	  transfection	  and	  frozen	  in	  liquid	  nitrogen	  for	  subsequent	  analyses.	  	  
2.3	  CUT	  OF	  THE	  SCIATIC	  NERVE	  	  
The	  right	  hindlimbs	  of	  3	  months	  old	  	  mice	  were	  denervated	  cutting	  the	  sciatic	  nerve	   unilaterally.	   The	   animals	   were	   anesthetized	   by	   an	   intraperitoneal	  injection	  of	  ketamine	  (75	  mg/Kg)	  and	  xylazine	  (20	  mg/Kg).	  The	  sciatic	  nerve	  was	   unilaterally	   cut	   at	   the	   level	   of	   trochanter.	   About	   0.5-­‐1	   cm	   of	   the	  peripheral	  nerve	  stump	  was	  removed	  and	   the	  proximal	   stump	  was	  sutured	  into	   a	   superficial	   muscle	   to	   avoid	   reinnervation	   and	   obtain	   a	   permanent	  denervation	   of	   the	   lower	   hindlimb.	   Mice	   were	   sacrificed	   3	   days	   after	  operation,	   for	   gene	   expression	   analyses,	   or	   after	   14	   days	   for	   biochemestry	  analyses.	  	  
2.4	  MEASUREMENTS	  OF	  MUSCLE	  FORCE	  IN	  VIVO	  	  	  Muscle	   force	   was	   measured	   in	   a	   living	   animal	   as	   previously	   described	  (Blaauw	   et	   al.,	   2008).	  We	   performed	   this	   experiment	   in	   collaboration	  with	  Bert	  Blaauw	  (VIMM,	  Padua).	  Briefly	  gastrocnemius	  (GCN)	  muscle	  contractile	  performance	   was	   measured	   in	   vivo	   using	   a	   305B	   muscle	   lever	   system	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(Aurora	   Scientific	   Inc.)	   in	   anaesthetized	   mice.	   Contraction	   was	   elicited	   by	  electrical	   stimulation	   of	   the	   sciatic	   nerve.	   Force	   generation	   capacity	   was	  evaluated	   by	   measuring	   the	   absolute	   maximal	   force	   that	   was	   generated	  during	   isometric	   contractions	   in	   response	   to	   electrical	   stimulation	  (frequency	  of	  75–150	  Hz,	  train	  of	  stimulation	  of	  500	  ms).	  Maximal	  isometric	  force	  was	  determined	  at	  L0	  (length	  at	  which	  maximal	  tension	  was	  obtained	  during	  the	  tetanus).	  Force	  was	  normalized	  to	  the	  muscle	  mass	  as	  an	  estimate	  of	   specific	   force.	   Following	   force	   measurements,	   animals	   were	   killed	   by	  cervical	  dislocation	  and	  muscles	  were	  dissected,	  weighed	  and	  frozen	  in	  liquid	  nitrogen	   or	   in	   isopentane	   precooled	   in	   liquid	   nitrogen.	   Ex	   vivo	   force	  measurements	   on	   soleus	   muscles	   were	   performed	   by	   dissecting	   it	   from	  tendon	   to	   tendon	   under	   a	   stereomicroscope	   and	   subsequently	   mounting	  between	  a	  force	  transducer	  (KG	  Scientific	  Instruments,	  Heidelberg,	  Germany)	  and	   a	   micromanipulator-­‐controlled	   shaft	   in	   a	   small	   chamber,	   in	   which	  oxygenated	  Krebs	  solution	  was	  continuously	  circulated	  and	  temperature	  was	  maintained	   at	   25	   °C.	   The	   stimulation	   conditions	   were	   optimized,	   and	   the	  length	  of	   the	  muscle	  was	   increased	  until	   force	  development	  during	   tetanus	  was	  maximal.	  
2.5	  MEASUREMENT	  IN	  VIVO	  OF	  PROTEIN	  SYNTHESIS	  	  	  
 In	   vivo	   protein	   synthesis	   was	   measured	   by	   using	   the	   SUnSET	   technique	  (Goodman	   et	   al.,	   2011;	   Schmidt	   et	   al.,	   2009).	   Mice	   were	   anesthetized	   and	  then	  an	  i.p.	  injection	  of	  0.040	  mmol/g	  puromycin	  was	  dissolved	  in	  100	  ml	  of	  PBS	  was	  given.	  At	  exactly	  30	  min	  after	   injection,	   tissues	  were	  collected	  and	  frozen	  in	  liquid	  N2	  for	  immunoblot	  analysis	  with	  a	  mouse	  IgG2a	  monoclonal	  anti-­‐puromycin	  antibody	  (clone	  12D10,	  1:5,000).	  	  
2.6	  HISTOLOGY	  ANALYSES	  AND	  FIBRE	  SIZE	  MEASUREMENTS	  	  	  Muscles	  were	  collected	  and	  directly	  frozen	  by	  immersion	  in	   liquid	  nitrogen.	  Then	  we	  cut	  muscle	  cryosections	  by	  using	  Cryostat	   (Leica	  CM	  1950),	  10μm	  thick	  for	  histology	  and	  for	  immunostaining	  analyses.	  TA	  Cryosections,	  10μm	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thick,	  were	  used	  to	  analyze	  tissue	  morphology	  with	  different	  methods,	  listed	  below.	   Images	   were	   collected	   with	   an	   epifluorescence	   Leica	   DM5000B	  microscope,	  equipped	  with	  a	  Leica	  DFC300-­‐FX	  digital	  charge-­‐coupled	  device	  camera,	   by	   using	   Leica	   DC	   Viewer	   software.	   For	   electron	   microscopy,	   we	  used	  conventional	  fixation-­‐embedding	  procedures	  based	  on	  glutaraldehyde-­‐osmium	  fixation	  and	  Epon	  embedding.	  	  
2.6.1	  Haematoxylin	  and	  Eosin	  staining	  (H&E)	  	  
	  Haematoxylin	   colors	   basophilic	   structures	   that	   are	   usually	   the	   ones	  containing	   nucleic	   acids,	   such	   as	   ribosomes,	   chromatin-­‐rich	   cell	   nuclei,	   and	  the	   cytoplasmc	   regions	   rich	   in	   RNA.	   Eosin	   colors	   eosinophilic	   structures	  bright	  pink.	  The	  method	  consist	  of:	  	  
Materials	   Times	  
PFA	  4%	   10	  minutes	  
3	  washs	  in	  PBS	   5	  mintes	  each	  
Harris	  Hematoxylin	  (	  SIGMA)	   6	  minutes	  
Wash	  in	  running	  tap	  water	   3	  minutes	  
Alcoholic	  acid	   10	  seconds	  
Wash	  in	  running	  tap	  water	   3	  minutes	  
Eosin	  Y	  Solution	  Alcoholic	  (	  SIGMA)	   1	  minute	  
Dehydratation	   	  
Ethanol	  70%	   5	  minutes	  
Ethanol	  95%	   2	  minutes	  
Ethanol	  100%	   3	  minutes	  
Xilen	  1	   5	  minutes	  
Xilen	  2	   5	  minutes	  
Mount	  with	  Entellan	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2.6.2	  Succinate	  dehydrogenase	  (SDH)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  The	   succinate	   dehydrogenase	   is	   an	   enzyme	   complex,	   bound	   to	   the	   inner	  mitochondrial	   membrane.	   With	   this	   staining	   it	   is	   possible	   to	   evaluate	  approximately	   the	   quantity	   of	   mitochondria	   present	   in	   the	   muscle	   fibres,	  through	  colorimetric	  evaluation.	  The	  reaction	  gives	  a	  purple	  coloration	  in	  the	  oxidative	   fibres.	   The	   sections	  were	   incubated	   for	   30	  minutes	   at	   37°C	  with	  SDH	   solution	   (0.2M	   sodium	   succinate)	   (Sigma-­‐Aldrich),	   0.2M	   phosphate	  buffer	   (Sigma)	   ph	   7.4	   and	   50mg	   of	   nitro	   blue	   tetrazolium	   (NBT)(Sigma-­‐Aldrich).	  After	  the	  incubation,	  the	  sections	  were	  washed	  3	  minutes	  with	  PBS	  and	  then	  mounted	  with	  Mounting	  medium	  (Dako).	  











	  	  	  	  	  	  	  	  
Materials	   Times	  
Fix	  in	  Carnoy’s	  fixative	  	   5	  minutes	  
Wash	  in	  water	  	   3	  times	  
0.5%	  periodic	  acid	  	   5	  minutes	  
Wash	  in	  water	  	   3	  times	  
Schiff’s	  solution	  (Sigma)	  	   10	  minutes	  
Wash	  in	  running	  tap	  water	  	   10	  minutes	  
Mount	  with	  Elvanol	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2.6	  IMMUNOHISTOCHEMISTRY	  ANALYSES	  	  	  TA	  muscle	  cryosections,	  10	  μm	  thick,	  were	  processed	  for	  immunostaining.	  All	  data	  are	  expressed	  as	   the	  mean	  SEM	  (error	  bars).	  Comparisons	  were	  made	  by	  using	  t	  test,	  with	  *P<0.05	  being	  considered	  statistically	  significant.	  The	  list	  of	  the	  antibody	  used	  for	  immunofluorescence	  is	  showed	  in	  the	  same	  table	  of	  antibody	  used	  for	  western	  blot/IP/CHIP.	  
2.6.1	  Fibre	  Type	  Determination	  
 Fibre	  typing	  was	  determined	  by	  immunofluorescence	  using	  combinations	  of	  the	   following	   monoclonal	   antibodies:	   BA-­‐D5	   that	   recognizes	   type	   1	   MyHC	  isoform	  and	  SC-­‐71	  for	  type	  2A	  MyHC	  isoform	  an	  BF-­‐F3	  for	  type	  2B	  ,	  type	  2X	  remain	  black.	  Images	  were	  captured	  using	  a	  Leica	  DFC300-­‐FX	  digital	  charge-­‐coupled	   device	   camera	   by	   using	   Leica	   DC	   Viewer	   software,	   and	  morphometric	  analyses	  were	  made	  using	  the	  software	  ImageJ	  1.47	  version.	  
2.6.2	  Fibre	  Cross-­‐Sectional	  Area	  (CSA)	  	  	  Fibre	   Cross-­‐Sectional	   Area	   was	   measured,	   by	   using	   ImageJ	   software	  (National	  Institutes	  of	  Health).	  All	  data	  are	  expressed	  as	  the	  mean	  SEM	  (error	  bars).	  Comparisons	  were	  made	  by	  using	  t	  test,	  with	  *P<0.05	  being	  considered	  statistically	  significant.	  
2.7	  IMMUNOBLOTTING	  
	  	  Cryosections	   of	   20	   μm	   of	   TA	   muscles	   were	   lysed	   with	   100	   μl	   of	   a	   buffer	  containing	  50	  mM	  Tris	  pH	  7.5,	  150	  mM	  NaCl,	  10	  mM	  MgCl2,	  0.5	  mM	  DTT,	  1	  mM	  EDTA,	  10%	  glycerol,	  2%	  SDS,	  1%	  Triton	  X-­‐100,	  Roche	  Complete	  Protease	  Inhibitor	  Cocktail	  and	  Sigma	  Protease	  Inhibitor	  Cocktail.	  After	   incubation	  at	  70°C	  for	  10	  minutes	  and	  centrifugation	  at	  11000	  g	  for	  10	  minutes	  at	  4°C,	  the	  surnatant	  protein	   concentration	  was	  measured	  using	  BCA	  protein	  assay	  kit	   
(Thermo Scientific)	  following	  the	  manufacturer’s	  instructions.	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2.7.1	  SDS-­‐PAGE	  
	  For	   Myosin	   analysis,	   gastrocnemius	   muscles	   were	   homogenized	   in	   myosin	  extraction	  buffer	  containing	  1M	  Tris	  pH	  6.8,	  10%	  SDS	  and	  80%	  glycerol.	  SDS–PAGE	   was	   performed	   using	   polyacrylamide	   gel	   with	   a	   high	   glycerol	  concentration,	  which	  allows	   the	  separation	  of	  MYH	   isoforms.	  Myosins	  were	  identified	  with	  Coomassie	  blu	  staining	  
2.7.2	  Protein	  gel	  Electrophoresis	  	  	  The	   extracted	   proteins	   from	   TA	  muscle	  were	   solubilized	   in	   Loading	   buffer	  composed	  by	  5μl	  of	  4X	  NuPAGE®	  LDS	  Sample	  Buffer	  (Life	  Technologies)	  and	  1μl	  of	  20X	  DTT	  (Life	  Technologies).	  The	  volume	  of	  each	  sample	  was	  brought	  to	  20μl	  with	  SDS	  1X.	  The	  samples	  were	  denaturated	  at	  70°C	  for	  10	  minutes.	  	  Samples	  were	   loaded	   on	   SDS	   4-­‐12%	   precast	   polyacrylamide	   gels	   (NuPAGE	  Novex-­‐Bis-­‐tris-­‐gels)	  or	  in	  SDS	  3-­‐8%	  depending	  on	  the	  protein	  to	  be	  analyzed	  (Life	  Technologies).	  The	  electrophoresis	  was	  run	  in	  1X	  MES/MOPS	  Running	  buffer	  or	  1X	  Tris-­‐Acetate	  Running	  buffer	  respectively	  (Life	  Technologies)	  for	  1	  hour	  and	  30	  minutes	  at	  150V	  constant.	  
2.7.3	  Transfer	  of	  the	  protein	  to	  the	  PVDF/nitrocellulose	  	  
membrane	  	  	  After	   the	   electrophoretic	   run,	   proteins	  were	   transferred	   from	  gels	   to	   PVDF	  membranes,	   previously	   activated	  with	  methanol	   or	   nitrollulose	  membrane.	  The	  gel	  and	  the	  membrane	  were	  equilibrated	  in	  Transfer	  Buffer.	  TheTransfer	  Buffer	  was	  prepared	  as	  following:	  20X	  NuPAGE®	  Transfer	  buffer(Invitogen)	  50	  ml	  10X	  NuPAGE®	  Antioxidant	  (Invitogen)	  1ml	  20%	  Methanol	  (Sigma-­‐Aldrich)	  200ml	  The	  volume	  was	  brought	  to	  1l	  with	  distilled	  water.	  The	  transfer	  was	  obtained	  by	  applying	  a	  current	  of	  400mA	  for	  1	  hour	  and	  30	  minutes	  at	  4°C.	  To	  evaluate	  the	   efficiency	   of	   transfer,	   proteins	   were	   stained	   with	   Red	   Ponceau	   1x	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(Sigma).	  The	  staining	  was	  easily	  reversed	  by	  washing	  with	  distilled	  water.	  
2.7.4	  Incubation	  of	  the	  membrane	  with	  antibodies	  
	  Once	   the	   proteins	   were	   transferred	   on	   PVDF	   membranes,	   the	   membranes	  were	   saturated	  with	  Blocking	  Buffer	   (5%	  no	   fat	  milk	  powder	   solubilized	   in	  TBS	   1X	   with	   0.1%	   TWEEN)	   for	   1	   hour	   at	   room	   temperature	   and	   were	  incubated	   overnight	   with	   various	   antibody	   at	   4°C	   .	   Membranes	   were	   then	  washed	   3	   times	  with	   TBS	   1X	  with	   0.1%	  TWEEN	   at	   RT	   and	   incubated	  with	  secondary	   antibody-­‐HRP	   Conjugate	   (Bio-­‐Rad),	   for	   1	   hour	   at	   room	  temperature.	   Immunoreaction	   was	   revealed	   by	   SuperSignal	   West	   Pico	  Chemiluminescent	  substrate	  (Pierce)	  and	  followed	  by	  exposure	  to	  Xray	  film	  (KODAK	  Sigma-­‐Aldrich).	  Antibodies	  used	  in	  this	  study	  are	  shown	  in	  TABLE1	  and	  TABLE2.	  	  
Antibody	   Customer	   Dilution	   Analysis	  mouse	  IgG2A	  anti-­‐puromycin	   12D10	   1:30000	   WB	  Rabbit	  anti-­‐FoxO1	   Cell	  signalling	  #9946	   1:1000	   WB	  Rabbit	  anti-­‐FoxO3	   Cell	  signalling	  #9946	   1:1000	   WB	  Goat	  anti	  Fbxo30	   Santa	  Cruz	  Biotechnology	   1:100	   WB	  Goat	  anti	  mouse	  IgG	   Biorad	  1706516	   1:2000	   WB	  Goat	  anti	  rabbit	  IgG	   Biorad	  1706515	   1:2000	   WB	  Goat	  anti	  mouse	  IgG-­‐2b	  DyLight405	   Jackson	  Immunoresearch	  115-­‐475-­‐207	   1:200	   IF	  Goat	  anti	  mouse	  IgG-­‐1	  DyLight405	   Jackson	  Immunoresearch	  115-­‐485-­‐205	   1:200	   IF	  Goat	  anti	  mouse	  IgG	  (H+L)	  Cy3	   Jackson	  Immunoresearch	  115-­‐026-­‐003	   1:200	   IF	  Goat	  anti	  Rabbit	  IgG-­‐(H+L)	  Cy3	   Jackson	  Immunoresearch	  111-­‐166-­‐003	   1:200	   IF	  
	  
Tab.	  1:	  Antibodies	  used	  for	  western	  blot	  analyses,	  IP,	  immunofluorescence.	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Tab.	  2:	  Antibodies	  used	  for	  western	  blot	  analyses,	  IP,	  immunofluorescence. 
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All	  the	  peroxidase-­‐conjugated	  secondary	  antibodies	  were	  from	  Bio-­‐Rad.	  Blots	  were	   stripped	   using	   Stripping	   Solution,	   containing	   25mM	   glycine	   and	   1%	  SDS,	  pH	  2.	  
2.8	  CO-­‐IMMUNOPRECIPITATION	  (CO-­‐IP)	  
	  Co-­‐immunoprecipitation	   (Co-­‐IP)	   is	   a	   popular	   technique	   to	   identify	  physiologically	  relevant	  protein-­‐protein	  interactions	  by	  using	  target	  protein-­‐specific	  antibodies	  to	  indirectly	  capture	  proteins	  that	  are	  bound	  to	  a	  specific	  target	  protein.	  For	  co-­‐IP	  experiment	  C2C12	  muscle	  cell	  lines	  were	  transfected	  with	  V5-­‐	   SMART,	  HA-­‐Skp1,	   FLAG-­‐Cul1	   and	  FLAG-­‐Roc1	   expression	  plasmids	  (Sartori	  et	  al.,	  2013).	  After	  24	  hours,	  cells	  were	   lysed	   in	  a	  buffer	  containing	  50mM	  Tris	  pH	  7.5,	  100mM	  NaCl,	  5mM	  ,MgCl2,	  1mM	  DTT,	  0.5%	  Triton	  X-­‐100,	  protease	   and	   phosphatase	   inhibitors.	   About	   1mg	   of	   total	   protein	   was	  incubated	  at	  a	  ratio	  of	  1:100	  with	  the	  mouse	  monoclonal	  anti-­‐FLAG	  antibody	  or	  non	  specific	  mouse	  IgG	  along	  with	  30	  ml	  of	  Protein	  A/G	  PLUS-­‐Agarose	  sc-­‐2003	   (Santa	   Cruz	   Biotechnology)	   overnight	   at	   4	   °C.	   The	   beads	   were	   then	  washed	   three	   times	   with	   PBS	   plus	   Roche	   Complete	   Protease	   Inhibitor	  Cocktail	   1X	   and	   were	   finally	   resuspended	   in	   30	   ml	   LDS	   Sample	   Buffer	  1X(NuPAGE	  Life	  Technolohy)	  and	  50mM	  DTT,	  then	  boiling	  at	  95°C	  for	  5	  min	  to	  be	  	  analysed	  by	  Western	  blotting.	  
2.9	  GENE	  EXPRESSION	  ANALYSIS	  	  
2.9.1	  Extraction	  of	  total	  RNA	  	  
	  Total	   RNA	  was	   isolated	   from	  TA	   using	   Trizol	   (Life	   Technologies)	   following	  the	  manufacturer’s	  instructions.	  	  
	   48	  
2.9.2	  Synthesis	  of	  the	  first	  strand	  of	  cDNA	  
	  400ng	   of	   total	   RNA	   was	   reversly	   transcribed	   with	   SuperScriptTM	   III	   (Life	  Technologies)	  in	  the	  following	  reaction	  mix:	  Random	  primer	  hexamers	  (50	  ng/μl	  random)	  1	  ml	  dNTPs	  10	  mM	  1	  ml	  H2O	  Rnase-­‐free	  8.5	  ml	  The	   samples	   were	   mixed	   by	   vortexing	   and	   briefly	   centrifuged	   and	  denaturated	  by	  incubation	  for	  5	  min	  at	  70°	  C	  to	  prevent	  secondary	  structures	  of	  RNA.	  Samples	  were	  incubated	  on	  ice	  for	  2	  minutes	  to	  allow	  the	  primers	  to	  align	  to	  the	  RNA;	  and	  the	  following	  components	  were	  added	  sequentially:	  First	  strand	  buffer	  5X(	  Invitrogen)	  	  	  	  	  	  	  	  5	  μl	  DTT	  100mM:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2μl	  	  RNase	  Out	  (Life	  Technologies):	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1μl	  SuperScriptTM	  III	  (Life	  Technologies):	  0.5μl	  	  The	  volume	  was	  adjusted	  to	  20	  μl	  	  with	  RNase	  free	  water.	  	  The	  used	  reaction	  program	  was:	  	  step1:	  25°C	  for	  10	  minutes	  	  step2:	  42°C	  for	  50	  minutes	  	  step3:	  70°C	  for	  15	  minutes	  	  At	   the	  end	  of	   the	  reaction,	   the	  volume	  of	  each	  sample	  was	  adjusted	   to	  50ul	  with	  RNase	  free	  water.	  
2.9.3	  	  Real-­‐Time	  PCR	  reaction	  
	  Quantitative	   Real-­‐time	   PCR	   was	   performed	   with	   SYBR	   Green	   chemistry	  (Applied	  Biosystems).	  SYBR	  green	  is	  a	   fluorescent	  dye	  that	   intercalates	   into	  double-­‐stranded	  DNA	  and	  produces	  a	  fluorescent	  signal.	  The	  Real-­‐Time	  PCR	  Instrument	   allows	   real	   time	   detection	   of	   PCR	   products	   as	   they	   accumulate	  during	   PCR	   cycles	   and	   create	   an	   amplification	   plot,	   which	   is	   the	   plot	   of	  fluorescence	  signal	  versus	  cycle	  number.	  In	  the	  initial	  cycles	  of	  PCR,	  there	  is	  little	   change	   in	   fluorescence	   signal.	   This	   defines	   the	   baseline	   for	   the	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amplification	  plot.	  An	   increase	   in	   fluorescence	   above	   the	  baseline	   indicates	  the	   detection	   of	   accumulated	   PCR	   products.	   A	   fixed	   fluorescence	   threshold	  can	  be	  set	  above	  the	  baseline.	  The	  parameter	  Ct	  (threshold	  cycle)	  is	  defined	  as	   the	   fractional	   cycle	   number	   at	   which	   the	   fluorescence	   passes	   the	   fixed	  threshold.	   So	   the	   higher	   the	   initial	   amount	   of	   the	   sample,	   the	   sooner	   the	  accumulated	  product	  is	  detected	  in	  the	  PCR	  process	  as	  a	  significant	  increase	  in	  fluorescence,	  and	  the	  lower	  is	  the	  Ct	  value. 
2.9.4	  Quantification	  of	  the	  PCR	  products	  and	  determination	  of	  
the	  level	  of	  expression	  	  	  A	  relative	  quantification	  method	  was	  used	  to	  evaluate	  the	  differences	  in	  gene	  expression,	   as	   described	   by	   Pfaffl	   (Pfaffl,	   2001).	   In	   this	   method,	   the	  expression	  of	  a	  gene	  is	  determined	  by	  the	  ratio	  between	  a	  test	  sample	  and	  a	  housekeeping	   gene.	   The	   relative	   expression	   ratio	   of	   a	   target	   gene	   is	  calculated	  based	  on	  the	  PCR	  efficiency	  (E)	  and	  the	  threshold	  cycle	  deviation	  (ΔCt)	  of	  unknown	  samples	  versus	  a	  control,	  and	  expressed	  in	  comparison	  to	  a	   reference	   gene.	   The	   mathematical	   model	   used	   for	   relative	   expression	   is	  represented	  in	  this	  equation	  :	  	  	  	  	  	  The	  internal	  gene	  reference	  used	  in	  our	  real	  time	  PCR	  was	  pan-­‐actin,	  whose	  abundance	  did	  not	  change	  under	  the	  experimental	  conditions.	  
2.9.5	  Primer	  pairs	  design	  	  
	  Gene-­‐specific	   primer	   pairs	   were	   selected	   with	   Primer	   Blast	   software	  (http://www.ncbi.nlm.nih.gov/tools/primer-­‐blast/).	   Primer	   pairs	   were	  selected	   in	   a	   region	   close	   to	   the	   3'-­‐end	   of	   the	   transcript,	   and	   amplified	  fragments	  of	  150-­‐250bp	  in	  length.	  To	  avoid	  the	  amplification	  of	  contaminant	  genomic	  DNA,	  the	  target	  sequences	  were	  chosen	  on	  distinct	  exons,	  separated	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Usp14	   CACGAGTTGCTTCGTATTCC	   TTCAGGGTTCCTCCTTTCAC	  
	  
Tab.	  3:	  Primers	  used	  for	  Quantitative	  PCR	  Analyses.	  
	  
	  























































Ezh1	   GTGTTTTCTTTTCTTCTTCTGTGC	   GTGTTTTCTTTTCTTCTTCTGTGC	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Tab.	  4:	  Primers	  used	  for	  Quantitative	  PCR	  Analyses.	  
	  
2.9.6	  Real-­‐Time	  PCR	  reaction	  	  
	  1μl	  of	  diluted	  cDNAs	  was	  amplified	  in	  10μl	  PCR	  reactions	  in	  a	  ABI	  Prism	  7000	  (Applied	  Biosystem)	  thermocycler,	  coupled	  with	  a	  ABI	  Prism	  7000	  Sequence	  Detection	   System	   (Applied	   Biosystems)	   in	   96-­‐wells	   plates	   (Micro	   Amp	  Optical,	  Applied	  Biosystems).	   In	  each	  well	  5ul	   Sample	  mix	  and	  5ul	   reaction	  mix	  were	  mixed.	  	  Sample	  mix	  was	  prepared	  as	  follows	  for	  5	  μl	  total	  volume:	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Template	  cDNA:	  1	  μl	  	  H2O	  Rnase-­‐free:	  4	  μl	  	  The	  SYBR	  Green	  qPCR	  (Applied	  Biosystem)	  was	  used	  for	  the	  Real-­‐Time	  PCR	  reaction	  as	  follows:	  	  SYBR	  Green	  qPCR	  (Applied	  Biosystem):	  4.8μl	  	  Mix	  Primer	  forward	  /reverse	  50mM:	  0.2μl	  	  The	  PCR	  cycle	  used	  for	  the	  Real-­‐Time	  PCR	  was:	  	  step	  1:	  95°	  C	  for	  15	  minutes	  	  step2:	  95°	  C	  for	  25	  seconds	  	  step3:	  58°	  C	  for	  1	  minute	  	  step4:	  go	  to	  step	  2	  for	  40	  times.	  	  
	  2.10	  PLASMID	  CLONING	  	  	  The	   cloning	   strategy	   required	   insertion	   of	   the	  DNA	  of	   interest	   in	   a	   specific	  plasmid.	   Then	   competent	   bacteria	   (Top	   10)	   (Life	   Technologies)	   were	  transformed	  and	  the	  plasmid	  was	  purified	  first	  with	  Mini-­‐prep	  kit	  (Machery-­‐Nagel)	   and	   then,	   to	   increase	   the	   quantity	   of	   DNA,	   in	   particular	   for	   in	   vivo	  transfection,	  we	  prepared	  Maxi-­‐prep	   (Qiagen)	   following	   the	  manufacturer’s	  instructions.	   Final	   DNA	   concentration	  was	   quantified	   by	  Nanovue	   Plus	   (GE	  Haelthcare). 
2.10.1	  FbxO21	  cloning	  	  
	  In	  vivo	  transfection	  experiments	  used	  the	  yellow	  fluorescent	  protein	  (YFP)–LC3	   (Mammucari	   et	   al.,	   2007)	   and	   Fbxo21SMART-­‐V5	   plasmid	   .	   For	   the	  cloning,	  FbxO21/SMART	  gene	  was	  amplified	  from	  mouse	  cDNA	  by	  PCR	  using	  the	   following	   primers	   primers	   forward:	   3’-­‐ACCATGGCGTCGGTAGCGGGGGACA-­‐5’	   and	   reverse:	   3’-­‐CTCGGCTGTGTCCTCCTTTGCACTG-­‐5’	  .	  The	  amplified	  sequence	  was	  cloned	  into	  pcDNA3.1/V5-­‐His	  TOPO	  (Invitrogen)	  expression	  vector	  and	  sequenced.	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2.10.2	  In	  Vivo	  RNAi	  	  
 In	   vivo	   RNAi	   experiments	   were	   performed	   using	   at	   least	   four	   different	  sequences	  for	  each	  gene(Invitrogen	  BLOCK-­‐iTTM	  Pol	  II	  miR	  RNAi	  Selected).	  The	  sequences	  are	  shown	  in	  Table	  5.	  For	  the	  validation	  of	  shRNA	  constructs,	  MEF	  cells	  were	  maintained	  in	  DMEM/10%	  FBS	  and	  transfected	  with	  shRNA	  constructs	  using	  Lipofectamine	  2000	  (Invitrogen).	  Cells	  were	  lysed	  24	  h	  later	  and	  immunoblotting	  was	  performed.	  
 
	  
Tab.	  5:	  Oligos	  used	  for	  siRNA	  production	  and	  used	  for	  in	  vivo	  trasfection. 
	  
2.11	  GENE	  EXPRESSION	  PROFILING	  
	  For	  each	  of	  the	  4	  conditions	  (FoxO1,3,4	  f/f	   fed	  or	  starved	  and	  FoxO1,3,4	  -­‐/-­‐	  fed	  or	   starved),	  we	   collected	   the	  gastrocnemius	  muscles	  of	   three	  mice	   thus	  yielding	   six	  muscles	   per	   condition.	   RNA	  was	   prepared	   from	   these	  muscles	  using	   the	   TRIzol	  method	   (Life	   Technologies)	   followed	   by	   cleanup	  with	   the	  RNeasy	   kit	   (Qiagen).	   RNA	   concentration	   was	   determined	   by	  spectrophotometry	  and	  quality	  of	  the	  RNA	  was	  monitored	  using	  the	  Agilent	  2100	  Bioanalyzer	  (Agilent	  Technologies).	  Then,	  RNA	  was	  pooled	  equimolarly	  and	  used	  for	  microarray	  analysis.	  RNA	  was	  prepared,	  labelled	  and	  hybridized	  to	  Affymetrix	  Mouse	  Genome	  430	  2.0	  Arrays	  using	  Affymetrix-­‐supplied	  kits	  and	   according	   to	   standard	   Affymetrix	   protocols.	   Expression	   values	   were	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summarized	   using	   the	   Mas	   5.0	   algorithm.	   Genes	   that	   were	   up	   or	  downregulated	   in	   starvation	   compared	   with	   the	   fed	   condition	   were	  determined	  using	  Excel	  software.	  A	  threshold	  of	  1.5	  was	  used	  for	  the	  fold	  up	  or	   downregulation	   consistent	   with	   the	   fold	   change	   that	   can	   be	   reliably	  detected	  with	  these	  type	  of	  arrays.	  
2.12	  COLCHICINE	  	  TREATMENT	  	  
	  We	  monitored	  autophagic	  flux	  in	  30	  hours	  of	  starvation	  using	  colchicine	  (Ju	  et	   al.,	   2010).	   Briefly,	  MLC	  FoxO1,3,4-­‐/-­‐and	  FoxO1,3,4	   f/f	  mice	  were	   treated	  with	   0,4mg/kg	   of	   colchicine	   or	   vehicle	   by	   i.p.	   injection	   and	   starved.	   The	  treatment	  was	  repeated	  15	  hours	  prior	  to	  muscle	  harvesting.	  	  
2.13	  STATISTICAL	  ANALYSIS	  	  AND	  EXPERIMENTAL	  DESIGN	  
	  The	   sample	   size	   was	   calculated	   using	   size	   power	   analysis	   methods	   for	   a	  priori	   determination	   based	   on	   the	   s.d.,	   and	   the	   effect	   size	   was	   previously	  obtained	  using	  the	  experimental	  methods	  employed	  in	  the	  study.	  For	  animal	  studies,	  we	  estimated	  sample	  size	  from	  expected	  number	  of	  knock-­‐out	  mice	  and	  littermate	  controls,	  which	  was	  based	  on	  mendelian	  ratios.	  We	  calculated	  the	   minimal	   sample	   size	   for	   each	   group	   by	   at	   least	   four	   organisms.	  Considering	  a	  likely	  drop-­‐off	  effect	  of	  10%,	  we	  set	  sample	  size	  of	  each	  group	  at	  five	  mice.	  To	  reduce	  the	  s.d.,	  we	  minimized	  physiological	  variation	  by	  using	  homogenous	  animals	  with	  same	  sex	  and	  same	  age.	  The	  exclusion	  criteria	  for	  animals	  were	  pre-­‐established.	   In	  case	  of	  death,	  cannibalism	  or	  sickness,	   the	  animal	  was	   excluded	   from	  analysis.	   Tissue	   samples	  were	   excluded	   in	   cases	  such	   as	   cryoartefacts,	   histological	   artefacts	   or	   failed	   RNA	   extraction.	   We	  included	  animals	   from	  different	  breeding	  cages	  by	  random	  allocation	  to	  the	  different	   experimental	   groups.	   Animal	   experiments	   were	   not	   blinded,	  however,	  when	  applicable,	   the	  experimenters	  were	  blinded	  to	  the	  nature	  of	  samples	   by	   using	   number	   codes	   until	   final	   data	   analysis	   was	   performed.	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Statistical	   tests	   were	   used	   as	   described	   in	   the	   figure	   legends	   and	   were	  applied	   on	   verification	   of	   the	   test	   assumptions	   (for	   example,	   normality).	  Generally,	  data	  were	  analysed	  by	   two-­‐tailed	  Student’s	   t-­‐test.	   For	  all	   graphs,	  data	  are	  represented	  as	  means±s.e.m.	  For	  the	  measurement	  variables	  used	  to	  compare	   KO	   animals	   versus	   controls,	   or	   innervated	   animals	   versus	  denervated	  ones,	  the	  variance	  was	  similar	  between	  the	  groups.	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3.	  RESULTS	  
3.1	  GENERATION	  OF	  MUSCLE-­‐SPECIFIC	  FoxO1,3,4	  KNOCK-­‐
OUT	  MICE	  
	  FoxO	   trascription	   factors	   are	   required	   for	   muscle	   wasting.	   However,	   the	  trascriptional	   program	   that	   regulate	   skeletal	   muscle	   atrophy	   is	   poorly	  understood.	   To	   delineate	   the	   role	   of	   FoxO	   in	   gene	   regulation	   and	   muscle	  adaptation	   during	   catabolic	   condition,	   we	   generated	   FoxO1,3,4	   muscle	  specific	  knock-­‐out	  mice.	  FoxO1,3,4	   floxed	   mice	   were	   crossed	   with	   a	   transgenic	   line	   expressing	   Cre	  recombinase	   under	   the	   control	   of	   MLC1f	   promoter	   to	   generate	   muscle-­‐specific	  FoxO1,3,4	  triple	  knock-­‐out	  mice,	  which	  are	  hereafter	   referred	   to	  as	  FoxO1,3,4-­‐/-­‐.	  We	  confirmed	  the	  successful	  deletion	  of	  all	  three	  FoxOs	  isoform	  with	   PCR	   analysis	   from	   genomic	   DNA	   extracted	   from	   skeletal	   muscle	   (Fig.	  1a).	  Quantitative	  RT-­‐PCR	  shows	  an	  important	  downregulation	  of	  FoxO1	  and	  FOXO3	  transcripts	  while	  FoxO4	  is	  almost	  undetectable	  (Fig.	  1b).	  Since	  FoxO4	  is	  mainly	  expressed	  in	  muscles	  while	  FoxO1	  and	  3	  are	  expressed	  in	  almost	  all	  tissues,	  the	  traces	  of	  FoxO1	  and	  3	  mRNAs	  come	  from	  endothelial,	  fibroblasts,	  macrophages	  and	  blood	  cells.	  Western	  Blot	  analyses	  confirmed	  the	  decrease	  of	  FoxO1	  and	  FoxO3	  proteins	  in	  muscles	  of	  FoxO1,3,4-­‐/-­‐	  mice	  	  (Fig.	  1c) .Thus,	  we	   confirm	   our	   genetic	   model	   of	   muscle-­‐specific	   inhibition	   of	   FoxO1,3,4	  family.	  
	  
Fig.1: Validation	  of	  FoxO1,3,4	  knock-­‐out	  model.	   (a)	  Genotyping	  of	  the	  FoxO1,3,4	  f/f	  PCR	  analysis	   with	   genomic	   DNA	   from	   gastrocnemius	   muscles.	   (b)	   FoxO1,	   FoxO3	   and	   FoxO4	  mRNA	   expression	   levels	   by	   RT–PCR	   in	   Tibialis	   Anterior	   (TA)	   muscle	   of	   FoxO1,3,4-­‐/-­‐	   and	  control	  mice.	   N=4	   each	   group.	   (c)	  Western	   blot	   analysis	   shows	   a	   reduction	   of	   FoxO1	   and	  FoxO3	  proteins	  in	  gastrocnemius	  muscles	  of	  FoxO1,3,4-­‐/-­‐	  and	  not	  in	  control	  mice.	  Data	  are	  representative	  of	  three	  independent	  experiments.  
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3.2	  FoxO1,	  FoxO3	  and	  FoxO4	  SIMULTANEOUS	  DELETION	  IN	  
MUSCLE	  DOES	  NOT	  AFFECT	  FIBRE	  TYPE	  
	  The	  resulting	  FoxO1,3,4-­‐/-­‐	  mice	  were	   indistinguishable	   in	  appearance	   from	  age-­‐matched	   control	   FoxO1,3,4	   f/f	   mice.	   Histological	   analysis	   of	   adult	  muscles	   revealed	   a	   normal	   muscle	   architecture	   and	   absence	   of	   myopathic	  features	  such	  as	  centrally	  nucleated	  fibers	  (Fig.	  2a).	  SDH	  staining	  showed	  no	  major	   alteration	   in	   distribution	   of	   small	   β-­‐oxidative	   mitochondrial	   rich	  versus	   large	   glycolytic	  mitochondrial	   poor	   fibers	   (Fig.	   2b).	   Since	   FoxOs	   are	  important	   regulator	  of	   energy	  metabolism	   in	  muscle	   and	   are	   important	   for	  glucose	   homeostasis	   in	   liver,	   we	   decide	   to	   monitor	   glycogen	   levels.	   PAS	  staining	  revealed	  an	  almost	  identical	  distribution	  of	  glycogen	  stores	  (Fig.	  2c)	  in	  muscle	  of	  controls	  and	  in	  FoxOs	  knock-­‐out	  mice.	  Analyses	  of	  Myosin	  Heavy	  Chain	   expression	   and	   distribution	   did	   not	   reveal	   any	   significant	   difference	  between	  wild	  type	  and	  FoxO1,3,4	  knockout	  mice	  (Fig	  2d,	  e).	  This	  first	  set	  of	  experiments	   suggests	   that	   FoxOs	   are	   not	   required	   for	   fiber	   type	  determination.	  
	  
	  
Fig.2:	  Deletion	  of	  FoxOs	  is	  permissive	  for	  normal	  muscle	  function.	  (a)	  Haematoxylin	  and	  eosin	  (Scale	  bar,	  100	  mm),	  (b)	  SDH	  (Scale	  bar,	  1mm)	  and	  (c)	  PAS	  staining	  (Scale	  bar,	  1mm)	  showing	  normal	  morphology,	  fibre	  type	  and	  glycogen	  of	  FoxO1,3,4-­‐/-­‐gastrocnemius	  muscle.	  
(d)	  SDS–PAGE	  and	  (e)	  immunohistochemistry	  analysis	  of	  myosin	  heavy	  chain	  type	  I,	  IIA,	  IIB	  and	  IIX	  proteins	  in	  gastrocnemius	  muscles	  showing	  no	  differences	  between	  FoxO1,3,4-­‐/-­‐	  and	  FoxO1,3,4f/f	  mice.	  Data	  are	  representative	  of	  three	  independent	  experiments.	  	  
a" c"b"
d" e"
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3.3	  FoxOs	  INHIBITION	  PREVENTS	  MUSCLE	  LOSS	  AND	  
WEAKNESS	  	  
	  To	   further	   characterize	   the	   role	   of	   FoxO1,3,4	   in	   skeletal	   muscles,	   we	   then	  analysed	   the	   phenotype	   of	   FoxO1,3,4-­‐/-­‐	   mice	   under	   conditions	   of	   muscle	  wasting.	   Initially,	   we	   used	   fasting	   as	   a	   model	   of	   muscle	   loss	   since	   it	   is	   an	  established	  condition	  that	  induces	  nuclear	  translocation	  of	  FoxO	  members	  to	  the	   nucleus	   and	   we	   compared	   FoxO1,3,4	   null	   muscles	   with	   controls.	  Importantly,	  FoxO1,3,4	  knockout	  mice	  were	  completely	  spared	  from	  muscle	  loss	  after	  fasting	  (Fig.	  3a).	  To	  understand	  whether	  sparing	  of	  muscle	  mass	  is	  also	  functionally	  relevant,	  we	  measured	  muscle	  force	  in	  living	  animals.	  While	  control	  fasted	  animals	  became	  significantly	  weaker	  than	  fed	  ones,	  FoxO1,3,4	  -­‐/-­‐	   gastrocnemius	   muscles	   did	   not	   loose	   strength	   after	   fasting	   (Fig.	   3b).	  Importantly	   the	   comparison	   of	   force/frequency	   curve	   of	   fasted	   wild-­‐type	  versus	   fasted	   FoxO1,3,4	   null	   muscle	   underlined	   the	   important	   protection	  achieved	   by	   the	   absence	   of	   FoxO	   family	  when	   nutrients	   are	   low	   or	   absent	  (Fig.	  3c).	  These	  findings	  confirm	  that	  the	  absence	  of	  FoxO	  members	  prevents	  atrophy	  and	  profound	  weakening.	  	  	  
	  
	  
Fig.3:	   Deletion	   of	   FoxOs	   prevents	   muscle	   loss	   and	   weakness	   during	   fasting.	   (a)	  Frequency	   histograms	   of	   cross-­‐sectional	   areas	   (mm2)	   of	   FoxO1,3,4f/f	   (black	   bars)	   and	  FoxO1,3,4_/_	  (magenta	  bars)	  fibres	  in	  fed	  (upper	  panel)	  and	  fasted	  (lower	  panel)	  conditions,	  n.4,	  each	  group.	  (b)	  Force	  measurements	  performed	  in	  vivo	  on	  gastrocnemius	  showed	  that	  FoxO1,3,4_/_	  muscles	  preserve	  maximal	  tetanic	  force	  after	  fasting;	  n.6	  muscles	  in	  each	  group.	  
(c)	   Force/frequency	   curve	   of	   starved	   gastrocnemius	   muscle	   underlines	   the	   important	  protection	  achieved	  by	  the	  absence	  of	  FoxOs;	  n=6	  muscles	  in	  each	  group.	  
a b c
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Fig.4: FoxO	   inhibition	   prevents	   protein	   ubiquitination	   during	   starvation.	   (a) Representative	  Immunoblot	  of	  MCH	  IIB	  in	  fed	  and	  in	  starved	  muscles	  of	  controls	  and	  FoxOs	  knock-­‐out	  mice.	   Quantification	   of	  MHC	   IIB	   content	   is	   shown	   in	   the	   graph.	   n=4	  muscles	   in	  each	   group.	   (b,	   c)	   Protein	   extracts	   from	   control	   and	   starved	  muscles	   of	   FoxO1,3,4-­‐/-­‐	   and	  FoxO1,3,4f/f	   mice	   were	   immunoblotted	   against	   (b)	   K63-­‐polyUbiquitin	   and	   (c)	   K48-­‐polyUbiquitin	   chains.	   The	   graphs	   show	   densitometry	   quantification	   of	   two	   different	  experiments	  of	  n=4	  for	  each	  group.	  Data	  are	  mean	  ±	  s.e.m.	  Error	  bars	  indicate	  s.e.m.	  *p<0.05	  **p<0.01	  (Student’s	  t-­‐test).F:	  fed,	  S:	  starved,	  Starv:	  starved.	  	  
a"
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3.4	  FoxOs	  ARE	  REQUIRED	  FOR	  AKT	  ACTIVITY	  AND	  ARE	  
CRITICAL	  FOR	  AUTOPHAGY	  	  
	  To	  explore	  the	  basis	   for	  sparing	  of	  muscle	  mass	   in	  absence	  of	  nutrients,	  we	  investigate	   the	   signalling	   pathways	   linked	   to	   Insulin/	   IGF1	   and	   energy.	  Interestingly,	   Akt,	   S6K	   and	   S6	   phosphorylation,	   both	   in	   fed	   and	   fasted	  muscles,	  were	   reduced	   in	   knockout	  mice,	  while	   phosphorylation	   of	   4EBP1,	  the	   other	  mTORC1	  downstream	   target,	  was	   increased	   in	   FoxO-­‐deficient	   TA	  muscles	  (Fig.	  5a).	  The	  energy–stress	  sensor	  AMPK	  and	  its	  downstream	  target	  ACC	   did	   not	   significantly	   differ	   from	   controls	   in	   fed	   and	   fasting	   conditions	  (Fig.	   5a).	   Therefore,	   the	   changes	   in	   the	   pathway	   downstream	  insulin/nutrients	  do	  not	  match	  with	  the	  important	  sparing	  of	  muscle	  mass	  in	  knockout	  mice	  when	  nutrients	  are	  absent.	  	  Since	  the	  absence	  of	  nutrients	  is	  a	  potent	  stimulus	   for	  autophagy-­‐dependent	  degradation	  and	  since	  FoxO	   is	  an	  inducer,	   while	   mTOR	   is	   a	   suppressor	   of	   autophagy–lysosome	   system,	   we	  checked	   the	   status	   of	   this	   system	   in	   FoxO1,3,4-­‐/-­‐mice.	   We	   monitored	   LC3	  lipidation,	   LC3-­‐positive	   vesicles	   and	   autophagy	   flux	   in	   FoxO1,3,4f/f	   and	  FoxO1,3,4	   -­‐/-­‐mice.	   Fasting	   induced	   LC3	   lipidation	   (Fig.	   5b)	   and	   vesicles	  formation	  (Fig.	  5c)	  in	  controls	  but	  not	  in	  FoxO-­‐deficient	  muscles.	  Autophagy	  flux	   was	   monitored	   by	   treating	   animals	   with	   colchicine,	   an	   established	  inhibitor	   of	  microtubule-­‐mediated	   delivery	   of	   autophagosome	   to	   lysosome.	  The	   inhibition	   of	   autophagosome	   delivery	   led	   to	   accumulation	   of	   lipidated	  LC3	  in	  controls	  but	  not	  in	  FoxO1,3,4	  deficient	  muscles	  (Fig.	  5d).	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3.5	  HALF	  OF	  THE	  ATROPHY-­‐RELATED	  GENES	  ARE	  UNDER	  
FOXO	  REGULATION.	  
	  Since	  muscle	  atrophy	  is	  characterized	  by	  transcription-­‐dependent	  regulation	  of	   atrogenes	   (atrophy-­‐related	   genes)	   and	   FoxO	   deficiency	   protects	   from	  muscle	   loss,	   we	   aimed	   to	   identify	   genes	   under	   FoxO	   regulation.	   Gene	  expression	  profiles	  of	  fed	  and	  fasted	  control	  and	  FoxO1,3,4-­‐/-­‐	  muscles	  were	  compared	  with	  identify	  genes	  with	  blunted	  induction	  in	  the	  fasted	  FoxO1,3,4-­‐/-­‐	   mice	   relative	   to	   controls.	   Cross-­‐referencing	   with	   the	   list	   of	   known	  atrogenes	   (Lecker	   et	   al.,	   2006),	   these	   analyses	   revealed	   that	   29	   of	   the	   63	  atrophy-­‐related	  genes	  require	  FoxO	  for	  their	  normal	  induction	  during	  fasting	  (Fig	  6).	  	  
	  	  
Fig.6: Half	  of	  the	  atrophy-­‐related	  genes	  are	  under	  FoxO	  regulation.	  	  The	  scheme	  shows	  the	   overlap	   between	  FoxO-­‐dependent	   genes,	   identified	   by	   gene	   expression	  profiling	   of	   fed	  (n=4)	   and	   fasted	   (n=4)	   muscles	   from	   FoxO1,3,4f/f	   and	   FoxO1,3,4_/_	   and	   atrophy-­‐related	  genes	   or	   atrogenes.	   The	   data	   in	   the	   graphs	   are	   shown	   as	  mean±s.e.m.	   Error	   bars	   indicate	  s.e.m.	  *P<0.05,	  **P<0.01	  (Student’s	  t-­‐test).	  	  	  Quantitative	   RT–PCR	   confirmed	   that	   26	   of	   the	   atrophy-­‐related	   genes	  were	  not	  induced	  in	  FoxO	  null	  muscles	  during	  fasting	  (Fig.	  7).	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Fig.7:	   	  Absence	   of	   FoxOs	   prevent	   the	   induction	   of	   critical	   atrogenes.	  Quantitative	  RT–PCR	  of	  atrogenes	  from	  fed	  and	  24-­‐h	  starved	  tibialis	  anterior	  of	  control	  and	  FoxO1,3,4-­‐/-­‐mice.	  Data	  are	  normalized	   to	  GAPDH	  and	  expressed	  as	   fold	   increase	  of	   control-­‐fed	  animals.	  N=4	  muscles	  in	  each	  group	  Values	  are	  mean±s.e.m.	  *P<0.05,**P<0.01.	  (Student’s	  t-­‐test).	  	  Consistent	  with	  morphology	  and	  force	  measurements,	  the	  induction	  of	  genes	  involved	  in	  protein	  breakdown	  was	  completely	  blocked	  in	  knockout	  mice.	  In	  fact,	   the	   ubiquitin	   system	   including	   the	   ubiquitin	   ligases	   (Atrogin1	   and	  MuRF1),	   the	   ubiquitin	   gene	   (UBC),	   the	   de-­‐ubiquitinating	   enzyme	   (USP14),	  the	   E3/E4	   enzyme	   (Ube4b),	   several	   proteasome	   subunits	   (Psme4/PA200,	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Psma1,	   Psmc4/Rpt3	   and	   Psmd11/Rpn6)	   as	   well	   as	   the	   autophagy-­‐related	  genes	  (LC3,	  Gabarapl,	  Bnip3,	  CathepsinL	  and	  p62/SQSTM1)	  were	  completely	  blocked	  in	  FoxO1,3,4-­‐/-­‐	  mice.	  Other	  pathways	  that	  are	  inhibited	  in	  knockout	  muscles	   are	   related	   to	   the	  unfolded	  protein	   response	   (ATF4	   and	  GADD34),	  protein	  synthesis	  (4EBP1	  and	  eIF4g),	  transcription	  regulators	  that	  negatively	  control	   Smad2/3	   (TGIF)	   or	   positively	   affect	   Myc	   (MAX),	   DNA	   repair/	  chromatin	   remodelling	   (GADD45a)	   and	   ribosome	  transcription/maturation/assembly	  (Nucleolin).	  Expression	  of	  genes	  that	  are	  related	  to	  oxidative	  stress	  were	  more	  variable.	  Nrf2/Nfe2l2	  was	  not	  affected	  by	   FoxO	   deletion,	  while	   Thioredoxin	  was	   suppressed	   and	  Metallothionein1	  was	   significantly	   induced	   in	   the	   absence	   of	   FoxO	   factors.	   Western	   blot	  analyses	   of	   some	   atrogenes	   involved	   in	   autophagy	   (p62,	   Gabarapl	   and	  Bnip3),	   chromatin	   remodelling/DNA	   repair	   (GADD45a),	   protein	   synthesis	  (4EBP1)	   and	   ubiquitin–proteasome	   confirmed	   their	   upregulation	   during	  fasting	  in	  control	  animals	  but	  not	  in	  FoxO1,3,4	  knock-­‐out.(fig.8	  a,b,c,d).	  
	  
	  
Fig.8:	   FoxOs	   are	   required	   for	   the	   expression	   of	   several	   atrogenes.	   (a)	  Representative	  Western	   blots	   of	   several	   atrophy-­‐related	   genes.	   Protein	   extracts	   from	   fed	   and	   starved	  muscles	   of	   FoxO1,3,4f/f	   and	   FoxO1,3,4-­‐/-­‐	   mice	   were	   immunoblotted	   against	   p62,	   Bnip3,	  Gabarapl,	  Gadd45α	  and	  4EBP1.	  Blots	  are	   representative	  of	   two	  groups	  of	  experiments.	  (b)	  The	  graphs	   show	   the	  densitometric	  quantification	  of	   the	  blots.	  At	   least	  4	  muscles	   for	   each	  group	   were	   used.	   (c)	   Representative	   Immunoblots	   of	   the	   novel	   atrophy-­‐related	   ubiquitin	  ligase	   SMART	   and	   MUSA1.	   (d)	   Densitometric	   quantification	   was	   performed	   from	   3	   fed	  gastrocnemius	  from	  FoxO1,3,4f/f	  and	  from	  FoxO1,3,4-­‐/-­‐	  and	  4	  starved	  gastrocnemius	  from	  FoxO1,3,4f/f	   and	   from	   FoxO1,3,4-­‐/-­‐.	   Data	   are	   shown	   as	  mean	   ±	   s.e.m.	   Error	   bars	   indicate	  s.e.m.	  *p<0.05	  (Student’s	  t-­‐test).	  F:	  fed,	  S:	  starved,	  Starv:	  starved	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3.6	  INDUCIBLE	  FoxOs	  LOSS	  PHENOCOPIES	  THE	  CONDITIONAL	  
KNOCK-­‐OUT	  




Fig.9:	   Tamoxifen-­‐inducible	   muscle-­‐specific	   FoxO1,3,4	   knockout	   mice.	   FoxO1,	   FoxO3,	  FoxO4	   mRNA	   expression	   were	   quantified	   by	   RT	   PCR	   in	   TA	   muscles	   of	   FoxO1,3,4-­‐/-­‐	   and	  control	   mice	   after	   tamoxifen	   treatment.	   Values	   are	   mean	   ±	   s.e.m.	   Error	   bars	   indicate	  s.e.m.*p<0.05,	  **p<0.01(Student’s	  t-­‐test)	  	  Similar	  to	  the	  data	  obtained	  with	  the	  conditional	  FoxOs	  knockout	  model,	  we	  found	   that	   somatic	   deletion	   of	   FoxO1,3,4	   prevented	  muscle	   loss	   (Fig.	   10a)	  and	   muscle	   weakness	   during	   fasting	   (Fig.	   10b).	   Consistent	   with	   the	  conditional	  knock-­‐out,	  Akt	  activation	  and	  LC3	  lipidation	  was	  reduced	  in	  FoxO	  knock-­‐out	   when	   compared	   with	   controls	   (Fig.	   10c).	   Autophagy	   flux	  measurements	   confirmed	   that	   FoxOs	   are	   required	   for	   autophagy	   induction	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(Fig.	  10d).	  The	   fact	   that	   two	  different	  FoxO1,3,4	  knock-­‐out	  mice	  resulted	   in	  comparable	  biological	  effects	  strongly	  supports	  the	  conclusion	  that	  the	  FoxO	  family	   is	   a	  master	   regulator	   of	   the	   atrophy	  programme	  under	   low	  nutrient	  conditions.	  
	  
	  
Fig.10:	  Acute	  inhibition	  of	  FoxOs	  phenocopies	  the	  conditional	  FoxO1,3,4	  knockout.	  (a)	  Frequency	  histograms	  of	  gastrocnemius	  muscles	  showing	  the	  distribution	  of	  cross-­‐sectional	  areas	   (mm2)	   of	   inducible	   muscle-­‐specific	   FoxO1,3,4	   mice	   after	   tamoxifen-­‐dependent	  deletion	  of	  FoxO1,3,4	  genes	  (FoxO1,3,4f/f:	  black	  bars	  and	  FoxO1,3,4-­‐/-­‐	  magenta	  bars)	  in	  fed	  (upper	  panel)	  and	  fasted	  (lower	  panel)	  conditions,	  n=3,	  each	  group.	  (b)	  Force	  measurements	  performed	   in	   vivo	   on	   gastrocnemius	   muscle	   showed	   that	   acute	   inhibition	   of	   FoxOs	   in	  adulthood	  prevents	  force	  drop	  during	  fasting.	  N=6	  muscles	  in	  each	  group.	  Freq:	  Frequency.	  
(c)	   Left,	   immunoblotting	   analyses	   of	   gastrocnemius	   homogenates	   after	   acute	   deletion	   of	  FoxO1,3,4-­‐/-­‐	  and	  controls.	  Right,	  quantification	  of	  LC3	  lipidation.	  Data	  are	  representative	  of	  three	   independent	   experiments.	   (d)	   Autophagy	   flux	   is	   not	   increased	   in	   FoxO-­‐deficient	   TA	  muscles.	   Inhibition	   of	   autophagy–lysosome	   fusion	   by	   colchicine	   treatment	   induces	  accumulation	  of	  LC3II	  band	  in	  starved	  control	  but	  not	  in	  starved	  FoxO1,3,4-­‐/-­‐muscles.	  Left,	  immunoblotting	   analyses	   of	   gastrocnemius	   homogenates.	   Right,	   quantification	   of	   LC3	  lipidation.	  
3.7	  FoxOs	  ARE	  REQUIRED	  FOR	  DENERVATION-­‐DEPENDENT	  
ATROPHY	  
	  To	   further	   determine	   whether	   the	   role	   of	   FoxO1,3,4	   is	   critical	   in	   different	  catabolic	  conditions,	  we	   then	  used	  denervation	  as	  another	  model	  of	  muscle	  atrophy.	   Quantification	   of	   fibre	   size	   revealed	   that	   FoxO-­‐deficient	   muscles	  
a" b"
c" d"
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Fig.	   11:	   Deletion	   of	   FoxOs	   in	   skeletal	   muscle	   partially	   prevents	   atrophy	   during	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Fig.12:	   FoxOs	   are	   required	   for	   expression	   of	   several	   atrogenes	   after	   denervation.	  Quantitative	   RT–PCR	   of	   the	   indicated	   atrogenes	   after	   3	   days	   from	   denervation.	   Data	   are	  normalized	  to	  GAPDH	  and	  expressed	  as	  fold	  increase	  of	  control	  innervated	  muscles.	  Values	  are	  mean±s.e.m.	  *P<0,05,	  **P<0.01	  (Student’s	  t-­‐test).;	  cont,	  control;	  den,	  denervated.	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3.8	  FoxOs	  REGULATE	  A	  NOVEL	  SET	  OF	  UBIQUITIN	  LIGASES	  
 When	   we	   looked	   at	   the	   gene	   expression	   profiles	   in	   fasted	   muscles	   of	  FoxO1,3,4	  knockout	  mice,	  we	  noticed	  a	  group	  of	  ubiquitin	   ligases	  that	  were	  upregulated	   in	   FoxO1,3,4f/f	   but	   not	   in	   FoxO1,3,4	   -­‐/-­‐	   mice.	   This	   set	   of	  ubiquitin	  ligases	  includes	  MUSA1,	  a	  novel	  E3,	  that	  we	  have	  recently	  found	  to	  be	   critical	   in	   muscle	   atrophy	   (Sartori	   et	   al.,	   2013),	   Fbxo31,	   an	   E3	   of	   SCF	  family	  involved	  in	  cyclinD	  degradation	  and	  tumour	  suppression	  (Santra	  et	  al.,	  2009),	   Itch,	   a	   HECT	   type	   ubiquitin	   ligase	   that	   regulates	   the	   half-­‐life	   of	  transcription	  factors	  such	  as	  JunB,	  c-­‐Jun	  and	  p63	  (Melino	  et	  al.,	  2008)	   ,	  and,	  finally,	  Fbxo21,	  a	  gene	  of	  unknown	  function	  but	  that	  contains	  an	  F-­‐box	  motif	  and	   that	   we	   named	   SMART	   (Specific	   of	   Muscle	   Atrophy	   and	   Regulated	   by	  Transcription).	  By	  quantitative	  RT–PCR,	  we	  confirmed	  that	  upregulation	  of	  MUSA1,	  SMART	  and	   FbxO31,	   but	   not	   Itch,	   is	   blunted	   or	   partially	   blocked	   in	   fasted	   or	  denervated	  muscles	  of	  FoxO1,3,4,	  knockout	  mice	  (Fig.	  13	  a,b).	  	  
	  
	  
Fig.13:	  FoxO	  members	  control	  a	  new	  set	  of	  ubiquitin	   ligases.	   (a)qRT–PCR	  of	  the	  novel	  ubiquitin	   ligases	  MUSA1,	  Fbxo21/SMART,	  Fbxo31,	   Itch	   from	  24	  starved	   	  or	  denervated	  (b)	  FoxO1,3,4f/f	   and	   FoxO1,3,4-­‐/-­‐	  mice.	  Data	   are	   normalized	   to	  GAPDH	   and	   expressed	   as	   fold	  increase	  of	  fed	  control	  mice.	  n.4	  muscles	  for	  each	  group.	  	  To	   further	   prove	   that	   the	   FoxO	   family	   is	   sufficient	   for	   their	   expression,	   in	  collaboration	  with	   Goldberg’s	   group	  we	   overexpressed	   FoxO3	   in	  myotubes	  and	   we	   checked	   the	   expression	   of	   these	   E3s.	   Interestingly,	   FoxO3	   was	  sufficient	   to	   induce	   the	   expression	   of	   MUSA1	   but	   not	   the	   other	   ubiquitin	  ligases	  (Figure	  14).	  	  	  
!!
a!! b!!
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Fig.14:	   FoxO3	   is	   sufficient	   to	   induce	   MUSA1,	   but	   not	   SMART,	   Itch	   or	   Fbox31.	  Quantitative	  RT-­‐PCR	  of	  the	  different	  ubiquitin	  ligases	  in	  myotubes	  overexpressing	  c.a.FoxO3	  and	  controls.	  Values	  are	  means	  ±	  s.e.m.Error	  bars	  indicate	  s.e.m**p<0.01(Student’s	  t-­‐test)	  c.a	  :constitutively	  active.	  
3.9	  SMART	  IS	  A	  NOVEL	  E3	  LIGASE	  REQUIRED	  FOR	  MUSCLE	  
ATROPHY	  	  	  To	  understand	  if	  Fbxo21	  was	  an	  E3	  ligase	  that	  belonged	  to	  the	  	  SCF	  group	  we	  performed	   an	   IP	   experiment.	   We	   immunoprecipitated	   Fbxo21	   with	   a	  components	   of	   the	   complex	   SCF,	   	   Skp1,	   Cullin1	   and	   Roc1,	   by	  western	   blot	  analysis	  confirmed	  that	  SMART	  forms	  an	  SCF	  complex	  with	  Skp1,	  Cullin1	  and	  Roc1	  (Fig.	  15)	  and	  therefore	  belongs	  to	  the	  SCF	  family	  of	  E3	  ligases.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
	  
Fig.15:	  Smart	  is	  a	  novel	  ubiquitin	  ligase	  required	  for	  denervation-­‐dependent	  atrophy.	  Co-­‐immunoprecipitation	   experiment	   showing	   that	   SMART	   is	   a	   F-­‐box	   protein	   that	   forms	   a	  SCF	   complex.	   C2C12	  muscle	   cell	   lines	  were	   transfected	  with	   SMART,	   Skp1,	   Cul1	   and	  Roc1	  expression	  plasmids.	  After	  24	  h,	  cells	  were	  lysed	  and	  immunoprecipitation	  against	  FLAG-­‐tag	  or	  control	  IgG	  was	  performed.	  Western	  blots	  for	  the	  different	  SCF	  components	  are	  shown.	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  Then,	   to	   confirm	   the	   role	   of	   SMART	   in	   promoting	   atrophy	   during	  denervation,	   we	   knocked	   down	   SMART	   in	   TA	   in	   vivo.	   Four	   different	   short	  hairpin	   RNAs	   (shRNAs)	   have	   been	   tested	   to	   specifically	   reduce	   SMART	  protein	   levels	   (Fig.	   16a),	   three	   of	   which	   efficiently	   knocked	   down	   SMART.	  Next,	  we	  transfected	  oligo	  4	  into	  innervated	  and	  denervated	  muscles.	  These	  shRNAs	  did	  not	  affect	   the	  expression	  of	   the	  other	  atrophy-­‐related	  ubiquitin	  ligases,	   MUSA,	  MuRF1	   and	   atrogin1	   both	   at	   protein	   and	  mRNA	   level	   (	   Fig.	  16b,	  Fig.	  17a).	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  Importantly,	   SMART	   inhibition	   significantly	   protected	   denervated	   muscles	  from	   atrophy	   (Fig.	   17b).	   This	   sparing	   is	   due	   to	   the	   fact	   that	   by	   blocking	  SMART	   we	   greatly	   reduced	   protein	   ubiquitination	   in	   denervated	   muscles	  (Fig.	  17c	  ).	  Therefore,	  we	  have	  identified	  SMART	  as	  an	  additional	  critical	  gene	  whose	  upregulation	  is	  required	  for	  atrophy,	  yet	  must	  be	  carefully	  controlled	  to	  avoid	  excessive	  protein	  breakdown.	  In	  conclusion,	  our	  findings	  underline	  the	  concept	  that	  FoxO	  members	  are	  the	  master	  regulatory	  factor	  for	  protein	  homeostasis	  during	  catabolic	  conditions.	  





Fig.17:	  Smart	  is	  a	  novel	  ubiquitin	  ligase	  required	  for	  denervation-­‐dependent	  atrophy.	  
(a)RNAi-­‐mediated	  knockdown	  of	  SMART	  revealed	  by	  quantitative	  RT–PCR	  (qRT–PCR).	  Adult	  TA	  muscles	  were	  transfected	  with	  bicistronic	  expressing	  vectors	  that	  encode	  either	  oligo	  4	  or	  scramble	  and	  GFP.	  Two	  weeks	  later	  TA	  muscles	  were	  collected,	  RNA	  extracted	  and	  endogenous	  SMART,	  MUSA1,	  Atrogin1,	  MuRF1	  and	  Fbxo31	  expression	  were	  analysed	  by	  qRT–PCR,	  n.4.	  (b)	  Inhibition	  of	  SMART	  prevents	  muscle	  atrophy	  in	  denervated	  muscles.	  Adult	  muscle	  fibres	  were	  co-­‐transfected	  with	  bicistronic	  expressing	  vectors	  that	  encode	  shRNAs	  against	  SMART	  (oligo	  4)	  or	  scramble	  and	  GFP	  and	  denervated.	  Two	  weeks	  later	  cross-­‐sectional	  area	  of	  transfected	  fibres,	  identified	  by	  GFP	  fluorescence,	  was	  measured.	  n.6	  muscles	  for	  each	  group.	  (c)	  Densitometric	  quantification	  of	  polyubiquitinated	  proteins	  in	  muscle	  extracts	  transfected	  with	  shRNAs	  against	  SMART	  or	  scramble.	  Values	  are	  normalized	  to	  GAPDH	  and	  expressed	  as	  fold	  increase	  of	  fed	  control	  mice.	  N=3	  muscles	  for	  each	  group.	  Data	  are	  shown	  as	  mean±s.e.m.	  Error	  bars	  indicate	  s.e.m.	  *P<0.05,	  **P<0.01	  (Student’s	  t-­‐test).	  con,	  control;	  den,	  denervated;	  IB,	  immunoblotting.	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4.	  DISCUSSION	  	  	  Muscle	  atrophy	  occurs	  in	  specific	  muscles	  with	  denervation	  or	  inactivity,	  but	  is	  also	  a	  systemic	  response	  to	  fasting	  and	  various	  diseases.	  The	  identification	  of	  the	  precise	  signaling	  cascades	  that	  regulate	  muscle	  wasting	  remains	  poorly	  understood.	  Forkhead	  box	  class	  O	  family	  member	  proteins	  (FoxOs)	  are	  highly	  conserved	  transcription	  factors	  with	  important	  roles	  in	  cellular	  homeostasis	  like	  apoptosis,	  ROS	  detoxification,	  glucose	  metabolism,	  DNA	  repair,	  cell	  cycle,	  stem	  cell	  maintenance	  and	  longevity.	  The	  role	  of	  FoxO	  transcription	  factors	  in	  the	  regulation	  of	  skeletal	  muscle	  protein	  degradation	  has	  been	  studied	  over	  the	   last	   years.	   FoxO	   has	   been	   shown	   to	   regulate	   the	   two	  major	   systems	   of	  protein	   breakdown	   in	   skeletal	   muscle,	   the	   ubiquitin–proteasome	   and	   the	  autophagy–lysosomal	   pathways.	   The	   ubiquitin-­‐proteasome	   system	   is	  constitutively	  active	   in	  muscle	  but	   its	   activity	   increases	   significantly	  during	  muscle	   atrophy	  due	   to	   activation	  of	   two	  ubiquitin	   ligases:	  Atrogin-­‐1/Mafbx	  and	   Murf1	   (Gomes	   et	   al.,	   2001).	   The	   activation	   of	   these	   two	   genes	   is	  regulated	   by	   the	   transcription	   factor	   FoxO3.	   This	   factor	   is	   normally	  phosphorylated	   and	   inactivated	   by	   AKT/PKB	   kinase	   and	   this	   is	   due	   by	   the	  exclusion	   of	   FoxO3	   from	   nucleus.	   Conversely,	   when	   this	   pathway	   is	  suppressed	  (es:	  during	  muscle	  atrophy),	  FoxO3	  translocates	  into	  the	  nucleus	  where	  it	  can	  trascribe	  its	  target	  genes	  (Sandri	  et	  al.,	  2004;	  Stitt	  et	  al.,	  2004).	  Among	  the	  three	  FOXO	  family	  members,	  FoxO1	  and	  FoxO3	  have	  received	  the	  most	  attention	  as	  they	  are	  probably	  activated	  in	  all	  types	  of	  atrophy	  (Sandri	  et	  al.,	  2004),	  and	   they	  both	   induce	  components	  of	   the	  UPS	  	  and	  autophagy	   .	  The	   critical	   contribution	   in	   understanding	  muscle	   atrophy	   comes	   from	   the	  pioneering	  studies	  on	  gene	  expression	  profiling	  performed	  independently	  by	  groups	  of	  	  Goldberg	  and	  Glass.	  They	  used	  microarray	  studies	  to	  identify	  a	  set	  of	   120	   atrophy-­‐related	   genes	   named	   atrogenes	   that	   were	   induced	   or	  repressed	   in	   various	   wasting	   conditions	   such	   as	   diabetes,	   chronic	   renal	  failure,	  cancer	  cachexia,	  fasting	  and	  denervation.	  Moreover,	   the	   trascription	   factors	   that	   orchestrate	   this	   complex	   gene	  network	   are	   still	   largely	   unknown.	   For	   this	   reason,	   we	   have	   decide	   to	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elucidate	   the	   specific	   function	   of	   FoxOs	   in	   skeletal	   muscle.	   Our	   findings	  highlight	  the	  FoxO	  family	  as	  one	  of	  the	  most	  important	  regulators	  of	  muscle	  loss.	   In	   fact,	  here	  we	  dissect	   the	  role	  of	   this	   family	  of	   trascription	   factors	   in	  the	   regulation	   of	   gene	   trascription	   	   and	   muscle	   adaptation	   during	   muscle	  atrophy	  by	  loss	  of	  function	  approaches.	  The	   data	   that	   different	   genes	   involved	   in	   different	   pathways,	   including	  several	   ubiquitin	   ligases	   and	   proteasome	   subunits,	   are	   under	   FoxO	  regulation,	   is	   an	   important	   step	   towards	   the	   understanding	   of	   FoxO-­‐dependent	   adaptation	   to	   stress	   such	   as	   nutritional	   deprivation.	   It	   is	  	  important	  to	  remember	  that	  one	  of	  the	  adaptive	  response	  to	  sustain	  muscle	  mass	  and	  cellular	  survival	  during	  catabolic	  condition	  is	  autophagy.	  Our	  data	  from	  different	  knockout	  mice	  highlight	   the	  concept	  that	  FoxOs	  are	  required	  to	   sustain	   autophagy	   induction	   under	   low	   nutrients	   and	   dominate	   mTOR	  signalling.	   It	   is	  worth	   to	   underline	   that	   FoxO	  deletion	  does	   not	   affect	   basal	  autophagy	   flux	   and	   indeed	   the	   knockout	   mice	   do	   not	   show	   any	   overt	  pathological	   phenotype	   that	   may	   resemble	   the	   features	   of	   muscle	   specific	  Atg7	   knockout	   mice	   (Masiero	   et	   al.,	   2009).	   This	   is	   in	   contrast	   with	   the	  phenotype	   of	   the	   TSC1	   knockout	   mice	   that	   display	   an	   hyperactivation	   of	  mTORC1	  pathway	  leading	  to	  inhibition	  of	  basal	  autophagy	  flux	  and	  resulting	  in	  myopathic	  phenotype	  (Castets	  et	  al.,	  2013).	  FoxOs	  trascription	  factors	  are	  necessary	  to	  maintain	  autophagy	  flux	  under	   low	  nutrients,	  we	  founded	  that	  induction	  and	  maintenance	  of	  high	  autophagic	  flux	  for	  hours/days	  is	  entirely	  dependent	  on	  the	  FoxO	  family.	  The	  deletion	  of	  FoxO	  both	  in	  a	  muscle-­‐specific	  manner	  and	  in	  an	  inducible	  muscle-­‐specific	  manner	  resulted	  in	  suppression	  of	  autophagy	  during	  fasting	  represented	  by	  a	  block	  of	  LC3	  lipidation	  and	  p62	  accumulation.	  Importantly,	  in	  our	  work,	  we	  have	  characterize	  also	  the	  single	  FoxO1,3	  and	  4	  knock-­‐out	  mice	  and	  we	  shown	  that	  deletion	  of	  a	  single	  FoxO	  member	   is	   not	   sufficient	   to	   prevent	   muscle	   loss	   and	   autophagy	   activation	  supports	   the	   conclusion	   that	   there	   is	   significant	   redundancy	   among	   family	  members	  (Milan	  et	  al.,	  2015).	  	  Interestingly,	  the	  sparing	  of	  muscle	  mass	  was	  observed	  only	  in	  FoxO3	  knock-­‐out	  mice	  after	  denervation,	  and	  was	  not	  only	  due	  to	  an	  effect	  on	  the	  classical	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ubiquitin	   ligase	   atrogin1	   and	   MuRF1	   but	   also	   by	   action	   of	   FoxO3	   on	   a	  different	  set	  of	  ubiquitin	  ligases.	  	  By	  microarray	  analysis,	  we	  have	  identified	  a	  group	  of	  novel	  ubiquitin	  ligases	  that	  are	  regulated	  by	  FoxO.	  Among	  the	  novel	  E3s	   we	   identified	   a	   gene	   that	   encodes	   an	   F-­‐box	   protein	   (FbxO21)	   whose	  function	  was	  completely	  unknown	  and	  that	  we	  named	  SMART.	  	  Gain-­‐	  and	   loss-­‐of-­‐function	  experiments	   showed	   that	  FoxOs	  are	   required	   for	  SMART	   regulation	   and	   ChIP	   experiments	   revealed	   that	   both	   FoxO1	   and	  FoxO3	  are	  recruited	  on	  the	  promoter	  of	  these	  genes	  (Milan	  et	  al.,	  2015).	  We	  discovered	   SMART	   as	   a	   new	   E3	   ligase	   that	   is	   part	   on	   a	   SCF	   complex,	   and	  future	  works	  are	  necessary	  to	  elucide	  its	  function	  in	  muscle	  atrophy	  and	  its	  substrates.	  However,	  deletion	  of	  FoxO3	  and	  not	  of	  FoxO1	  completely	  blunted	  SMART	  induction	  after	  denervation,	  suggesting	  that	  SMART	  is	  mainly	  under	  FoxO3	  regulation.	  However,	  when	  we	  overexpressed	  FoxO3	  only	  MUSA1	  was	  induced,	   suggesting	   that	   FoxO3	   is	   required	   for	   SMART	   induction	   but	   not	  sufficient	   and	   that	   other	   transcription	   factors	   are	   therefore	   involved	   in	   its	  regulation.	  MUSA1	  is	  a	  novel	  ubiquitin	  ligase	  that	  we	  found	  to	  be	  critical	  for	  muscle	   atrophy	   during	   denervation	   and	   fasting.	   Expression	   of	   MUSA1	   is	  regulated	  by	  Smad	  transcription	  factors	  in	  denervated	  muscles	  (Sartori	  et	  al.,	  2013).	  The	  possibility	  that	  Smads	  and	  FoxO	  cooperate	  for	  MUSA1	  expression	  is	  consistent	  with	  the	  data	  that	  Smads	  recognize	  a	  very	  simple	  sequence	  that	  is	  extremely	  common	  in	  the	  genome	  and	  therefore,	  activated	  Smad	  proteins	  must	  associate	  with	  different	  DNA-­‐binding	  cofactors	  for	  the	  recognition	  and	  regulation	   of	   specific	   target	   genes.	   Importantly,	   in	   keratinocytes,	  glioblastoma	   and	  neuroepithelial	   cells	   FoxOs	   are	   critical	   Smad	  partners	   for	  the	   expression	   of	   p21	   and	   p15	   genes	   (Seoane	   et	   al.,	   2004).	   Therefore,	   it	   is	  possible	   that	  Smads	  are	   the	  partners	  of	  FoxO	  and	  both	  are	  required	   for	   the	  optimal	  activation	  of	  the	  atrogenes	  during	  denervation.	  Nevertheless,	  during	  fasting	  most	  of	  the	  atrophy-­‐related	  genes	  are	  completely	  dependent	  on	  FoxO.	  In	  addition	  to	  the	  FoxO	  dependent	  regulation	  of	  different	  ubiquitin	  ligases,	  it	  is	  important	  to	  emphasize	  that	  several	  proteasome	  subunits,	  ubiquitin	  C,	  the	  E4	  enzyme	  and	   the	  de-­‐ubiquitinating	   enzyme	  USP14	  are	   also	   controlled	  by	  FoxOs.	   These	   genes	   are	   critical	   in	   several	   steps	   of	   ubiquitination	   and	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Regulation of autophagy and the ubiquitin–
proteasome system by the FoxO transcriptional
network during muscle atrophy
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Stresses like low nutrients, systemic inflammation, cancer or infections provoke a catabolic
state characterized by enhanced muscle proteolysis and amino acid release to sustain liver
gluconeogenesis and tissue protein synthesis. These conditions activate the family of Fork-
head Box (Fox) O transcription factors. Here we report that muscle-specific deletion of FoxO
members protects from muscle loss as a result of the role of FoxOs in the induction of
autophagy–lysosome and ubiquitin–proteasome systems. Notably, in the setting of low
nutrient signalling, we demonstrate that FoxOs are required for Akt activity but not for mTOR
signalling. FoxOs control several stress–response pathways such as the unfolded protein
response, ROS detoxification, DNA repair and translation. Finally, we identify FoxO-dependent
ubiquitin ligases including MUSA1 and a previously uncharacterised ligase termed SMART
(Specific of Muscle Atrophy and Regulated by Transcription). Our findings underscore the
central function of FoxOs in coordinating a variety of stress-response genes during catabolic
conditions.
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Environmental transformations have selected for speciesthat are able to quickly and efficiently regulate theirphysiology. Under stress conditions, mammalian cells
activate compensatory mechanisms to adapt themselves to new
situations. Depending on the stimuli, the adaptive response either
require minor and fast metabolic changes or involves major and
sustained adjustments that need transcription-dependent adapta-
tions. Muscles are the largest protein reservoir in the body and
serve as a source of amino acids that can be used for energy
production by various vital organs (including heart, liver and
brain) during catabolic periods, such as in cancer, sepsis, burn
injury, heart failure and AIDS1. However, excessive and sustained
protein degradation in skeletal muscle, and the resulting muscle
loss (cachexia), is highly detrimental and can lead to death.
Moreover, excessive loss of muscle mass is a poor prognostic
index and impairs the efficacy of many different therapeutic
treatments. Thus, cachexia ultimately aggravates diseases and
increases morbidity and mortality.
In eukaryotic cells, most proteins are degraded via two
proteolytic systems: the ubiquitin–proteasome and the
autophagy–lysosome. In skeletal and cardiac muscles the two
systems are coordinately regulated to remove proteins and
organelles in atrophying cells2,3. Muscle atrophy requires a
transcription-dependent programme to regulate a group of genes
that are commonly up or downregulated in atrophying muscles
during different catabolic conditions and that are named atrophy-
related genes or atrogenes1,4–8. These genes encode enzymes that
catalyse important steps in autophagy–lysosome, ubiquitin–
proteasome, unfolded protein response, ROS detoxification,
DNA repair, mitochondrial function and energy balance
pathways. The transcription factors that orchestrate this
complex gene network have been the focus of active investigation.
The two atrogenes with the greatest induction are two muscle-
specific ubiquitin ligases, namely atrogin1/MAFbx and MuRF14,5.
Mice lacking these two enzymes are partially resistant to muscle
atrophy induced by denervation4. However, the action of these two
ubiquitin ligases cannot account for the degradation of all muscle
proteins. A number of additional unknown ubiquitin ligases (E3s)
are presumably activated during atrophy to promote the clearance
of myofibrillar and soluble proteins and/or to limit anabolic
processes. We have recently established that these atrophy-related
ubiquitin ligases, as well as protein breakdown in general, are
blocked by the growth-promoting IGF1/AKT pathway8,9. Members
of the Forkhead Box (Fox) O family (FoxO1, 3 and 4), downstream
targets of AKT, were identified as the main transcription factors
regulating atrogin1 expression8. Importantly, we have also found
that FoxO3 regulates autophagy coordinating the proteasomal-
dependent removal of proteins with the autophagy-dependent
clearance of organelles2,10. The use of FoxO1 knockout mice has
established a role in muscle protein homeostasis showing partial
protection from muscle loss during chronic kidney disease11.
FoxO1 deficiency was associated with partial reduction in the
expression of atrogin1, MuRF1 and the lysosomal enzyme,
Cathepsin-L11,12. These studies linking FoxOs and muscle
wasting prompted us to explore more fully the specific function
of the entire FoxO family in skeletal muscle maintenance/loss and
the potential for functional redundancy among the FoxO members
and to illuminate the atrogene expression network focused on the
identification of novel FoxO-dependent atrophy-related genes.
Here we show that specific deletion of FoxOs in skeletal
muscles prevents muscle loss and force decline in response to
fasting and denervation because the FoxO family is required for
the induction of several atrophy-related genes. Moreover, we
identify a novel ubiquitin ligase, named SMART (Specific of
Muscle Atrophy and Regulated by Transcription), that plays a
critical role in protein ubiquitination after denervation.
Results
Generation of a triple FoxO1,3,4 muscle-specific knockout.
Since muscle wasting requires a transcriptional-dependent pro-
gramme to induce the expression of a subset of genes and because
FoxO family is sufficient to induce muscle atrophy, we generated
mice with adult skeletal muscle-specific deletion of all three FoxO
family members to unravel the role of this family in gene reg-
ulation and muscle adaptation during catabolic conditions. To
that end, FoxO1/3/4-floxed mice (FoxO1/3/,4f/f) were crossed with
a transgenic line expressing Cre recombinase under the control of
muscle-specific MLC1f promoter (hereafter referred to as
FoxO1,3,4! /! ). PCR analysis confirmed deletion of the floxed
sequence from genomic DNA extracted from skeletal muscle
(Fig. 1a). Quantitative reverse transcription–PCR (RT–PCR) and
Western blot analyses showed a significant decrease or elimina-
tion of FoxO1, FoxO3 and FoxO4 transcripts and proteins,
respectively (Fig. 1b,c). Since FoxO4 is mainly expressed in stri-
ated muscles13, while FoxO1 and 3 are expressed in a variety of
tissues, the traces of FoxO1 and 3 messenger RNAs (mRNAs)
come from endothelial, fibroblasts, macrophages and blood cells.
Thus, we confirm a genetic model of muscle-specific inhibition of
FoxO1,3,4 family.
Triple FoxO1,3,4 deletion in muscle does not affect fibre type.
FoxO1,3,4! /! mice were indistinguishable in gross appearance
from age-matched control FoxO1,3,4f/f mice and histological
analysis of adult muscles revealed normal muscle architecture and
absence of myopathic features such as centrally nucleated fibres
(Fig. 1d). Succinate dehydrogenase staining showed no major
changes in distribution of small b-oxidative mitochondrial rich
versus large glycolytic mitochondrial poor fibres (Fig. 1e). Since
FoxOs are important for glucose homeostasis in liver, we mon-
itored glycogen levels in muscle. PAS staining revealed an almost
identical distribution of glycogen stores (Fig. 1f). Analyses of
myosin heavy chain expression (Fig. 1g) and distribution (Fig. 1h)
did not reveal any significant difference between wild-type and
FoxO1,3,4 knockout mice. These findings support the view that
FoxO deficiency does not affect fibre type determination and
basal glucose homeostasis and is permissive for normal muscle
function. Quantification of cross-sectional area of fast muscles
(Tibialis Anterior (TA) and Gastrocnemius) did not show any
significant difference between knockout and controls (Fig. 1i,
Supplementary Fig. 1).
FoxO inhibition prevents muscle loss and weakness. To further
characterize the role of FoxO1,3,4 in skeletal muscles, we then
analysed the phenotype of FoxO1,3,4! /! mice under conditions
of muscle wasting. Initially, we used fasting as a model of muscle
loss since it is an established condition that induces nuclear
translocation of FoxO members and their binding to target pro-
moters2,8,14 (Supplementary Fig. 2) and we compared FoxO1,3,4
null muscles with controls. Importantly, FoxO1,3,4 knockout
mice were completely spared from muscle loss after fasting
(Fig. 2a, Supplementary Fig. 3). To understand whether sparing of
muscle mass is also functionally relevant, we measured muscle
force in living animals. While control fasted animals became
significantly weaker than fed ones, FoxO1,3,4! /! gastrocnemius
muscles did not loose strength after fasting (Fig. 2b). Importantly
the comparison of force/frequency curve of fasted wild-type
versus fasted FoxO1,3,4 null muscle underlined the important
protection achieved by the absence of FoxO family when
nutrients are low or absent (Fig. 2c). These findings confirm
that the absence of FoxO members prevents atrophy and
profound weakening. To explain this profound effect on
sparing force and muscle mass, we monitored the level of the
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contractile protein, myosin, when nutrients are removed. As
expected, fasting induced an important reduction of myosin
content in controls, while FoxO1,3,4 knockout were completely
protected (Supplementary Fig. 4a). The maintenance of myosins
in knockout is consequent to inhibition of protein ubiquitination
(Supplementary Fig. 4b-c).
FoxOs are critical for autophagy and protein ubiquitination.
To explore the basis for sparing of muscle mass in absence of
nutrients, we audited the signalling pathways linked to Insulin/
IGF1 and energy. Interestingly, Akt, S6K and S6 phosphorylation,
both in fed and fasted muscles, were reduced in knockout mice,
while phosphorylation of 4EBP1, the other mTORC1 down-
stream target, was increased in FoxO-deficient TA muscle
(Fig. 2d, Supplementary Fig. 5a). The energy–stress sensor AMPK
and its downstream target ACC did not significantly differ from
controls in fed and fasting conditions (Fig. 2d). Therefore, the
changes in the pathways downstream energy and insulin/nutri-
ents do not match with the important sparing of muscle mass in
knockout mice when nutrients are absent.
Since the absence of nutrients is a potent stimulus for
autophagy-dependent degradation and since FoxO is an inducer,
while mTOR is a suppressor of autophagy–lysosome system, we
checked the status of this system in FoxO1,3,4! /! mice. We
monitored LC3 lipidation, LC3-positive vesicles and autophagy
flux in FoxO1,3,4f/f and FoxO1,3,4 ! /! mice. Fasting induced
LC3 lipidation (Fig. 2e, Supplementary Fig. 5b) and vesicles
formation (Fig. 2f) in control but not in FoxO-deficient muscles.
Autophagy flux was monitored by treating animals with
colchicine, an established inhibitor of microtubule-mediated
delivery of autophagosome to lysosome15. The inhibition of
autophagosome fusion to lysosomes led to accumulation of
lipidated LC3 in controls but not in FoxO1,3,4-deficient muscles
(Fig. 2g). In conclusion, during fasting, despite mTOR signalling
being partially inhibited, autophagy enhancement is completely
blocked in FoxO1,3,4! /! muscle.
Absence of nutrients activates also the ubiquitin–proteasome
system, leading to an increase of protein ubiquitination and,
consequently, in proteasome-dependent degradation. Fasting
resulted in an increase in both lysine-48 and lysine-63 poly-
ubiquitinated proteins (Supplementary Fig. 4b,c), confirming an
activation of the ubiquitination process in controls. Importantly,
this increase was totally abolished in FoxO1,3,4 knockout mice.
Half of the atrophy-related genes are under FoxO regulation.
Since muscle atrophy is characterized by transcription-dependent
regulation of atrogenes (atrophy-related genes) and FoxO defi-
ciency protects from muscle loss, we sought to identify genes
under FoxO regulation. Gene expression profiles of fed and fasted
control and FoxO1,3,4! /! muscles were compared with identify
genes with blunted induction in the fasted FoxO1,3,4! /! mice



























































































































































Figure 1 | Deletion of FoxOs is permissive for normal muscle function. (a) PCR analysis with genomic DNA from FoxO1,3,4f/f and FoxO1,3,4! /!
gastrocnemius muscles. (b) FoxO1, FoxO3 and FoxO4 mRNA expression were quantified by RT–PCR in Tibialis Anterior (TA) muscle of FoxO1,3,4! /!
and control mice. n¼4 each group. (c) Immunoblot showing reduction of FoxO1 and FoxO3 proteins in homogenates of FoxO1,3,4! /! gastrocnemius
muscles. Data are representative of three independent experiments. (d) Haematoxylin and eosin (Scale bar, 100mm), (e) SDH (Scale bar, 1mm) and
(f) PAS staining (Scale bar, 1mm) showing normal morphology, fibre type and glycogen of FoxO1,3,4! /! gastrocnemius muscle. (g) SDS–PAGE and
(h) immunohistochemistry analysis of myosin heavy chain type I, IIA, IIB and IIX proteins in gastrocnemius muscles showing no differences between
FoxO1,3,4! /! and FoxO1,3,4f/f mice. Data are representative of three independent experiments. (i) Frequency histograms showing the distribution of
cross-sectional areas (mm2) in TA of FoxO1,3,4f/f (white bars) and FoxO1,3,4! /! (black bars) fibres, n¼4, each group. Data are shown as mean±s.e.m.
Error bars indicate s.e.m. **Po0.01 (Student’s t-test).
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atrogenes7, these analyses revealed that 29 of the 63 atrophy-
related genes require FoxO for their normal induction during
fasting (Fig. 2h, Supplementary Fig. 10). Quantitative RT–PCR
confirmed that 26 of the atrophy-related genes were not induced
in FoxO null muscles during fasting (Fig. 3). Consistent with
morphology and force measurements, the induction of genes
involved in protein breakdown was completely blocked in
knockout mice. In fact both the ubiquitin system including the
ubiquitin ligases (Atrogin1 and MuRF1), the ubiquitin gene
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(Ube4b), several proteasome subunits (Psme4/PA200, Psma1,
Psmc4/Rpt3 and Psmd11/Rpn6) as well as the autophagy-related
genes (LC3, Gabarapl, Bnip3, Cathepsin L and p62/SQSTM1)
were completely blocked in FoxO1,3,4! /! mice. Other pathways
that are inhibited in knockout muscles are related to the unfolded
protein response (ATF4 and GADD34), protein synthesis (4EBP1
and eIF4g), transcription regulators that negatively control
Smad2/3 (TGIF) or positively affect Myc (MAX), DNA repair/
chromatin remodelling (GADD45a) and ribosome transcription/
maturation/assembly (Nucleolin). Expression of genes that are
related to oxidative stress were more variable; Nrf2/Nfe2l2 was not
affected by FoxO deletion, while Thioredoxin was suppressed and
Metallothionein1 was significantly induced in the absence of
FoxO factors.
Western blot analyses of some atrogenes involved in autophagy
(p62, Gabarapl and Bnip3), chromatin remodelling/DNA repair
(GADD45a), protein synthesis (4EBP1) and ubiquitin–
proteasome confirmed their upregulation during fasting in
control animals but not in FoxO1,3,4 knockout (Supplementary
Fig. 6).
Inducible FoxOs loss phenocopies the conditional knockout.
To corroborate our findings, we also explored the impact of
somatic deletion of FoxO in the adult via a tamoxifen-inducible
muscle-specific FoxO knockout model. Following documentation
of tamoxifen-induced deletion of FoxOs (Supplementary Fig. 7),
we assessed muscle loss during fasting by monitoring muscle
mass and muscle force. Similar to the above, we found that
somatic deletion of FoxO1,3,4 prevented muscle loss (Fig. 4a) and
muscle weakness during fasting (Fig. 4b). Consistent with the
conditional knockout, Akt activation and LC3 lipidation was
reduced in FoxO knockout when compared with controls
(Fig. 4c). Autophagy flux measurements confirmed that FoxOs
are required for autophagy induction (Fig. 4d). We then tested
whether inhibition of FoxO members in adulthood blocked the
activation of the atrogenes. Indeed, we confirmed most of the data
obtained by the conditional FoxO1,3,4 knockout (Supplementary
Fig. 8). The fact that two different FoxO1,3,4 knockout mice
resulted in comparable biological effects strongly supports the
conclusion that the FoxO family is a master regulator of the
atrophy programme under low nutrient conditions.
FoxOs directly regulate atrophy-related genes. To determine
whether the regulation of these atrogenes requires direct binding
of FoxO transcription factors to their promoters and to identify
the binding sites we performed chromatin immunoprecipitation
(ChIP) experiments on fasted muscles of FoxO1,3,4f/f. We also
used FoxO1,3,4! /! as a negative control to validate the speci-
ficity of the immunoprecipitation. FoxO3 was recruited to almost
all of the promoters so far analysed (Fig. 4e). We then asked
whether the activation of these genes is strictly dependent on
FoxO3 or whether other FoxO members can bind the same
promoter region. We could immunoprecipitate FoxO1 but not
FoxO4 because we did not find any ChIP grade antibody that was
specific for FoxO4 without crossreacting with other FoxOs.
Interestingly, FoxO1 was found to be significantly recruited to
some promoters such as MuRF1, p62, Cathepsin L and TGIF
(Fig. 4f). This finding suggests that regulation of some genes is
shared by different FoxO members, while others preferentially
recruit FoxO3.
FoxOs are required for denervation-dependent atrophy. To
further determine whether the role of FoxO1,3,4 is critical in
different catabolic conditions, we then used denervation as
another model of muscle atrophy. Quantification of fibre size
revealed that FoxO-deficient muscles were partially protected
from atrophy (Fig. 5a, Supplementary Fig. 9). When we mon-
itored muscle force, we confirmed the histological data. Soleus
muscle of FoxO1,3,4 knockout mice generated higher strength
than controls in the basal condition (Fig. 5b) and FoxO deletion
was able to partially prevent weakness and maintain the same
force of innervated FoxO1,3,4f/f (Fig. 5b,c). The decrease of force
in denervated FoxO1,3,4-deficient soleus muscle is related to the
presence of FoxO proteins in type I fibres that can promote
protein breakdown in these myofibres. It is important to
emphasize that the type I fibres express FoxOs because the pro-
moter (MLC1f) driving the expression of Cre recombinase is
active in type II fibres and not in type I fibres. However, com-
parison of the force/frequency curves of denervated wild-type
versus denervated FoxO1,3,4 null soleus muscles underlines the
important protection conferred by the absence of FoxO family
when nerve is damaged (Fig. 5c). Analyses of signalling confirmed
the downregulation of P-AKT in knockout muscles. Denervation
induced an increase of total and phospho-4EBP1 protein in
FoxO1,3,4f/f but not in FoxO1,3,4! /! muscle (Fig. 5d). The
changes in the phosphorylation of 4EBP1 were not ascribed to
activation of the cellular energy sensor AMPK, revealed by
checking its phosphorylation level or the downstream target
ACC. In contrast to fasting, the autophagy system was mildly
affected by the absence of FoxOs. Indeed, LC3 lipidation was
slightly decreased in FoxO1,3,4! /! compared with controls after
denervation (Fig. 5e). However, and consistent with fasting, the
transcriptional upregulation of p62/SQSTM1 in denervated
muscles was greatly attenuated (Figs 5e and 6). When we tested
the expression of the different atrophy-related genes, we found
only a partial suppression of these genes (Fig. 6). Interestingly, the
lists of FoxO-dependent genes during denervation and fasting do
not completely overlap (Supplementary Fig. 10). For instance, the
Figure 2 | Deletion of FoxOs prevents muscle loss and weakness during fasting. (a) Frequency histograms of cross-sectional areas (mm2) of FoxO1,3,4f/f
(black bars) and FoxO1,3,4! /! (magenta bars) fibres in fed (upper panel) and fasted (lower panel) conditions, n¼4, each group. (b) Force measurements
preformed in vivo on gastrocnemius showed that FoxO1,3,4! /! muscles preserve maximal tetanic force after fasting; n¼6 muscles in each group.
(c) Force/frequency curve of starved gastrocnemius muscle underlines the important protection achieved by the absence of FoxOs; n¼6 muscles in each
group. (d) Immunoblot of protein extracts from gastrocnemius muscles. Phosphorylation of AKTand S6 is reduced in fed and starved FoxO1,3,4! /! muscles
when compared with controls. Data are representative of three independent experiments. (e) Immunoblot analysis of p62 and LC3 in homogenates of
gastrocnemius muscles from fed and starved FoxO1,3,4! /! or controls. Fasting did not induce LC3 lipidation and p62 upregulation in FoxO-deficient
muscles. Data are representative of three independent experiments. (f) Quantification of GFP–LC3-positive vesicles in FoxO1,3,4f/f and FoxO1,3,4! /! TA
muscles; n¼4 muscles in each group (g) Autophagy flux is not increased in FoxO-deficient TA muscles. Inhibition of autophagy–lysosome fusion by
colchicine treatment induces accumulation of LC3II band in starved control but not in starved FoxO1,3,4! /! muscles. Upper panel: immunoblot analysis of
gastrocnemius homogenates. Lower panel: quantification of LC3 lipidation. n¼4 muscles in each group (h) The scheme shows the overlap between
FoxO-dependent genes, identified by gene expression profiling of fed (n¼4) and fasted (n¼4) muscles from FoxO1,3,4f/f and FoxO1,3,4! /! and
atrophy-related genes or atrogenes. The data in the graphs are shown as mean±s.e.m. Error bars indicate s.e.m. *Po0.05, **Po0.01 (Student’s t-test).
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ROS detoxifying factor, Nrf2/Nfe2l2, was not affected by FoxO
deletion in fasting, while it was less activated in denervated
FoxO1,3,4 null muscles. Therefore, FoxO family members are
necessary for muscle loss but their involvement in the atrophy
programme depends on the catabolic condition.
FoxO members are redundant. Since all FoxO members are
expressed in muscles and are under AKT regulation, we investi-
gated whether they play synergistic roles or have specific
functions. To address this point, we generated muscle-specific
individual FoxO knockout animals. We used denervation as a
model of muscle atrophy. Deletion of FoxO1 did not protect from
muscle atrophy (Fig. 7a, Supplementary Fig. 11). However the
presence of FoxO1 is required for the optimal induction of several
atrophy-related genes including MuRF1, Cathepsin L, Gabarap L,
GADD45a and TGIF (Supplementary Fig. 12).
Inhibition of FoxO3 led to a small but significant protection
from denervation-induced muscle atrophy (Fig. 7b). The
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Figure 3 | Absence of FoxOs prevent the induction of critical atrogenes. Quantitative RT–PCR of atrogenes from fed and 24-h starved tibialis anterior of
control and FoxO1,3,4! /! mice. Data are normalized to GAPDH and expressed as fold increase of control-fed animals. n¼4 muscles in each group
Values are mean±s.e.m. *Po0.05,**Po0.01. (Student’s t-test).
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(Supplementary Fig. 13). Interestingly, when we checked the level
of gene expression we found that FoxO4 was strongly down-
regulated in FoxO3! /! mice (Supplementary Fig. 14). Optimal
expression of Gabarapl, 4EBP1, Maf, Gadd45a, Pfkf3 and Txn1
requires the presence of FoxO3 (Supplementary Fig. 14).
Ablation of FoxO4 did not significantly protect myofibres from
atrophy after denervation (Fig. 7c and Supplementary Fig. 15)
and did not reduce the expression of any atrogenes with the
exception of a slight reduction of GADD45a and Thioredoxin
(Supplementary Fig. 16).
FoxOs regulate a novel set of ubiquitin ligases. To explain why











































































































































































































Figure 4 | Acute inhibition of FoxOs phenocopies the conditional FoxO1,3,4 knockout. (a) Frequency histograms of gastrocnemius muscles showing the
distribution of cross-sectional areas (mm2) of inducible muscle-specific FoxO1,3,4 mice after tamoxifen-dependent deletion of FoxO1,3,4 genes (FoxO1,3,4f/f:
black bars and FoxO1,3,4! /! : magenta bars) in fed (upper panel) and fasted (lower panel) conditions, n¼ 3, each group. (b) Force measurements
preformed in vivo on gastrocnemius muscle showed that acute inhibition of FoxOs in adulthood prevents force drop during fasting. n¼ 6 muscles in each
group. Freq: Frequency. (c) Left, immunoblotting analyses of gastrocnemius homogenates after acute deletion of FoxO1,3,4! /! and controls. Right,
quantification of LC3 lipidation. Data are representative of three independent experiments. (d) Autophagy flux is not increased in FoxO-deficient TA
muscles. Inhibition of autophagy–lysosome fusion by colchicine treatment induces accumulation of LC3II band in starved control but not in starved
FoxO1,3,4! /! muscles. Left, immunoblotting analyses of gastrocnemius homogenates. Right, quantification of LC3 lipidation. (e,f) ChIP quantitative RT–
PCR shows the recruitment of FoxO3 and FoxO1 on the promoters of selected atrophy-related genes. ChIP assays were performed in starved control and
FoxO1,3,4! /! TA muscles. IgG was used as the reference. n¼ 3 for each group. Data are shown as mean±s.e.m. Error bars indicate s.e.m. *Po0.05,
**Po0.01 (Student’s t-test). S1: FoxO binding site 1; S2: FoxO binding site 2.
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limited effects on induction of the atrophy-related genes, we
looked for novel genes that might be involved in protein break-
down and that are selectively regulated by this FoxO member in
denervated muscles. When we looked at the gene expression
profiles in fasted muscles of FoxO1,3,4 knockout mice, we noticed
a group of ubiquitin ligases that were upregulated in FoxO1,3,4f/f
but not in FoxO1,3,4! /! mice. This set of ubiquitin ligases
includes MUSA1, a novel E3, that we have recently found to be
critical in muscle atrophy16, Fbxo31, an E3 of SCF family involved
in cyclinD degradation and tumour suppression17, Itch, a HECT-
type ubiquitin ligase that regulates the half-life of transcription
factors such as JunB, c-Jun and p6318, and, finally, Fbxo21, a gene
of unknown function but that contains an F-box motif and that
we re-named SMART.
By quantitative RT–PCR, we could validate that upregulation
of MUSA1, SMART and FbxO31, but not Itch, is blunted or
partially blocked in fasted or denervated muscles of FoxO1,3,4,
knockout mice (Fig. 7d,e). To further prove that the FoxO family
is sufficient for their expression, we overexpressed FoxO3 in
myotubes and we checked the expression of these E3s.
Interestingly, FoxO3 was sufficient to induce the expression of
MUSA1 but not the other ubiquitin ligases (Supplementary
Fig. 17). We then analysed the promoter regions of these
genes and checked whether endogenous FoxO1 and FoxO3
directly bind these regions. ChIP experiments on fasted muscle
confirmed that both FoxO1 and FoxO3 bind to the promoters
of MUSA1 and SMART (Fig. 7f,g). However, we did not find
any significant recruitment of FoxOs on Itch and Fbxo31
promoters (Fig. 7f,g).
We checked whether expression of these ubiquitin ligases
was suppressed in denervated muscles of the single FoxO
knockout mice. Interestingly, FoxO3 deletion completely
blunted the induction of SMART while ablation of the other
FoxO members did not elicit any effect on the upregulation
of these ubiquitin ligases (Fig. 7h–j). Therefore, FoxO3 is
the main regulator of SMART in denervated muscles
and inhibition of SMART may explain the partial protection
of FoxO3 null muscles after denervation (Fig. 7b and
Supplementary Fig. 13).
SMART is a novel E3 ligase required for muscle atrophy. IP
experiments confirmed that SMART forms an SCF complex with
Skp1, Cullin1 and Roc1 (Fig. 8a) and therefore belongs to the SCF
family of E3 ligases. To confirm the role of SMART in promoting
atrophy during denervation, we knocked down SMART in TA
in vivo. Four different short hairpin RNAs (shRNAs) have been
tested to specifically reduce SMART protein levels
(Supplementary Fig. 18a), three of which efficiently knocked
down SMART. Next, we transfected oligo 4 into innervated and
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Figure 5 | Deletion of FoxOs in skeletal muscle partially prevents atrophy during denervation. (a) Frequency histograms of gastrocnemius muscles from
FoxO1,3,4! /! and control mice showing the distribution of cross-sectional areas (mm2) of FoxO1,3,4f/f (black bars) and FoxO1,3,4! /! (magenta bars) in
control (upper panel) or in denervation (lower panel). n¼4 muscles each groups. (b) Force measurements preformed ex vivo on soleus muscles show that
FoxO1,3,4! /! muscles are stronger than controls, both in basal condition and after 14 days from denervation. n¼6 muscles in each group. (c) Force/
frequency curves of denervated soleus highlight the higher strength generated by FoxO1,3,4! /! muscles when compared with controls. n¼6 muscles in
each group. (d) Immunoblots of gastrocnemius protein extracts reveal a decrease of AKTphosphorylation both in contralateral and in denervated muscles
of FoxO1,3,4! /! mice. The increase of 4EBP1 protein is blunted in FoxOs knockout mice. (e) Immunoblots of autophagy-related proteins. FoxOs are
required for p62 induction, while LC3 is less lipidated after 3 days of denervation. Data are representative of three independent experiments. Data are
shown as mean±s.e.m. Error bars indicate s.e.m. *Po0.05, **Po0.01 (Student’s t-test). C, control; D, denervated.
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denervated muscles. These shRNAs did not affect the expression
of the other atrophy-related ubiquitin ligases, MUSA, MuRF1 and
atrogin1 both at protein and mRNA level (Supplementary
Fig. 18b, Fig. 8b). Importantly, SMART inhibition significantly
protected denervated muscles from atrophy (Fig. 8c). This spar-
ing is due to the fact that by blocking SMART we greatly reduced
protein ubiquitination in denervated muscles (Fig. 8d,
Supplementary Fig. 18c). Therefore, we have identified SMART as
an additional critical gene whose upregulation is required for
atrophy, yet must be carefully controlled to avoid excessive pro-
tein breakdown. In conclusion, our findings underline the
concept that FoxO members are the master regulatory factor for
protein homeostasis during catabolic conditions.
Discussion
FoxOs are involved in a variety of biological process such as
autophagy, apoptosis, ROS detoxification, glucose metabolism,
DNA repair, cell cycle, stem cell maintenance and longevity19,20.
Our work and that of others has shown that muscle atrophy is
regulated by a transcription-dependent process that requires the



























































































































































































Figure 6 | FoxOs are required for expression of several atrogenes after denervation. Quantitative RT–PCR of the indicated atrogenes after 3 days from
denervation. Data are normalized to GAPDH and expressed as fold increase of control innervated muscles. Values are mean±s.e.m. *Po0,05, **Po0.01
(Student’s t-test).; cont, control; den, denervated.
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this complex gene network are still largely unknown but our
findings highlight the FoxO family as one of the most important
regulators. The finding that different genes involved in different
pathways, including several ubiquitin ligases and proteasome
subunits, are under FoxO regulation, is an important step towards
the understanding of FoxO-dependent adaptation to stress such
as nutritional deprivation. For instance, one of the most
important adaptive responses that is induced to maintain
cellular survival under stress conditions is autophagy21. Our



























































































































































































































































































































































































Figure 7 | FoxO members are redundant and control a new set of ubiquitin ligases. (a–c) Frequency histograms showing the distribution of cross-sectional
areas (mm2) of gastrocnemius muscles from muscle-specific (a) FoxO1! /! , (b) FoxO3! /! and (c) FoxO4! /! mice. Data are shown as mean±s.e.m. of
four muscles each group. *Po0.05, **Po0.01. (d,e) qRT–PCR of the novel ubiquitin ligases MUSA1, Fbxo21/SMART, Fbxo31, Itch from 24 starved (d) or
denervated (e) FoxO1,3,4f/f and FoxO1,3,4! /! mice. Data are normalized to GAPDH and expressed as fold increase of fed control mice. n¼4 muscles for
each group. (f) ChIP qPCR of FoxO3 and (g) FoxO1 on the promoters of MUSA1, Fbxo21/SMARTand Itch. IgG was used as the reference. n¼ 3. (h–j) qRT–PCR
ofMUSA1, Fbxo21/SMART, Fbxo31, Itch in (h) FoxO1, (i) FoxO3 and (j) FoxO4 knockout mice after 3 days of denervation. Values are normalized to GAPDH and
expressed as fold increase of control mice. n¼4 muscles for each group. Data are shown as mean±s.e.m. Error bars indicate s.e.m. *Po0.05, **Po0.01
(Student’s t-test). con control; den, denervated. MUSA1 S1, FoxO-binding site1; MUSA1 S2, FoxO-binding site2; MUSA1 S3, FoxO-binding site3.
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FoxOs are required to sustain autophagic flux under low nutrients
and dominate mTOR signalling on autophagy regulation. It is
worth underlining that FoxO deletion does not affect basal
autophagic flux and indeed the knockout mice do not show any
overt pathological phenotype that may resemble the features of
muscle-specific Atg7 knockout mice22. This is in contrast with the
phenotype of TSC1 knockout mice, which display hyperactivation
of the mTORC1 pathway leading to inhibition of basal
autophagic flux and resulting in a myopathic phenotype23.
Altogether these findings suggest that basal autophagy is
controlled by mTOR and not by FoxOs, while induction and
maintenance of high autophagic flux for hours/days is
entirely dependent on the FoxO family. Indeed, deletion of
FoxO both in a muscle-specific manner and in an inducible
muscle-specific manner resulted in suppression of autophagy
during fasting in face of mTOR inhibition. Importantly, the
demonstration that deletion of a single FoxO member is not
sufficient to prevent muscle loss and autophagy activation
supports the conclusion that there is significant redundancy
among family members.
Among the family members, FoxO3 deletion is less compen-
sated by the other factors suggesting that FoxO3 is the most
critical factor for the atrophy programme. Interestingly, the
sparing of muscle mass in the single knockout is not only due
to an effect on the classical ubiquitin ligase atrogin1 and MuRF1
but is due to FoxO action on a different set of ubiquitin ligases.
Indeed we have identified a group of novel ubiquitin ligases
that are regulated by FoxO. Among the novel E3s, we identified
a gene that encodes an F-box protein (FbxO21) whose
function was completely unknown and that we named SMART.
Gain- and loss-of-function experiments showed that FoxOs are
required for SMART regulation and ChIP experiments
revealed that FoxO1 and FoxO3 are recruited on the promoter.
However, deletion of FoxO3 and not of FoxO1 completely
blunted SMART induction after denervation, suggesting that
SMART is mainly under FoxO3 regulation. However, when we
overexpressed FoxO3 only MUSA1 was induced, suggesting that
FoxO3 is required for SMART induction but not sufficient and
that other transcription factors are therefore involved in its
regulation.
MUSA1 is a novel ubiquitin ligase that we found to be critical
for muscle atrophy during denervation and fasting. Indeed,
RNAinterference (RNAi)-mediated inhibition of MUSA1 expres-
sion, in vivo, in denervated muscles, spares muscle mass.
Conversely, excessive MUSA1 induction exacerbates muscle loss
causing muscle cachexia16. Expression of MUSA1 is regulated by
Smad transcription factors16 in denervated muscles. The
possibility that Smads and FoxO cooperate to promote MUSA1
expression is consistent with the finding that Smads require FoxO
for the regulation of specific target genes. Therefore, it is possible
that Smads are the partners of FoxO and both are required for the
optimal activation of the atrogenes, at least during denervation.
However, during fasting most of the atrophy-related genes are
completely dependent on FoxO. In addition to the FoxO-
dependent regulation of different ubiquitin ligases, it is
important to emphasize that several proteasome subunits,
ubiquitin C and the de-ubiquitinating enzyme USP14 are also
controlled by FoxOs. These genes are critical in several steps of
ubiquitination and proteasome-dependent degradation and might
have an important role in control of protein degradation. For
instance, it has recently been reported that expression of PSMD11





























































































Figure 8 | Smart is a novel ubiquitin ligase required for denervation-dependent atrophy. (a) Co-immunoprecipitation experiment showing that SMART
is a F-box protein that forms a SCF complex. C2C12 muscle cell lines were transfected with SMART, Skp1, Cul1 and Roc1 expression plasmids. After 24 h,
cells were lysed and immunoprecipitation against FLAG-tag or control IgG was performed. Western blots for the different SCF components are shown.
(b) RNAi-mediated knockdown of SMART revealed by quantitative RT–PCR (qRT–PCR). Adult TA muscles were transfected with bicistronic expressing
vectors that encode either oligo 4 or scramble and GFP. Two weeks later TA muscles were collected, RNA extracted and endogenous SMART, MUSA1,
Atrogin1, MuRF1 and Fbxo31 expression were analysed by qRT–PCR, n¼4. (c) Inhibition of SMART prevents muscle atrophy in denervated muscles. Adult
muscle fibres were co-transfected with bicistronic expressing vectors that encode shRNAs against SMART (oligo 4) or scramble and GFP and denervated.
Two weeks later cross-sectional area of transfected fibres, identified by GFP fluorescence, was measured. n¼ 6 muscles for each group. (d) Densitometric
quantification of polyubiquitinated proteins in muscle extracts transfected with shRNAi against SMART or scramble. Values are normalized to GAPDH
and expressed as fold increase of fed control mice. n¼ 3 muscles for each group. Data are shown as mean±s.e.m. Error bars indicate s.e.m. *Po0.05,
**Po0.01 (Student’s t-test). con, control; den, denervated; IB, immunoblotting.
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and activity and, in C. elegans, a PSMD11 homologue induces
resistance to oxidative stress and poly-glutamine aggregation and
extends lifespan24.
Further work is needed to understand the interplay between
the autophagy–lysosome and ubiquitin–proteasome systems in
the context of different catabolic or even anabolic conditions,
however, this work sets out the fundamentals for understanding
the regulation of proteostasis in striated muscles.
Methods
Generation of muscle-specific FOXO1,3,4 knockout mice. Mice bearing
FoxO1,3,4-floxed alleles (FoxO1,3,4f/f) 25 were crossed with transgenic mice
expressing Cre either under the control of a Myosin Light Chain 1 fast promoter
(MLC1f-Cre)2,26 or with transgenic expressing a Cre-ER driven by human skeletal
actin promoter27. Genomic DNA isolated from FoxO1,3,4f/f mice was subjected to
PCR analysis. Cre-mediated recombination was confirmed by PCR with genomic
DNA from gastrocnemius muscles using the primers Cre forward: 30-CACCAGCC
AGCTATCAACTCG-50 and Cre reverse: 30-TTACATTGGTCCAGCCACCAG-50 .
Tamoxifen-inducible Cre was activated by special tamoxifen diet (Tam400/Cre-ER
Harlan) or by i.p. Tamoxifen injection.
The genotyping analysis for each specific FoxO member was performed with
the combination of the following primers: FoxO1 forward: 30-GCT TAG AGC
AGA GAT GTT CTC ACA TT-50 , FoxO1 reverse1: 30-CCA GAG TCT TTG TAT
CAG GCA AAT AA-50, FoxO1 reverse2: 30-CAA GTC CAT TAA TTC AGC ACA
TTG A-50 , FoxO3 forward1: 30-AGA TTT ATG TTC CCA CTT GCT TCC T-50 ,
FoxO3 forward2: 30-TGC TTT GAT ACT ATT CCA CAA ACC C-50, FoxO3
reverse: 30-ATT CCT TTG GAA ATC AAC AAA ACT-50 , FoxO4 forward1:
30- TGA GAA GCC ATT GAA GAT CAG A-50 , FoxO4 forward2: 30-CTA CTT
CAA GGA CAA GGG TGA CAG-50 , FoxO4 reverse: 30-CTT CTC TGT GGG AAT
AAA TGT TTG G-50 .
Animals and in vivo transfection experiments. Animals were handled by spe-
cialized personnel under the control of inspectors of the Veterinary Service of the
Local Sanitary Service (ASL 16—Padova), the local officers of the Ministry of
Health. Mice were housed in individual cages in an environmentally controlled
room (23 !C, 12-h light–dark cycle) with ad libitum access to food and water. All
procedures are specified in the projects approved by the Italian Ministero Salute,
Ufficio VI (authorization numbers C65) and by the Ethics Committee of the
University of Padova. All experiments were performed on 2- to 4-month-old male
(28–32g) and female mice (25–28g); mice of the same sex and age were used for
each individual experiment. In vivo transfection experiments were performed by
i.m. injection of expression plasmids in TA muscle followed by electroporation8.
For fasting experiments, control animals were fed ad libitum; food pellets were
removed from the cages of the fasted animals. Denervation was performed by
cutting the sciatic nerve of the left limb, while the right limb was used as control.
Muscles were removed at various time periods after transfection and frozen in
liquid nitrogen for subsequent analyses.
Gene expression analyses. Total RNA was prepared from TA muscles using
Promega SV Total RNA Isolation kit. Complementary DNA (cDNA) generated
with Invitrogen SuperScript III Reverse Transcriptase was analysed by quantitative
real-time RT–PCR using Qiagen QuantiTect SYBR Green PCR Kit. All data were
normalized to GAPDH and actin expression. The oligonucleotide primers used are
shown in Supplementary Table 1.
Plasmids and antibodies for Western blot. In vivo transfection experiments used
the yellow fluorescent protein (YFP)–LC32 and Fbxo21SMART-V5 plasmids. For
the cloning of mouse Fbxo21/SMART gene, muscle cDNA was amplified by PCR
using the primers forward: 30-ACCATGGCGTCGGTAGCGGGGGACA-50 and
reverse: 30-CTCGGCTGTGTCCTCCTTTGCACTG-50 .
The amplified sequence was cloned into pcDNA3.1/V5-His TOPO TA
(Invitrogen) expression vector and sequenced. The list of the antibodies is
described in Supplementary Table 2.
Uncropped blots are shown in Supplementary Fig. 19.
In vivo RNAi. In vivo RNAi experiments were performed using at least three
different sequences for each gene(Invitrogen BLOCK-iTTM Pol II miR RNAi
Selected). The sequences are shown in Supplementary Table 3. For the validation of
shRNA constructs, MEF cells were maintained in DMEM/10% FBS and transfected
with shRNA constructs using Lipofectamine 2000 (Invitrogen). Cells were lysed
24 h or 48 h later and immunoblotting was performed.
Gene expression profiling. For each of the 4 conditions (FoxO1,3,4f/f fed or
starved and FoxO1,3,4! /! fed or starved), we collected the gastrocnemius muscles
of three mice thus yielding six muscles per condition.
RNA was prepared from these muscles using the TRIzol method (Life
Technologies) followed by cleanup with the RNeasy kit (Qiagen). RNA
concentration was determined by spectrophotometry and quality of the RNA was
monitored using the Agilent 2100 Bioanalyzer (Agilent Technologies). RNA of the
six muscles per condition was pooled equimolarly and used for further microarray
analysis. cRNA was prepared, labelled and hybridized to Affymetrix Mouse
Genome 430 2.0 Arrays using Affymetrix-supplied kits and according to standard
Affymetrix protocols. Expression values were summarized using the Mas 5.0
algorithm. Genes that were up or downregulated on starvation compared with the
fed condition were determined using Excel software. A threshold of 1.5 was used
for the fold up or downregulation consistent with the fold change that can be
reliably detected with these type of arrays.
In vivo ChIP assay. We performed ChIP assay in adult skeletal muscles using the
Magna ChIP A/G Chromatin Immunoprecipitation Kit (Millipore)2,28. Soluble
chromatin was co-immunoprecipitated with rabbit polyclonal anti-FKHRL1
(FoxO3) sc-11351X (Santa Cruz Biotechnology), rabbit polyclonal anti-FKHR
(FoxO1) sc-11350X (Santa Cruz Biotechnology) or an equal amount of normal
rabbit IgG, sc-2027 (Santa Cruz Biotechnology). After decrosslinking of the DNA,
samples were subjected to quantitative RT–PCR. The oligonucleotide primers used
are shown in Supplementary Table 4. The regions of amplification contain the
FOXO-binding sites for the promoter studied.
Immunoblotting and IP. Frozen gastrocnemius muscles were powdered by pestle
and mortar and lysed in a buffer containing 50mM Tris pH 7.5, 150mM NaCl,
5mM MgCl2, 1mM DTT, 10% glycerol, 2% SDS, 1% Triton X-100, Roche Com-
plete Protease Inhibitor Cocktail, 1mM PMSF, 1mM NaVO3, 5mM NaF and
3mM b-glycerophosphate. The lysis buffer used for MEF and C2C12 cells con-
tained 50mM Tris pH 7.5, 150mM NaCl, 5mM MgCl2, 1mM DTT, 10% glycerol,
1mM EDTA, 0.5% Triton X-100 and the protease inhibitors listed above. Alter-
natively, lysis buffer contained 50mM Tris HCl pH 7.2, 250mM NaCl, 2% NP40,
0.1% SDS, 0.5% sodium deoxycholate 2.5mM, EDTA pH8 with anti-phosphatase
and anti-protease. The samples were immunoblotted and visualized with Super-
Signal West Pico Chemiluminescent substrate (Pierce). Blots were stripped using
Restore Western Blotting Stripping Buffer (Pierce) according to the manufacturer’s
instructions and reprobed if necessary. For Myosin analysis, gastrocnemius muscles
were homogenized in myosin extraction buffer containing 1M Tris pH 6.8, 10%
SDS and 80% glycerol. SDS–PAGE was performed using polyacrylamide gel with a
high glycerol concentration, which allows the separation of MYH isoforms.
Myosins were identified with Coomassie blu staining.
For co-IP experiment C2C12 muscle cell lines were transfected with V5-
SMART, HA-Skp1, FLAG-Cul1 and FLAG-Roc1 expression plasmids. After 24 h,
cells were lysed in a buffer containing 50mM Tris pH 7.5, 100mM NaCl, 5mM
MgCl2, 1mM DTT, 0.5% Triton X-100, protease and phosphatase inhibitors.
About 1mg of total protein was incubated at a ratio of 1:100 with the mouse
monoclonal anti-FLAG antibody or non specific mouse IgG along with 30 ml of
Protein A/G PLUS-Agarose sc-2003 (Santa Cruz Biotechnology) overnight at 4 !C.
The beads were then washed three times with PBS plus Roche Complete Protease
Inhibitor Cocktail 1X and were finally resuspended in 30 ml LDS Sample Buffer 1"
(NuPAGE Life Technolohy) and 50mM DTT to be further analysed by Western
blotting.
Histology and microscopy. Cryosections of transfected TA muscles were exam-
ined in a fluorescence microscope Leica DM5000B equipped with a Leica DFC300-
FX digital charge-coupled device camera by using Leica DC Viewer software.
Cryosections of TA were stained for haematoxilin and eosin and as well as for
Succinate dehydrogenase and Periodic acid-Schiff. Cross-sectional area was mea-
sured using ImageJ software in at least 400 transfected fibres and compared with
the area of age-matched control.. The fibre diameter was calculated as caliper
width, perpendicular to the longest chord of each myofibre. The total myofibre
number was calculated from entire muscle section based on assembled mosaic
image (" 20 magnification). Fibre typing was determined by immunofluorescence
using combinations of the following monoclonal antibodies: BA-D5 that recognizes
type 1 MyHC isoform and SC-71 for type 2A MyHC isoform. Images were cap-
tured using a Leica DFC300-FX digital charge-coupled device camera by using
Leica DC Viewer software, and morphometric analyses were made using the
software ImageJ 1.47 version.
LC3-vesicle quantification. Cryosections of fed and 30-h fasted muscles from
control and FoxO1,3,4! /! mice that were transfected in vivo with YFP–LC3 were
examined using an epifluorescence Leica DM5000B microscope equipped with a
Leica DFC300-FX digital charge-coupled device camera by using Leica DC Viewer
software. The fluorescent dots were counted and normalized for cross-sectional
area.
Autophagic flux quantification. We monitored autophagic flux in 30 h of star-
vation using colchicine15. Briefly MLC FoxO1,3,4! /! and FoxO1,3,4f/f mice were
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treated with 0,4mg kg! 1 colchicine or vehicle by i.p. injection and starved. The
treatment was repeated at 15 h prior to muscle harvesting.
Adenovirus production and myotube transfection. FOXO3 was cloned into a
shuttle vector pAdTrack-CMV, which contains green fluorescent protein (GFP)
under the control of a separate promoter. C2C12 mouse myoblasts were cultured in
DMEM 10% FCS until the cells reached confluence. The medium was then
replaced with DMEM 2% horse serum (‘differentiation medium’) and incubated for
4 days to induce myotube formation before proceeding with experiments. For
infection, myotubes were incubated with adenovirus at a multiplicity-of-infection
of 250 in differentiation medium for 18 h, and then the medium was replaced. The
infection efficiency was typically 490%.
Muscle physiology. To determine force and contraction kinetics of gastro-
cnemius, mice were anesthetized by a mixture of Xylor and Zoletil, and a small
incision was made from the knee to the hip, exposing the sciatic nerve. Before
branching of the sciatic nerve, TeflonTM-coated 7 multistranded steel wires
(AS 632; Cooner Sales, Chatsworth, CA, USA) were implanted with sutures on
either sides of the sciatic nerve. To avoid recruitment of the ankle dorsal flexors the
common peroneal nerve was cut. Torque production of the stimulated plantar
flexors was measured using a muscle lever system (Model 305C; Aurora Scientific,
Aurora, ON, Canada).
Ex vivo force measurements on soleus muscles were performed by dissecting it
from tendon to tendon under a stereomicroscope and subsequently mounting
between a force transducer (KG Scientific Instruments, Heidelberg, Germany) and
a micromanipulator-controlled shaft in a small chamber, in which oxygenated
Krebs solution was continuously circulated and temperature was maintained at
25 !C. The stimulation conditions were optimized, and the length of the muscle
was increased until force development during tetanus was maximal.
Data were analysed using the PowerLab system (4SP, ADInstruments) and
software (Chart 4, ADInstruments). The sciatic nerves were stimulated using
supramaximal square wave pulses of 0.1-ms duration. Force generation capacity
was evaluated by measuring the absolute maximal force that was generated during
isometric contractions in response to electrical stimulation (frequency of 75–
150Hz, train of stimulation of 500ms). Maximal isometric force was determined at
L0 (length at which maximal tension was obtained during the tetanus). Force was
normalized to the muscle mass as an estimate of specific force. Following force
measurements, animals were killed by cervical dislocation and muscles were
dissected, weighed and frozen in liquid nitrogen or in isopentane precooled in
liquid nitrogen.
Statistical analysis and general experimental design. The sample size was
calculated using size power analysis methods for a priori determination based on
the s.d., and the effect size was previously obtained using the experimental methods
employed in the study. For animal studies, we estimated sample size from expected
number of knockout mice and littermate controls, which was based on mendelian
ratios. We calculated the minimal sample size for each group by at least four
organisms. Considering a likely drop-off effect of 10%, we set sample size of each
group at five mice. To reduce the s.d., we minimized physiological variation by
using homogenous animals with same sex and same age. The exclusion criteria for
animals were pre-established. In case of death, cannibalism or sickness, the animal
was excluded from analysis. Tissue samples were excluded in cases such as cryo-
artefacts, histological artefacts or failed RNA extraction. We included animals from
different breeding cages by random allocation to the different experimental groups.
Animal experiments were not blinded, however, when applicable, the experi-
menters were blinded to the nature of samples by using number codes until final
data analysis was performed. Statistical tests were used as described in the figure
legends and were applied on verification of the test assumptions (for example,
normality). Generally, data were analysed by two-tailed Student’s t-test. For all
graphs, data are represented as means±s.e.m. For the measurement variables used
to compare KO animals versus controls, or innervated animals versus denervated
ones, the variance was similar between the groups.
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